Wnt/β-catenin signaling in malignant mammary tumor progression and metastasis formation & Mechanisms of evasive resistance to sorafenib in hepatocellular carcinoma by Büchel, David Martin
 
 
Wnt/β-catenin signaling in malignant mammary 
tumor progression and metastasis formation 
& 
Mechanisms of evasive resistance to sorafenib in 
hepatocellular carcinoma 
 
Inauguraldissertation 
zur  
Erlangung der Würde eines Doktors der Philosophie 
vorgelegt der 
Philosophisch-Naturwissenschaftlichen Fakultät 
der Universität Basel 
 
von 
 
David Martin Büchel 
 
aus Rüthi (SG), Schweiz 
 
Basel, 2019 
 
Originaldokument gespeichert auf dem Dokumentenserver 
der Universität Basel 
edoc.unibas.ch
 
 
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf 
Antrag von: 
Prof. Dr. Gerhard Christofori 
Prof. Dr. Markus Heim 
 
 
 
 
Basel den 19.02.2019 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          Prof. Dr. Martin Spiess 
          Dekan 
  
 
 
Table of contents 
 
Table of contents  
1. General Introduction 1 
1.1 Cancer 1 
2. Project I: Wnt/β-catenin signaling in malignant mammary tumor progression 
and metastasis formation 4 
2.1 Summary 4 
2.2 Introduction 6 
2.2.1 Breast cancer 6 
2.2.1.1 Breast development 6 
2.2.1.2 Breast cancer 7 
2.2.2 Wnt signaling pathway 9 
2.2.2.1 Canonical-Wnt signaling 11 
2.2.2.2 Non-canonical Wnt signaling 13 
2.2.2.3 β-catenin 15 
2.2.2.3.1 β-catenin at the membrane 16 
2.2.2.3.2 β-catenin signaling 18 
2.2.2.4 Wnt signaling in mammary gland development 22 
2.2.2.5 Wnt signaling in cancer 23 
2.2.2.6 Wnt signaling in breast cancer 25 
2.2.3 Epithelial-to-mesenchymal transition 28 
2.2.3.1 Wnt in EMT 31 
2.2.4 Mouse models of metastatic breast cancer 32 
2.3 Aim of the study 36 
2.4 Results 38 
2.4.1 Abstract 39 
2.4.2 Introduction 40 
2.4.3 Knockout of β-catenin leads to apoptosis in vitro and in vivo 42 
2.4.4 Abrogating the binding of BCL9/9L to β-catenin affects tumor growth and metastasis 
formation 45 
2.4.5 Binding of C-terminal coactivators is essential for tumor growth but not for metastasis 
formation 47 
 
 
2.4.6 Block of transcriptional β-catenin output decreases tumor growth and metastasis formation
 50 
2.4.7 Loss of N- and C-terminal coactivators completely abrogates canonical Wnt activity and the 
inability of β-catenin to bind BCL9/9L results in an abrogated EMT response 53 
2.4.8 β-catenin N- and C- terminal coactivators contribute to the expression of specific Wnt target 
genes and alter the regulation of Wnt pathway components 56 
2.5 Discussion 62 
2.5.1 Effect of β-catenin knockout in mammary tumor cells 62 
2.5.2 Wnt signaling in mammary tumor growth, tumor progression and metastasis formation 63 
2.5.3 The contribution of N- and C-terminal coactivators of β-catenin to Wnt signalig activity and 
EMT 64 
2.5.4 Wnt target genes and pathway components affected by ablation of coactivator binding to β-
catenin 66 
2.6 Material and Methods 71 
2.7 Supplementary data 81 
3. Project II: Mechanisms of evasive resistance to sorafenib in hepatocellular 
carcinoma 87 
3.1 Summary 87 
3.2 Introduction 89 
3.2.1 Hepatocellular carcinoma (HCC) 89 
3.2.2 HCC treatment 90 
3.2.3 Drug resistance 92 
3.2.3.1 Epigenetic regulation involved in drug resistance 96 
3.3 Aim of the study 100 
3.4 Results 101 
3.4.1 Development of sorafenib-resistant cell lines 101 
3.4.2 Characterization of the resistant cell lines 103 
3.4.3 HDAC inhibitor treatment reverts the mesenchymal morphology of resistant HCC cells and 
sensitizes them to sorafenib treatment 107 
3.4.4 Pathway analysis of differentially expressed genes common to the established resistant cell 
lines 109 
3.5 Discussion 113 
3.5.1 Sorafenib resistance and EMT 113 
3.5.2 HDAC inhibition, EMT and sorafenib resistance 115 
3.5.3 Transcriptomic analysis of sorafenib resistance 116 
3.6 Material and Methods 119 
 
 
3.7 Supplementary Data 123 
4. References 124 
5. Acknowledgements 142 
6. Curriculum Vitae 143 
 
1 
 
1. General Introduction 
1.1 Cancer 
Cancer is a general term for a group of diseases which can originate and affect nearly 
all organs and tissues and is the second leading cause for death worldwide (WHO, 
2018). These malignancies share some but also have their own characteristics, risk 
factors and treatment approaches. Each cell in our body has a specific function and a 
functioning tissue architecture underlies stringent control mechanisms as for example 
precise control of cell division and function to ensure homeostasis. Cancer cells, on 
the other hand, manage to escape these mechanisms resulting in uncontrolled growth 
and acquisition of altered functions that may hamper the function of non-cancerous 
cells around them. The majority of such neoplasms arise from epithelial cells. They can 
be either benign or be/become malignant. Benign tumors remain confined to the 
location of origin and do not spread or invade the surrounding tissue. Malignant tumors, 
however, are able to invade the surrounding tissue and spread throughout the body 
via blood and/or the lymphatic system. Most cancer deaths are not caused by the 
primary tumor itself but rather by the metastatic outgrowth [1]. Cancer development 
also depends on the interaction and collaboration with the tumor microenvironment. 
The tumors are not only composed of cancer cells but also of several other cell types, 
such as immune cells, endothelial cells, pericytes and fibroblasts [2]. The probability to 
develop cancer increases with age and thus more cancer are diagnosed rather late in 
life with an increase at approximately 50 years of age. Some of the known risk factors 
include genetic predisposition, environmental / lifestyle influences, chronic 
inflammation and viral infections [3-6]. The development of cancer is a multistep 
process requiring the acquisition of genomic alterations often involving tumor 
suppressor genes as well as proto-oncogenes. The common features that collectively 
dictate malignant growth acquired during this multistep development of cancer have 
been proposed in 2000 by Weinberg A. and Hanahan D and comprised six hallmarks 
that were revised in 2011 and updated due to observations and progress in cancer 
research [7, 8]. These hallmarks are: 
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- Sustaining proliferative signaling: The ability of cancer cells to sustain chronic 
proliferation by deregulation of mechanisms controlling tissue homeostasis. 
- Evading growth suppressors: To evade regulation of cell number and tissue 
homeostasis, cancer cells are able to circumvent or even eliminate negative regulators 
of cell proliferation. These regulatory genes – mostly belonging to the family of the so-
called tumor suppressor genes – operate as central points of intersection acting on 
decisions of proliferation or, alternatively, activate senescence and thus apoptotic 
pathways. 
- Deregulating cellular energetics: The deregulated proliferation of cancer cells 
requires an adjustment of the energy household. Under normoxia, cells rely on 
oxidative phosphorylation and switch to glycolysis under hypoxic conditions. However, 
cancer cells are able to use glycolysis even in the presence of oxygen (aerobic 
glycolsis) also called “Warburg effect”. 
- Resisting cell death: The balance between cell proliferation and cell death that would 
maintain tissue homeostasis is disturbed in cancer cells. Apoptosis has been found 
being attenuated in high-grade and therapy-resistant tumors. 
- Genomic instability & mutation: Certain epigenetic changes and/or genomic 
mutations can confer a growth advantage of certain cells leading to clonal expansions 
of altered cells. An increased sensitivity to mutagenic agents and ablation of the 
genomic maintenance machinery can increase the mutation rate, respectively impair 
the repair mechanisms, leading to accumulation of mutations by impairing genomic 
integrity surveillance which would force genetically damaged cells into senescence or 
apoptosis. Thus, increasing the chance of mutation acquisition with evasion of genome 
maintenance systems facilitates tumor cell growth. 
- Inducing angiogenesis: To ensure and sustain the increased nutrient and oxygen 
supply as well as disposal of metabolic wastes and carbon dioxide during tumor growth, 
an angiogenic switch is activated leading to the expansion and generation of the 
normally quiescent vasculature. 
- Activating invasion and metastasis: Progression to higher pathological grades is often 
associated with local invasion and distant metastasis formation. The cancer cells adapt 
their cell morphology and alterations in cell-cell attachment as well as cell attachment 
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to the ECM are found. This enables intravasation into lymphatic vessels or blood 
vessels and spreading into distant tissues and organs in a multistep process termed 
“invasion-metastasis cascade”. Within this process, the developmental regulatory 
program referred as the epithelial-mesenchymal transition (EMT) by which epithelial 
cells undergo a transformation by which they gain migratory and invasive capabilities 
which will be further discusses later in this thesis (see chapter “Epithelial-to-
mesenchymal transition”). 
- Tumor-promoting inflammation: Infiltration of cells of the innate and adaptive immune 
system in neoplastic tissue is known for a long time and has been thought to only 
reflect an antagonizing effort of the immune system on tumor cells. The current state 
of scientific knowledge also adds an unanticipated and paradoxical effect of promoting 
tumorigenesis and progression by releasing factors to the tumor microenvironment, 
such as survival-factors, ECM-modifying enzymes, growth factors and enzymes 
facilitating angiogenesis, invasion and metastasis. 
- Avoiding immune destruction: The immune system monitors cells and tissues and is 
suggested to contribute to tumor eradication by recognizing and eliminating cancer 
cells. Hence, for cancer cells to outgrow, they have to evade immune surveillance or 
limit their removal by immune cells. 
- Enabling replicative immortality: The ability to form macroscopic tumor tissue requires 
a prolonged life span and thus abolishment of senescence and crisis in tumor cells. 
This transition, called immortalization, has been observed in various immortalized cell 
cultures as well as in tumor tissue and was associated with enhanced activity of the 
specialized DNA polymerase Telomerase, an enzyme responsible for adding telomere 
repeats to the ends of telomeric DNA. The length of telomeric DNA has been shown 
indicative of the cells lifespan or ability to further replicate, since without these hexamer 
repeats, the protection from end-to-end fusions ending up in unstable dicentric 
chromosomes in mitosis leads to unbalanced chromosomes and thus threatens cell 
viability. The maintenance of telomeric DNA by enhanced telomerase activity or less 
frequently by an alternative recombination-based telomere maintenance mechanism 
hence provides means to protect the chromosomal ends enabling cancer cells to have 
an unlimited replicative potential. 
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2. Project I: Wnt/β-catenin signaling in malignant mammary 
tumor progression and metastasis formation 
2.1 Summary 
β-catenin exerts a dual role as the key nuclear effector of the canonical Wnt signaling 
pathway and as a crucial component of the E-cadherin-mediated cell-cell adhesion 
complex. In breast cancer, aberrations in the canonical Wnt signaling pathway have 
been found in correlation with poor prognosis. To provide a better understanding of β-
catenin’s function in breast tumor progression and metastasis formation, we have 
performed functional in vivo analysis in the MMTV-PyMT mouse model. We first 
analyzed breast cancer progression and metastasis formation in the complete absence 
of β-catenin by conditional knockout. We found that the knockout of β–catenin and 
hence the loss of its signaling and adhesion function leads to apoptosis in vitro and in 
vivo. To specifically dissect its transcriptional function without affecting its role in cell 
adhesion, we have used mice expressing mutant forms of β-catenin which retained 
their function in cell adhesion but lacked either the N- or C-terminal transcriptional 
output or both, resulting in the abrogation of β-catenin’s transcriptional activity and thus 
the canonical Wnt signaling output. Introducing the N-terminal mutation D164A 
abrogates the interaction of β-catenin with its coactivators BCL9 and BCL9L, deletion 
of the C-terminus (ΔC) on the other hand prevents binding of multiple coactivators to 
the C-terminus. The double mutant (dm) combines both, the D164A mutation and the 
C-terminal truncation and thereby completely abrogates Wnt signaling. From the 
different mouse tumor genotypes, cell lines have been established to further 
characterize and examine the effects of an altered canonical Wnt signaling output. As 
compared to the β-catenin knockout cells, these cells were viable, suggesting a key 
role of β-catenin’s adhesion function in cell survival. Here, we demonstrate that 
selective abrogation of the N- and/or C-terminal transcriptional output of β-catenin 
affects tumor progression and tumor cell proliferation. Lack of the N-terminal 
transcriptional output only or the complete abrogation of Wnt signaling activity in the 
dm form of β-catenin also affects metastasis formation in vivo and epithelial-to-
mesenchymal transition (EMT) in vitro. Furthermore, the different mutant forms exert 
a dominant-negative effect. RNA sequencing analysis to examine global changes in 
transcription and signaling pathways affected by the expression of the different β-
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catenin mutant forms upon activation of the Wnt pathway and during EMT by Wnt3a 
or TGFβ treatment, respectively, has been performed. With this approach we were 
able to identify candidate genes, which seem to be either regulated by N- and C-
terminal or specifically by N- or C-terminal coactivators binding to β-catenin. 
Furthermore, preventing the binding of coactivators to β-catenin in the β-catenindm/- cell 
line resulted in the almost complete abrogation of the canonical Wnt pathway showing 
only minor expression changes in some known Wnt target genes as well as pathway 
components. Moreover, also upon TGFβ treatment we detected target genes that 
seem to be specifically regulated by either the N- or the C-terminal coactivators during 
EMT. The mutant forms of β-catenin were able to alter and partially ablate the EMT 
response as compared to wild-type β-catenin, however, the cell lines are still able to 
upregulate most of the mesenchymal markers examined so far. In summary this study 
provides new insight of the involvement of the canonical Wnt signaling pathway in 
breast tumor progression and metastasis formation and allows the identification of β-
catenin target genes important for EMT and tumor progression. These data may help 
identifying new therapeutic targets in breast cancer tumor progression and metastasis 
formation. 
  
6 
 
2.2 Introduction  
2.2.1 Breast cancer 
2.2.1.1 Breast development 
Over the lifetime, the breast tissue undergoes many changes from birth to puberty and 
pregnancy until the menopause. The mammary glands are complex secretory organs 
composed of various different cell types. In brief, they are composed of epithelial cells 
that grow from the nipple into a fat pad formed by adipocytes that is infiltrated by 
vascular endothelial cells, fibroblasts and immune cells. Most information on breast 
development has been obtained from studies in rodents, however there are some 
architectural and hormonal differences between rodents and humans. Morphogenesis 
of the mouse mammary gland starts on embryonic day 10.5 (E10.5) with the ventral 
formation of two mammary lines called milk lines. At E11.5, five pairs of placodes are 
formed by those cells which are multilayered ectodermal structures. In contrast, human 
mammary glands comprise only a single pair of placodes. [9] Subsequently, the murine 
mammary placodes expand and form buds of epithelial cells that descend into the 
underlying mesenchyme, where the cells start to extent and sprout from the buds. 
Once these cells reach the fat pat they start branching and give rise to a rudimental 
ductal tree which is formed without hormonal input. During E16-18, the lumen is formed, 
before the invading epithelium becomes a more solid structure. During puberty, the 
hormones promote the expansion of the ductal tree throughout the mammary fat pads 
with proliferation structures located at the tips of the growing ducts called terminal end 
buds (TEBs). [10, 11] The growth is driven by a single layer of cells at the tip of the 
TEB called cap cells that have been found to differentiate into myoepithelial cells [12]. 
Later on, the proliferating TEBs are replaced by terminal end-ducts (TEDs) and 
alveolar end buds which are mitotically quiescent. During pregnancy the number of 
blood vessels increases and the mammary epithelium expands, estrogen and growth 
hormones drive this expansion of the ductal network. Furthermore, alveologenesis 
takes place which is mainly orchestrated by progesterone and prolactin. The alveolar 
end buds become mature alveoli which are small cavities for milk production and 
storage. The functional units for milk production and storage are called terminal ductal 
lobular units (TDLUs) and show a comparable structure to the TEBs in murine breast 
tissue (Fig. 1A).  [13-16] During weaning, the lacking milk demand initiates the process 
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of involution, compromising apoptosis of the milk-producing cells which is followed by 
tissue transformation and widespread apoptotic remodeling of the epithelial tree to a 
state similar to a virgin adult mouse [17]. The mammary epithelium is composed of a 
double-layer originating form adult mammary stem cells (MaSCs) comprising an inner 
layer of luminal epithelial cells and an outer layer of contractile myoepithelial/basal 
epithelial cells secreting and lying on the basement membrane (Fig. 1B) [18]. These 
cell types can be distinguished using a number of cytokeratins, intermediate filament 
proteins that can act as lineage markers in the mammary epithelium. For example, K4 
and K18 mark luminal cells, whereas K5 and K14 identify basal/myoepithelial cells [19-
21]. 
  
 
Figure 1. The mammary gland. (A) Schematic representation of the human and mouse mammary 
gland. (B) Schematic representation of a duct (top) and a terminal end bud (TEB) (bottom). The 
mammary gland epithelium is composed out of two layers, the inner layer of luminal cells line and the 
basal myoepithelial cells which are surrounded by the basement membrane [21]. 
 
2.2.1.2 Breast cancer 
Breast cancer is a malignant disease caused by an uncontrolled growth of cells in the 
breast tissue. It is the most common cancer type in women and the second leading 
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cause for cancer-related death in women after lung cancer in the United States [6, 22]. 
Several risk factors have been associated with the development of breast cancer which 
include inherent factors such as age, sex, race, genetic predisposition but also extrinsic 
factors like the lifestyle, diet or long-term medical interventions. Furthermore, it has 
been shown that an earlier age at menarche, a higher age at first pregnancy as well 
as a late menopause may increase the risk of breast cancer development [22-25]. A 
rather small portion of breast cancers has been shown to be caused by hereditary 
germline mutations in susceptibility genes (5-10%). Among the most frequently 
mutated genes predisposing to hereditary breast are the tumor suppressor genes 
BRCA1 (BRCA1, DNA repair associated) and BRCA2 (BRCA2, DNA repair 
associated) which are both involved in DNA damage response [26-30]. Meanwhile, 
many other genes have been found that are involved in increasing the risk to develop 
breast cancer, including CHEK2 (checkpoint kinase 2), PTEN (phosphatase and tensin 
homolog), TP53 (tumor protein p53), CDH1 (cadherin 1) and STK11 (serine/threonine 
kinase 11). Mutations in these genes confer an increased risk to develop breast cancer 
[31].  
Human breast cancer is a heterogenous group of neoplasms originating from the 
epithelial cells lining the milk ducts of the mammary gland. There appears to be an 
intra- as well as inter-tumoral heterogeneity as well as a high degree of diversity among 
patients [32]. To deal with this complexity and to provide the best possible treatment 
for patients, classification in clinically relevant subtypes is applied. This is achieved by 
characterization of the histopathological and immunological features as well as gene 
expression profiles. The combination of classical immunohistochemistry (IHC) markers 
such as ER (estrogen receptor), PR (progesterone receptor) and HER2 (human 
epidermal growth factor receptor 2), together with the patients anamneses (age of 
development, family history, etc.), clinicopathological variables including tumor size, 
tumor grade and nodal involvement are conventionally used for patient prognosis and 
management. Classical pathology has classified breast tumors according to their 
morphology and structural organisation into invasive ductal carcinoma (IDC), the most 
common type, invasive lobular carcinoma (ILC) and the remaining types, which are 
summed up as tumors of special type [33, 34].  
Analysis of gene expression profiling lead to the identification of different subtypes 
according to transcriptional signatures. For the use in clinics a classification has been 
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adopted which correlates with the expression of biomarkers that has been performed 
already before but adds another level of differentiation to it. Immunohistochemical 
(IHC) characterization of the ER, PR and HER2 expression combined with a Ki-67 
labeling index are used for the clinicopathological classification of mammary cancer 
tissue into subtypes. These include normal-breast-like, claudin-low, basal-like, luminal 
A or B, and HER2/ERBB2-overexpressing subtypes [35-39]. This characterization is 
important, since the expression or loss of these receptors can sensitize or de-sensitize 
the tumors for specific chemotherapeutics. The majority of diagnosed breast tumors 
are ER-positive and generally more responsive to anti-estrogen therapy. Thus, patients 
benefit from treatment using ER antagonists or aromatase inhibitors [40]. HER2-
overexpressing tumors can be targeted using monoclonal antibodies, such as 
trastuzumab or also using Antibody–drug conjugates like trastuzumab emtansine [41, 
42]. However, for triple-negative breast cancers (TNB), characterized by the 
expression loss of PR, ER, and HER2, there is no targeted therapy available and they 
tend to be more aggressive and to show a worse prognosis [43-45].  
 
2.2.2 Wnt signaling pathway 
The Wnt signaling pathway is a conserved pathway in metazoan animals and has been 
identified over 30 years ago by discovering the segment polarity gene Wingless in 
Drosophila melanogaster. Flies harboring mutations in this gene were found to not 
develop wings. Furthermore, embryos of these flies showed impaired epidermis 
segmentation [46, 47]. Experiments in mice studying the mammary tumor virus 
(MMTV) which causes mammary tumors in mice, has led to the discovery of the 
common integration site of MMTV within the promotor of a gene referred to as int-1 
[48, 49]. In 1987, Rijsewijk and collegues isolated the Drosophila homologue of int-1 
and discovered that it is identical to the wingless gene and called it Wnt-1(Wnt family 
member 1) [50]. The Wnt pathways are generally subdivided into canonical and non-
canonical Wnt pathways. Meanwhile, in humans 19 secreted Wnt glycoproteins (Wnts) 
have been discovered which are able to either induce the canonical β-catenin-
dependant or the non-canonical β-catenin-independent cell polarity (PCP) and the 
calcium/protein kinase C (PKC) Wnt pathway.  
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Wnts are cysteine-rich glycoproteins which are glycosylated and lipid-modified in the 
endoplasmic reticulum and were found to be able to act over short and long distance 
ranges. Palmitoylation by the acetyltransferase porcupine has been found to be 
essential for Wnt activity, whereas glycosylation seems to be rather important for 
proper folding and secretion [51-53]. Another important factor for the secretion of Wnts 
is Wntless (WLS), a multipass transmembrane protein localized amongst others in the 
Golgi apparatus where it binds Wnt and helps to transport it to the plasma membrane 
to be secreted [54-57]. There are different models proposed how Wnts are transmitted 
between cells. Wnts may bind to some extracellular proteins, to extracellular vesicles 
or form multiprotein complexes. Furthermore, extracellular matrix components like 
heparin sulphate proteoglycans (HSPGs) as well as trafficking via filopodia like 
protrusions (cytonemes) and the transport by exosomal vesicles are potential ways of 
spreading Wnts [58, 59]. In the extracellular matrix, several secreted proteins are 
present that can act as Wnt signaling inhibitors by binding to Wnts and prevent their 
interaction with cell membrane receptors. Amongst them are DKK (Dickkopf Wnt 
signaling pathway inhibitor), WIF (Wnt inhibitory factor) and SFRP (secreted frizzled-
related protein). There are also factors like R-spondins which can bind to cell 
membrane receptors LRP5/6 (low density lipoprotein receptor-related protein 5/6) and 
activate Wnt signaling independent of the Wnt ligands [60-63].  
The three best-characterized Wnt signaling pathways are the canonical Wnt/β-catenin 
signaling pathway, the non-canonical planar cell polarity pathway (PCP) and the non-
canonical Wnt/calcium pathway (Wnt/Ca2+). Generally, the Wnt proteins 
Wnt1/2/3a/8a/8b/10a/10b are thought to belong to the canonical Wnts, whereas 
Wnt4/5a//6/7a/7b/11 are classified as non-canonical Wnts. [64] However, some of 
them have been found to be able to activate both the canonical and non-canonical 
pathways. For example, Wnt5a that has been identified as non-canonical Wnt, was 
found to be able to also activate the canonical Wnt pathway [65]. Another study has 
found that Wnt5a can inhibit canonical Wnt/β-catenin signaling or induce it, depending 
on the receptors context [66, 67]. Several studies suggest that the signaling specificity 
is dictated by the co-receptors with LRP5/6 being specific for canonical Wnt signaling, 
whereas PTK7 (PTK7 protein tyrosine kinase 7) and ROR2 (receptor tyrosine kinase-
like orphan receptor 2) seem to be specific for the non-canonical pathway [68, 69]. 
However, it has also been found that there are different affinities between Wnt ligands 
and Frizzled receptors, hence it is thought that the receptor context induces different 
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Wnt responses [70, 71]. Moreover, there seems to be a high complexity of cross talk 
between the canonical- and non-canonical Wnt pathways, as for example, the non-
canonical pathway has been found to be able to inhibit canonical signaling [72, 73].  
 
2.2.2.1 Canonical-Wnt signaling  
The first step in mediating the intracellular Wnt/β-catenin signaling pathway, also 
named canonical Wnt signaling pathway is triggered by an extracellular stimulus, 
namely by binding of a Wnt ligand to the cell membrane receptors. Without Wnt ligand-
binding to the transmembrane receptors Frizzled (10 distinct family members FZD1 - 
FZD10) and the single-pass transmembrane co-receptors LRP5/6, the pathway is in 
an off state and free cytosolic β-catenin is targeted and phosphorylated by the so called 
destruction complex. This complex is composed of the scaffold proteins Axin and APC 
(adenomateous polyposis coli) and the kinases GSK3β (glycogen synthase kinase 3β) 
and CK1α (casein kinase 1α) which phosphorylate β-catenin at amino-terminal Ser and 
Thr residues, and protein phosphatase 2A (PP2A) [74-76]. There are two Axin genes 
in vertebrates, namely Axin1 and Axin2. Since Axin2 is a transcriptional target of the 
canonical Wnt pathway, it hence constitutes a negative feedback loop [77]. CK1α 
phosphorylates the serine residue in codon 45 of β-catenin. GSK3β has been found to 
favour substrates that were primed by phosphorylation by other kinases. Hence, 
GSK3β phosphorylates threonine 41 serine 33 and serine 37 of β-catenin starting from 
the C-terminus [78]. Both Axin and APC have been found to be phosphorylated by 
GSK3β as well which increases their binding capacity to β-catenin [79, 80]. Following 
its phosphorylation, β-catenin is recognized by the SCFβ-TRCP E3 ubiquitin ligase 
complex via the F box protein β-TrCP1 (Beta-transducin repeat containing E3 ubiquitin 
protein ligase), following ubiquitination and subsequent degradation by the 26S 
proteasome [81, 82]. It has furthermore been found that β-catenin is ubiquitylated by 
the E3 ligase JADE1 (Jade family PHD finger 1). However, β–TrCP1 ubiquitinates only 
phosphorylated β-catenin, whereas JADE1 is able to act on both, phosphorylated and 
non-phosphorylated β-catenin with preference for phosphorylated β-catenin [83].  
Binding of a canonical Wnt ligand to the transmembrane receptor Frizzled and its co-
receptor LRP5/6 results in the destabilization of the destruction complex. Since FZDs 
can mediate the activation of canonical as well as non-canonical pathways, Liu and 
colleagues have demonstrated that functional interaction of ligands with LRP5/6 
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distinguishes activation of canonical versus non-canonical Wnt. This was shown by 
fusing of Wnt5A, which is known for being a non-canonical Wnt ligand to a fraction of 
Dickkopf-2 (DKK2) which can interact with LRP5/6. This fusion protein was found to 
be able to activate the canonical Wnt signaling pathway in comparison to normal 
Wnt5A which was not [69]. Upon ligand binding, the FZD and LRP5/6 complexes 
become activated, oligomerize and recruit Dishevelled (DVL) to the receptor complex. 
Three human homologues Dvl1 to Dvl3 have been identified (Dsh in Drosophila 
melanogaster). Dsh multimerizes via its DIX domain and has been found to interact 
with and to recruit Axin, thereby facilitating Axin binding to LRP. Axin has been found 
to be required for LRP6 phosphorylation by binding GSK3β. Zeng et al. and others 
have shown that GSK3 phosphorylation seems to be the primary Wnt-inducible event, 
priming the subsequent phosphorylation by CK1α. Phosphorylated LRP6 provides 
docking sites and seems thereby to recruit additional Axin-GSK3. Hence upon Wnt 
stimulation, Axin-GSK3 is recruited to the plasma membrane and disrupts the 
formation of the destruction complex leading to the stabilization of β-catenin in the 
cytoplasm [84-86]. Unphosphorylated β-catenin accumulates in the cytoplasm and 
translocates to the nucleus where it binds to the TCF/LEF family of transcription factors 
(TCF1, LEF1, TCF3, TCF4). Without binding of β-catenin, TCF/LEF associates with 
Groucho/Transducin-like Enhancer of split (TLE) acting as transcriptional repressors. 
β-catenin binding displaces Groucho/TLE and thereby leading to the transcription of 
specific target genes (Fig. 2) [75, 87-89]. Several nuclear cofactors are known to bind 
to β-catenin and thereby to modulate and fine-tune transcriptional activity. The target 
genes during development are stage and tissue-specific and are involved in several 
processes, such as cell fate, proliferation, migration and cell survival [75]. Wnt signaling 
itself can promote the expression of several Wnt pathway components, like FZD, 
TCF7, LEF1 and Axin2. Furthermore, also the Wnt pathway inhibitor Dkk is among the 
target genes, indicating that feedback control is an important feature of Wnt signaling 
regulation [77, 89-93]. 
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Figure 2. Schematic representation of β-catenin’s dual function. β-catenin together with E-cadherin 
and α-catenin at the cell membrane can form the cell adhesion complex. The immobilised β-catenin at 
the cell membrane can be released into the cytoplasm upon downregulation of E-cadherin or by the 
activity of protein kinases. Cytoplasmic β-catenin is either retained in the cytoplasm by binding to APC 
or immediately degraded by binding to the destruction complex. Wnt ligand binding to cell membrane 
receptors inhibits the formation of the destruction complex, thus releasing β-catenin in the cytoplasm 
leading to its accumulation and translocation to the nucleus. There, binding to the TCF/LEF transcription 
factor leads to the transcription of canonical Wnt target genes. β-catenin was also found to bind to other 
DNA-binding transcription factors (TF) [75].  
 
2.2.2.2 Non-canonical Wnt signaling  
Non-canonical Wnt signaling is also referred to as β-catenin-independent Wnt 
signaling. The non-canonical pathways can be further subdivided into the Wnt/Ca2+ 
and planar cell polarity (PCP) pathways. To activate the Wnt/PCP signaling pathway, 
Wnt ligands bind to Frizzled receptors and to one of the co-receptors like ROR1/2 
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(receptor tyrosine kinase-like orphan receptor 1 or 2), RYK (ryk receptor-like tyrosine 
kinase), NRH1 (neurotrophin-receptor-related protein), or PTK7 (protein-tyrosine 
kinase PTK7) resulting in the recruitment and activation of DVL. This subsequently 
activates two parallel pathways. On one hand, it activates the Rac GTPase which 
stimulates JNK (c-jun kinase). On the other hand, DVL forms a complex with DAAM1 
(dishevelled-associated activator of morphogenesis 1) which leads to the activation of 
small GTPase RhoA further triggering the activity of Rho kinase (ROCK) (Fig. 3). 
Thereby this pathway has been found to regulate cytoskeletal rearrangements and AP-
1 (Activator protein 1)-dependant gene transcription involved in regulating cell polarity 
in morphogenetic processes and cell motility [94-99].  
In the Wnt–Ca2+ pathway, Wnts trigger FZD-mediated activation of DVL and 
heterotrimeric G proteins, which in turn activate phospholipase C (PLC). Subsequently, 
PLC cleaves PIP2 (phosphatidyl-inositol bisphosphate) into DAG (Diacyl-glycerol) and 
IP3 (inositol triphosphate). IP3 triggers the release of intracellular calcium and thereby 
calcium-sensitive calcineurin and CAMKII (calcium/calmodulin-dependent protein 
kinase type II) are activated which in turn activate NFAT (nuclear factor of activated T 
cells) which acts as a transcription activator. On the other hand, DAG activates PKC 
(protein kinase C). CAMKII and PKC can activate various regulatory proteins, including  
NFκB (nuclear factor kappa-B) and CREB1 (cAMP response element-binding protein 
1) which act as nuclear transcription factors and transcribe various downstream 
regulatory genes found to be involved in processes like vertebral axis formation in 
embryonic development (Fig. 3) [98-100]. 
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Figure 3. Schematic representation of non-canonical Wnt pathways. Wnt/PCP pathway: Binding of 
Wnt ligands to the cell membrane receptor complex ROR1/2-Fzd, leads to the recruitment of DVL. DVL 
then activates RAC1 and together with DAAM1 then RHOA. Those in turn mediates the activation of 
JNK and ROCK. In Wnt/Ca2+pathway, G-protein triggered phospholipase C is activated by binding of 
Wnt ligand leading to cleavage of PIP2 by PLC into DAG and IP3. The latter induces intracellular calcium 
release whereas DAG activates PKC. Calcium sensitive enzymes such like CAMKII and calcineurin are 
thereby activated. This leads to calcium-dependent cytoskeletal and/or transcriptional responses [101]. 
 
2.2.2.3 β-catenin 
β-catenin has been initially discovered on the basis of its two different functions in 
signaling and structure. Its first identification has been due to its structural function as 
part of the adherens junction complex since it was isolated together with α-catenin and 
16 
 
plakoglobin (γ-catenin) associated with E-cadherin (Fig. 2) [102]. Its signaling function 
has further been revealed in D. melanogaster, with the finding of its orthologue 
Armadillo that was identified in a screen performed to detect genes required in 
embryonic development for early patterning and morphogenesis [103]. Subsequently, 
-catenin was found to be the vertebrate homologue of the D. melanogaster segment 
polarity gene product Armadillo [104, 105]. β-catenin has been found to be the key 
component of the canonical Wnt signaling pathway and being tightly regulated at three 
hierarchical levels: protein stability, subcellular localization and transcriptional activity. 
The β-catenin gene (Ctnnb1, catenin beta 1, MGI: 99276; further referred as -catenin) 
encodes for a highly conserved protein encoded by 781 amino acids (aa). The protein 
consists of 12 imperfect Armadillo (ARM) repeats and an N- and C-terminal domain 
(NTD and CTD respectively). The ARM repeats form a superhelix with a positively 
charged groove, which is important for the interaction of β-catenin to other proteins. -
catenin has a dual role: it is a crucial component of the E-cadherin-mediated cell 
adhesion complex as well as the key nuclear effector of the canonical Wnt signaling 
pathway. With its 12 ARM repeats β-catenin it is able to bind and thus interact with a 
number of different proteins and distinguish between its function in cell adhesion by 
binding to E-cadherin at the cell membrane, APC in the cytoplasm or TCF/LEF in the 
nucleus since all these binding partners have overlapping binding sites within β-catenin 
[75, 106]. 
 
2.2.2.3.1 β-catenin at the membrane 
As a component of the cell adherens junction complex, it binds to the intracellular 
domain of cadherins thereby linking them via the adaptor protein α-catenin to the actin 
cytoskeleton. Cadherins are Ca2+-dependent single-pass transmembrane proteins 
named after the tissue they have been found to be most prominently expressed in. By 
binding to E-cadherin in the endoplasmic reticulum, β-catenin inhibits degradation of 
E-cadherin, since in covers a PEST motif of E-cadherin. On the other hand, binding of 
E-cadherin to β-catenin prevents the binding of components of the destruction complex 
to β-catenin. In addition, -catenin can also bind to the cytoplasmic domain of all the 
other catenins [107]. Together, they then move to the cell membrane where other 
catenin family members α-catenin and P120 (CTNND1) which is important for cadherin 
stability and the function of the adherens complex. α-catenin can be found in either in 
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a heterodimeric form (α-catenin/β-catenin heterodimer) or as a homodimer. Since its 
binding site to β-catenin and its homodimerization domain overlap, it can only bind to 
β-catenin as a monomer. In its homodimer form it interacts with actin filaments. 
However, it is thought that α-catenin links the Cadherin/β-catenin complex to the actin 
cytoskeleton. [108] Moreover, the binding site of α-catenin and BCL9 have been found 
to be in close proximity. Phosphorylation of β-catenin at tyrosine 142 (Tyr142) affects 
the binding of α-catenin and rather direct β-catenin into its signaling function. The 
phosphorylation of this residue is needed for efficient interaction of BCL9-2 with β-
catenin [109-111]. Also the phosphorylation at Tyr654 has been observed to have a 
similar effect by affecting the binding of E-cadherin to β-catenin [112]. Reduction of E-
cadherin on the other hand has been found to be connected with increased cytoplasmic 
levels of β-catenin. Cleavage of E- or N-cadherin by proteases like ADAM10 for 
example, can direct β-catenin away from its cell adhesion function and into signaling. 
Since ADAM10 is described as a target of canonical Wnt signaling, it acts in a positive 
feedback loop [113-115]. In H-Ras-infected immortalized human breast epithelial cells 
(HMLE), knockdown of E-cadherin has been observed to result in the localization of 
unphosphorylated and hence active β-catenin in the cytoplasm and nucleus [116]. In 
colorectal cancer cells, which show constitutive activation of Wnt signaling, knock-
down of E-cadherin augmented -catenin-/TCF-dependent transcription, whereas it 
had no effect in keratinocytes that do not show Wnt signaling activity [117]. 
Furthermore, Herzig and colleagues have shown that by loss of E-cadherin expression, 
canonical Wnt signaling is not induced in the absence of Wnt ligands and β-catenin 
rather gets degraded [118]. Hence, it seems that the mere loss of E-cadherin does not 
activate Wnt signaling but might be rather context- and cell type-dependent. Moreover, 
also in breast cancer cell lines, the absence of E-cadherin was found to have no effect 
on Wnt signaling activity [119]. Plakoglobin (γ-catenin), a close relative of β-catenin 
has been found to be able to compensate in some cases the loss of β-catenin at the 
cell adhesion complex [120]. The loss of E-cadherin is also one of the hallmarks of 
EMT and several transcriptional repressors of E-cadherin are known, some of them 
have also been found to be canonical Wnt target genes, amongst them are Snai2, 
Zeb1 and Twist. Hence, the canonical Wnt pathway fulfills also a role in regulating EMT 
which will be further discussed below [75].  
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2.2.2.3.2 β-catenin signaling 
In the cytoplasm, if recognized by the destruction complex, -catenin binds to the 
scaffolding proteins Axin and APC and is subsequently phosphorylated by CK1α at 
serine 45 (Ser45) and following by GSK3β at threonine 41 (Thr41), Ser37, and Ser33 
marking it for degradation. β-TrCP recognizes phosphorylated -catenin which is then 
recruited to the Skp1/Cul1/F-boxβ-TrCP (SCFβ-TrCP) E3 ubiquitin ligase and degraded by 
the 26s proteasome. The phosphorylation of -catenin has so far been regarded as a 
progressive process. In recently published studies, it has been suggested that rather 
sequential phosphorylation takes place and β-catenin is able to dissociate from the 
destruction complex between the phosphorylation events [75, 121, 122]. Upon 
activation of the canonical Wnt signaling pathway by ligand binding, β-catenin escapes 
its degradation and can translocate to the nucleus (Fig. 2). The process of its nuclear 
translocation is not yet fully understood, since β-catenin’s sequence does neither 
contain a nuclear localization (NLS) nor a nuclear export signal (NES). It has been 
shown that it can directly interact with nuclear pore complexes which might be a 
mechanism by which it could pass and localize to the nucleus [75]. Also, BCL9 and 
Pygopus (PYGO) have been proposed to be important for its nuclear localization [123]. 
Another hypothesis suggests that it binds to transcription factors containing an NLS, 
for example FOXM1 (forkhead box M1), which is found to interact with β-catenin and 
thus might promote its nuclear translocation [124]. In the nucleus, β-catenin displaces 
Groucho/TLE from TCF/LEF and thereby turns the latter into transcriptional activators 
[87]. Additionally, a plethora of nuclear transcriptional cofactors are known to bind to 
-catenin which can initiate, enhance and alter the transcriptional output. At the C-
terminus, of β-catenin several cofactors are found to bind which are not specific to β-
catenin only. Among these are CBP (CREB binding protein, CREBBP), EP300 (E1A 
binding protein p300) and TIP60 (lysin acetyltransferase 5, KAT5) which belong to the 
chromatin remodeling complexes, SWI/SNF (SWItch/Sucrose Non-Fermentable) and 
ISWI (imitation Switch) which can affect nucleosome rearrangement or the Mediator 
complex which connects β-catenin to the transcriptional machinery [57, 75, 125]. 
Whereas at the N-terminus, the β-catenin-specific cofactor BCL9 (legless in 
Drosophila) binds which in turn recruits Pygopus. Together they have been shown to 
fine tune the transcriptional activity of β-catenin (Fig. 4). In mammals, there are two 
paralogues of both, BCL9 namely BCL9 (β-catenin specific cofactor-cell 
CLL/lymphoma 9) and BCL9l (β-catenin specific cofactor-cell CLL/lymphoma 9-like) 
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and for Pygopus, Pygopus1 (PYGO1) and Pygopus2 (PYGO2). BCL9 interacts via its 
homology domain 2 (HD2) with β-catenin and functions as a transcriptional coactivator 
by recruiting Pygopus and binds to it via its HD1 domain. Pygopus has two distinct 
domains, an N-terminal homology domain and a C-terminal plant homolog domain. 
Pygopus binds to BCL9 via the PHD domain [126, 127]. Via the same domain it can 
also bind methylated histones (H3K4me3) marks and is thereby thought to be involved 
in chromatin-mediated transcriptional control. However, Drosophila Pygopus was 
found not being able to bind to histones due to a single amino acid in the PHD [128]. 
BCL9 can also directly interact with some of -catenin’s C-terminal binding cofactors 
namely CBP/P300, TRRAP (Transformation/transcription domain-associated 
protein)/GCN5 (lysine acetyltransferase 2A) and enhance their binding (Fig. 4). 
Similarly, Pygopus has been found to interact with components of the Mediator 
complex in Drosophila. Both, BCL9 and Pygopus are also thought to have β-catenin-
independent functions which are under further examination [127, 129-131]. In 
Drosophila, mutants of legless (BCL9) and Pygopus have been found to result in 
phenotypes similar to that of the wingless (wg) mutant [126, 132]. Pygo1 null mice have 
been found to be viable and fertile, whereas Pygo2 null mice died shortly after birth. 
Thus in mice, loss of Pygo was found to lead to rather mild phenotypes in certain 
tissues like the kidney or in the lung [133, 134]. In mice Pygo2 has been found being 
ubiquitously expressed whereas Pygo1 seems to be mainly expressed in heart tissue 
[135]. Also, BCL9 and BCL9/L seem to be essential during development, since their 
knockout has been found to result in lethality. Also disrupting the interaction of BCL9/9L 
with Pygopus or β-catenin results in embryonic lethality enforcing the importance of 
those interactions during development [131].   
β-catenin’s dual function in signaling and cell adhesion, made it difficult to specifically 
study its signaling function. Observed phenotypes by β-catenin knockout could result 
from the loss of cell adhesion as well as from the loss of Wnt signaling activity. 
Therefore, to specifically characterize β-catenin’s function in Wnt signaling it is required 
to separate those two functions. In 2011, Valenta et al. generated mutant forms of β-
catenin/Armadillo only affecting its transcriptional function by ablating the binding of N-
terminal and/or C-terminal cofactors without affecting its binding to E-cadherin or 
TCF/LEF. The ΔC mutation leads to a truncation of the C-terminus of β-catenin/Arm 
and thereby prevents the binding of C-terminal transcriptional coactivators. The D164A 
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mutation in mice or D172A in Drosophila (DA) leads to an amino acid change from 
aspartic acid to alanine in codon 164 resulting in the abrogation of the binding of Bcl9 
and Bcl9L to the N-terminus. Finally, the double-mutant (dm) strain, β-catenin-D164A-
ΔC/D172A-ΔC combines both, the D164A mutation and the C-terminal deletion and 
thereby completely abrogates Wnt signaling. Thereby, they have found that both the 
N- and the C-terminal cofactors are important for β-catenin-mediated transcription. 
Amongst other experiments, they were using a TOPflash/FOPflash reporter assay and 
removed endogenous β-catenin/Arm in mouse embryonic fibroblasts (MEFs) derived 
from β-catenin conditional knockout mice (β-cateninflox/flox) and in Drosophila KC cells. 
Expression of the β-catenin/Arm mutant forms has revealed, that both the N- and the 
C- terminal coactivators are important for β-catenin’s transcriptional function. In mouse 
and Drosophila cells, the response to Wnt3a/Wg stimulation was diminished by the 
expression of the different mutant forms. However, in the murine cells, the 
transcriptional function was more affected by the loss of the C-terminal cofactors, 
similar to the effect of the dm mutation, compared to the N-terminal ones, whereas in 
Drosophila the opposite was found. These observations confirm previous results 
showing that loss of Pygopus or BCL9 does not entirely phenocopy the ablation of 
canonical Wnt signaling in mice unlike in Drosophila [126, 132, 133, 136]. In both mice 
and Drosophila, the dm was shown to completely block the Wnt/β-catenin/Arm 
transcriptional output. Subsequently Valenta and colleagues replaced endogenous β-
catenin by knock-in technology with its mutant forms and examined the effect in 
development. All three mutant forms were shown to be homozygous lethal. The 
embryos of ΔC mice, similar to β-catenin knockout mice were not able to undergo 
gastrulation, whereas the D164A mice developed normally until E10, from there on 
they started to show developmental defects. To further examine β-catenin’s signaling 
function during development, the mutant alleles were combined with a conditional 
knockout allele and a tissue-specific Cre driver. Crossing the mice with Wnt1-Cre mice 
showed that the β-catenindm/fl mice had a milder effect than the complete loss of -
catenin suggesting that this is due to the maintenance of the cell adhesion function. 
The β-cateninD164A/fl or β-cateninΔC/fl mutant had even less severe phenotypes than the 
dm mutant hence both seem to contribute to the transcriptional β-catenin output. 
Further examination specifically in the dorsal neural tube have demonstrated ablation 
of neuronal differentiation in the dorsal neural tube by expression of the dm allele, 
however no effects on proliferation or apoptosis were observed [137]. 
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.  
Figure 4. β-catenin interaction partners. (A) Overview of β-catenin interaction partners and their 
binding sites. β-catenin protein consists of a central region composed of 12 conserved armadillo repeats 
(numbered boxes) and an amino-terminal domain (NTD) and carboxy-terminal domain (CTD).  (B) 
Binding of C-Terminal transcriptional activators (CTTA) to β-catenin. The coloured bars depict 
experimentally validated binding sites for β-catenin interaction partners (purple: components of 
adherens junction complex; blue: members of the -catenin destruction complex; red: transcriptional co-
activators; green: transcription factors providing DNA binding; grey: transcriptional inhibitors. 
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2.2.2.4 Wnt signaling in mammary gland development 
Wnt signaling is known to play an important role in the morphogenesis of several 
organs during development. In mice, disruption of Wnt genes has been found to 
result in severe developmental defects. Wnt signals have been implicated playing a 
role of different processes like proliferation, migration, adhesion, tissue patterning 
and apoptosis. The canonical Wnt signaling pathway has also been found to be 
important for the development of the mammary gland. In the different stages of 
development, the expression of several members of the canonical Wnt pathway has 
been discovered. For example, cells expressing LRP1 (low density lipoprotein 
receptor-related protein 1) have been found having an increased capability to 
regenerate the mammary tree when transplanted into cleared mammary fat pad 
hence increases there stem cell activity, whereas loss of Lrp5 depleted this capability 
[138]. Furthermore, treatment of mammary stem cells (MaSCs) with Wnt3a in vitro 
enabled clonal expansion of the cells for several generations and retained their 
developmental potential in vivo [139].The morphogenesis of the mouse mammary 
gland starts on E10.5. Canonical Wnt signaling defines the cells of the mammary 
lines and subsequently localizes to the cells that form the placodes. In particular the 
expression of Wnt10b is found in cells of the mammary line. The five pairs of 
placodes are formed by those cells. Targeting components of the canonical Wnt 
pathway, such as Lrp6, Lrp5, Lef1 (lymphoid enhancer binding factor 1) and also 
Pygo2 has been found to lead to adverse effects resulting in reduced size or loss of 
the placodes. Stimulation of the canonical Wnt signaling, has been found to result in 
the opposite: an induction and expansion of the placodes. Also, the ectopic 
expression of the canonical Wnt inhibitor DKK1 in the surface epithelium inhibited 
placode formation. At E11.5-12.5 the cells invaginate into the mesenchyme and form 
buds. In Lef1-/- mice, the buds fail to invaginate [140]. Millar and colleagues have 
found by RT-PCR and in-situ hybridization the expression of several Wnts, Fzds 1-
9, Tcf1 (Tcf7), Tcf3 (Tcf7l1) and Tcf4 (Tcf7l2), Lef1, Dvl1 and Lrp5/6 in mammary 
buds [141]. Subsequently, around E15.5-16.5, the cells start to proliferate and sprout 
into the developing mammary fat pad. Branching is then initiated giving rise to the 
ductal tree. Also sprouting and branching has been found to be affected in Pygo2-/- 
and Lrp6-/- mice [142, 143]. The expression of Wnt1 or Wnt10b under the control of 
the MMTV-promotor has been found to induce hyperbranching of the ductal tree 
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[144, 145]. During puberty, the ovarian hormones produced lead to the expansion of 
the ductal tree throughout the mammary fat pads. During this process, enriched 
expression of Wnt5a  and Wnt7b has been discovered mainly in the terminal end 
buds (TEBs), which are proliferating structures located at the tips of the growing duct 
[140]. 
 
2.2.2.5 Wnt signaling in cancer 
Aberrations in the canonical Wnt signaling pathway have been found to cause a wide 
range of pathologies in humans. In many different cancer types mutations in at least 
one of the canonical Wnt signaling components have been found. In colorectal cancer, 
around 85% loss-of-function mutations in APC have been detected resulting in 
elevated β-catenin levels. Furthermore, mutations in β-catenin have been detected in 
many different cancer types, stabilizing β-catenin by affecting N-terminal 
phosphorylation sites. These mutations affect its targeted degradation by the 
destruction complex [146, 147]. Mutations in APC and -catenin have been found to 
be mutually exclusive. Axin loss-of-function mutations are also found in about 5-10% 
of HCCs (hepatocellular carcinoma cells) which again result in stabilization of β-catenin 
[148]. Amongst the target genes of the canonical Wnt signaling pathway are c-Myc and 
Cyclin-D1 (Ccnd1) which are important for cell cycle regulation. Association of nuclear 
β-catenin with upregulated expression of c-MYC and Cyclin-D1 are often found in 
cancer. In clinical studies, enhanced activity of β-catenin has been found to correlate 
with a poor prognosis in breast cancer patients [146, 149-151]. Another Wnt target 
gene, MMP7 (matrix metallopeptidase 7), has also been unveiled being upregulated in 
different cancer types and, similar to -catenin, its enhanced expression seems to 
correlate with poor prognosis. MMP7 is involved in ECM degradation and thereby can 
promote cancer invasion as well as activate other MMPs, like MMP2 (matrix 
metallopeptidase 2) and MMP9 (matrix metallopeptidase 9) [152]. The canonical Wnt 
pathway is also involved in the regulation of EMT (epithelial-to-mesenchymal 
transition). EMT is a process thought to be important for cells to gain invasive 
properties and thus contributing to metastasis formation. Wnt target genes, such as 
Snai2 (snail family zinc finger 2), Twist1 (twist basic helix-loop-helix transcription factor 
1) and Zeb1 (zinc finger E-box binding homeobox 1), also function as regulators of the 
EMT process. [75] The increased expression of Fibronectin1 (Fn1), another Wnt target 
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gene involved in EMT, has also been found to correlate with a worse clinical outcome 
in patients with invasive breast cancer [153]. Lgr5 (leucine rich repeat containing G 
protein-coupled receptor 5), another Wnt target gene which has been identified as a 
stem cell marker in the colon, intestine kidney and mammary gland, is also found to be 
aberrantly expressed in colon as well as other cancer cells [154-160]. Also, the N-
terminal cofactors of β-catenin BCL9/9L and Pygopus have been shown to have 
implications in cancer formation and progression. BCL9 was found to be aberrantly 
expressed in human multiple myeloma and colon carcinoma. Bcl9 overexpression 
furthermore increased cell proliferation, migration and invasion of tumor cells, 
knockdown of Bcl9 on the other hand also seemed to affect the localization of EMT-
related markers analyzed (E-cadherin, Vimentin and β-catenin) [161]. In another study, 
the loss of Bcl9/9l resulted in a decreased expression of intestinal stem cell markers 
and an impaired regeneration of the intestinal epithelium. Additionally, comparing wild 
type with Bcl9−/−/Bcl9l−/− colon tumor cell lines revealed that the loss of Bcl9/9l leads to 
a reduced expression of EMT and stem cell–associated markers [162]. Pygo2 
overexpression has been reported in ovarian, breast, cervical and lung cancers [163]. 
Pygo2 knockdown in HCC cell lines has been found to inhibit cell invasion and 
migration, whereas the opposite has been found upon ectopic expression of Pygo2. 
By binding to the E-cadherin promotor, it seemed to increase its methylation properties 
and thereby downregulate its expression. Additionally, PYGO2 seems to regulate E-
cadherin expression also indirectly by up-regulating Zeb2. Furthermore, Pygo2 
knockdown was able to inhibit HCC metastasis in vivo [163]. In lung cancer, Pygo2 
knockdown has been found to result in reduced proliferation in vitro and supressed the 
growth of lung cancer in a xenograft mouse model in vivo [164]. Many studies indicate 
that Wnt signaling also contributes to cancer progression by maintaining cancer stem 
cells (CSCs), a subset of cancer cells capable of self-renewal and differentiation into 
heterogeneous tumor cells. Wnt signaling in mammals is known to be involved in the 
control of maintenance, self-renewal and differentiation of stem cells. Studies in mice 
have led to the suggestion that aberrant canonical Wnt signaling can increase breast 
cancer risk by inducing early progenitor and stem cell accumulation. Several 
developmental pathways like the Notch, Hippo, Hedgehog as well as the Wnt signaling 
pathway have been found to drive CSC formation. Stem cells in cancer are able to self-
renew and are thought to contribute to the initiation, progression, reoccurrence and 
resistance to drug treatment of tumors [165, 166]. Expression of Wnt1 in human 
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mammary epithelial cells has been found to lead to an increased self-renewal of stem 
cells and resistance to apoptosis. MMTV-Wnt1 mice also showed an expanded stem 
cell population. In line with these observations were also the findings that mice 
expressing β-catenin or c-MYC driven by the MMTV-promoter showed similar results. 
In further studies, CSCs with higher activity of the canonical Wnt pathway have been 
found to be more tumorigenic. Moreover, the inhibition of the pathway decreased the 
amount of breast cancer metastases. Also, LGR4 (leucine rich repeat containing G 
protein coupled receptor 4) has been found to play a role in maintaining cancer stem 
cells in breast cancer and to modulate tumor initiation and metastases formation. The 
expression of LGR4 correlated with worse prognosis for breast cancer patients. Also 
in MMTV- PyMT and Wnt1 mouse models, its deletion inhibited tumor growth and 
metastases formation [167, 168]. Similarly, LGR5 has been found to be a marker for 
colorectal CSCs and LGR5 positive cells have been found to have an increased 
capacity to form colonies, self-renewal and tumorigenicity [169, 170]. Another study 
has revealed, that silencing of Lgr5 reduced proliferation, migration and colony 
formation of colorectal carcinoma cell lines in vitro and tumorigenicity in vivo [171]. 
Moreover, Wnt signaling has been shown to be able to promote the CSC phenotype in 
various cancer cell lines [172]. Hence, several cell surface markers that have been 
used to enrich for CSC populations relate to Wnt activity or are even canonical Wnt 
target genes like CD44 (CD44 antigen) and LGR5 [173, 174]. Targeting the Wnt 
signaling pathway proves to be quite a challenge since it is crucial during both normal 
embryonic development and throughout the life of the organism. There are only few 
FDA approved drugs that have been found to inhibit the canonical Wnt pathway, for 
example niclosamide downregulating DVL-1, sulindac affecting DVL and pyrvinium 
activating CK1α. These and a few others drugs are already in clinical trials as reviewed 
in [175, 176]. 
 
2.2.2.6 Wnt signaling in breast cancer 
Although mutations in the Wnt signaling pathway are observed in many cancer types, 
mutations in β-catenin or other canonical Wnt signaling components like AXIN or APC 
are only rarely found in breast cancer. However, there is evidence for aberrant Wnt/β-
catenin signaling activation in the majority of breast cancers which results in 
translocation of β-catenin to the nucleus and the subsequent transcription of its target 
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genes [2]. Hence by immunohistochemical staining elevated levels of cytoplasmic or 
nuclear β-catenin can be detected which is linked to reduced overall survival. 
Consistent with these findings, canonical Wnt target genes like Cyclin-D1 can be found 
to be upregulated in the majority of breast cancer patients [149]. This leads to the 
suggestion that further upstream and/or other pathways that lead to the stabilization of 
-catenin are deregulated. Experimental evidence suggests that the Wnt pathway in 
breast cancer may be changed by the loss of expression of negative pathway 
regulators or overexpression of individual Wnt ligands. For example, upregulation of 
Wnt2, Wnt4, Wnt7b and Wnt10b has been confirmed in a subset of breast cancers 
[177, 178]. Epigenetic silencing of negative pathway regulators like Wnt inhibitory 
factor 1 (WIF1), secreted frizzled-related protein (SFRP), Dickkopf 1 and Dickkopf 3 
(DKK1 and DKK3) as well as APC (Adenomatous polyposis coli) and also E-cadherin 
(CDH1) are found to be hypermethylated and their expression to be significantly 
reduced in human breast cancers [179-183]. Consistently, increased nuclear β-catenin 
is detected in many breast tumors. The modulation of the receptor activation might be 
another mechanism resulting in hyperactive Wnt/-catenin signaling. Aberrant splicing 
of Lrp5 affecting the interaction with DKK1, an extracellular antagonist has been 
discovered. In line with these results the upregulation of the Wnt signaling component 
DVL1 in breast cancer as well as the epigenetic silencing of inhibitors of DVL1 have 
been found [184-186]. Furthermore, nuclear co-factors of -catenin like BCL9 and 
PYGO2 have been found to be upregulated [187, 188]. In patient samples of ductal 
carcinoma and invasive ductal carcinoma, BCL9 expression has been shown to 
correlate with the tumor nuclear grade (grading system according to size and shape of 
the nucleus in the tumor cells) and ERBB2/HER2 expression [188]. Furthermore, 
knockdown of Bcl9 in in vivo and in vitro experiments showed that the proliferation and 
the migratory and invasive capability of ductal carcinoma in situ (DCIS) cells was 
inhibited [189]. Target genes like c-Myc and Cyclin-D1 (CCND1) seem to be amplified 
in many of human breast cancers [149, 190, 191]. The expression of Limb Heart Bud 
(LBH) embryonic patterning gene has also been found to be upregulated in tumors of 
MMTV-Wnt1 transgenic mice and in human breast cancers [192]. Twist1 (twist basic 
helix-loop-helix transcription factor 1), another Wnt target gene, has rather been found 
to be associated with increased invasion. Twist1 has been shown to be essential for 
metastasis formation from the mammary gland to the lung by the knockdown of Twist1 
in highly metastatic 4T1 cells and their injection into the mammary fat pad of BALB/c 
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mice, however no effect was observed on primary tumor formation [193]. Consistent 
with these findings, studies in mouse models have revealed that activated Wnt 
signaling leads to mammary tumorigenesis [3, 4]. The Wnt1 oncogene was first  
identified being activated by MMTV leading to hyperplasia and subsequently to 
development into mammary carcinomas. From then on, the oncogenic potential of 
different Wnts has been confirmed in the mammary gland. For example, transgenic 
expression of Wnt10b produced similar effects as MMTV-Wnt1 in mice [144]. 
Meanwhile, the deregulation of several Wnt components has been found to be able to 
induce tumor formation, for example in transgenic mice expressing stabilized β-catenin, 
and overexpressed Lrp or the loss of Apc in the mammary gland also leads to 
hyperplasia or tumor formation. Furthermore, Rspo2 expression under the control of 
the MMTV promotor alone or together with the expression of Wnt1 can also induce 
mouse mammary tumors [194]. Hence deregulation or ectopic Wnt ligand expression 
of Wnt ligands or mutations in pathway components like Axin, Apc or -catenin can 
induce tumorigenesis [140]. RNA sequencing in a chemically induced as well as in a 
transgenic (loss of Apc and Kras (Kirsten rat sarcoma viral oncogene homolog)) mouse 
model revealed that the ablation of Bcl9/9l abrogated the expression of genes related 
to EMT, stemness and intestinal Wnt targets [162, 195]. In a study from 2014 of 
Brembeck and colleagues have found that BCL9/L expression induced premalignant 
changes in the mammary gland and high ER expression which however seemed to be 
β-catenin independent. ER-positive breast cancers showed an increased expression 
of BCL9/L [196]. Also PYGO2 has been found to be upregulated in malignant breast 
tumors and several breast cancer cell lines and to be important for the proliferation of 
MF7 and MDA-MB-231 cell lines [197]. In the colon, tumor growth was also affected 
by Pygo2 loss in a chemically (AOM and DSS)-induced, Apc loss-of-function 
(Apclox(ex15)/lox(ex15)) and a Ctnnb1 gain-of-function (Ctnnb1lox(ex3)/+) tumor mouse model. 
Pygo2 loss was able to reduce the overexpression of Wnt target genes, like Lef/Tcfs, 
Axin2, Cyclin-D1, Ascl2 and Lgr5 in the Ctnnb1 GOF (gain-of-function) mice. Whereas 
this was not observed in the more severe Apc LOF (loss-of-function) mouse model in 
which the target genes seemed to be even higher upregulated, suggesting that Pygo2 
loss can reduce the canonical Wnt signaling output to a certain threshold [198]. Also 
in the MMTV-Wnt1 tumor mouse model, loss of Pygo2 delays tumor onset [187]. The 
expression of CD44, another direct Wnt target gene, has also been found to identify 
CSCs in primary and metastatic breast cancer [174]. The same is true for Epcr (Protein 
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C Receptor, Procr), a direct Wnt target that has been found to function as a mammary 
gland specific stem cell marker. Hypomorphic PyMT-EPCRLow/Low mice showed a 
reduced overall tumor burden as compared to controls. Moreover, using antibodies 
blocking the EPCR receptor revealed that blocking attenuates tumor initiation and 
growth when cells were injected into the mammary fat pad [199]. High Epcr levels have 
also been found to correlate with adverse clinical outcome in breast cancer patients 
[200].  
 
2.2.3 Epithelial-to-mesenchymal transition 
Epithelial-to-mesenchymal transition (EMT) is a process of cell remodelling critical 
during embryonic development and organogenesis. Epithelial cells are tightly packed 
in a highly organized tissue. The cells are connected by adhesion junctions, tight 
junctions, desmosomes and gap junctions [201]. During an EMT, the cells undergo 
morphological and functional changes: the epithelial cells lose the cell-cell connections 
by delocalization or degradation of the cell-cell junctions and also lose their apical-
basal polarity. Furthermore, ECM remodelling and changes in cell-matrix interactions 
take place as well as cytoskeleton rearrangements, thereby the epithelial cells convert 
to mesenchymal cells. These changes result in an elongated cell shape and an 
increased migratory and invasive capability. [202, 203] A hallmark of EMT is the loss 
of E-cadherin, a component of the adherens junction complex, which is subsequently 
replaced by N-cadherin. This process is also termed “cadherin switch” [204-206]. EMT 
is a plastic process and thus mesenchymal cells are able to convert back into epithelial 
cells by the so called mesenchymal-to-epithelial transition (MET) (Fig. 5)[201].  
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Figure 5. Schematic representation of structural and functional changes associated with EMT. 
Epithelial cells are connected via cell-cell junctions (desmosomes, adherens junctions and gap 
junctions) which are disassembled and lost during EMT. The apical-basal polarity of epithelial cells 
changes into a front-rear polarity and changes in ECM interactions are induced. Moreover, cortical F-
Actin is reorganized to actin stress fibres and ECM remodelling is induced facilitating migration and 
invasion. Cells are also able to revert from a mesenchymal to an epithelial state (MET) [207]. 
 
EMT is classified into three different subgroups based on the biological context. Type 
1 Developmental EMT, Type 2 EMT involved in physiological and pathological context 
like wound healing, tissue remodelling and fibrosis  and Type 3 oncogenic EMT [208]. 
During embryonic development, cells of the primitive streak undergo an EMT at the 
gastrulation stage to form the mesoderm and endoderm, the cells remaining in the 
epiblast become ectodermal and thereby form the three germ layers. Furthermore, 
EMT plays a crucial role during neural crest formation, heart valve formation and 
myogenesis. During embryonic development, several rounds of EMT and MET were 
found to take place. EMT is also induced by tissue injury or by inflammation. 
Keratinocytes, the skin epithelial cells are able to undergo an EMT and then migrate to 
reconstruct and repair the tissue. Also, chronic inflammation can lead to a sustained 
activation of EMT, leading to fibrosis by the increased production of ECM by the 
mesenchymal cells, finally resulting in organ failure. Oncogenic EMT describes the 
process observed in cancer cells. [203, 208, 209] Oncogenic EMT is thought to 
promote dissemination of cancer cells and the formation of metastasis. In order to 
establish a metastasis in a different organ it is thought that epithelial cells have to gain 
motile properties thereby EMT might contribute to the metastatic cascade. It is 
proposed that EMT provides cancer cells with the ability to intravasate into the blood 
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circulation, extravasation into distant organs where MET takes place for metastatic 
colonisation. Additionally, EMT is also implicated in anoikis resistance, evasion of 
immune surveillance, acquisition of stem-cell like properties and resistance to 
chemotherapy (Fig. 5) [203, 210, 211]. There are two prominent models of metastasis 
formation which are still debated. The linear model states that metastasis formation 
occurs at rather late stages of tumor progression, whereas in the parallel model it is 
thought that metastasis formation already occurs during earlier stages [212]. Due to 
EMT being a transient process, a full EMT is rarely observed in patients, and the 
involvement of EMT in metastasis formation is still under debate with some reports 
even questioning a pivotal role of EMT in metastasis formation. However, there are 
many observations demonstrating and supporting EMT/MET plasticity occurring in 
tumor cells and promoting metastasis formation. In vitro and in vivo studies have 
demonstrated that EMT promotes migration and invasion of tumor cells, whereas 
inhibition has been found to reduce metastasis formation [203, 210, 213]. Circulating 
tumor cells (CTCs) of patients have also been found to express rather mesenchymal 
markers as compared to the primary tumor tissue and show an increase in expression 
of stem cell markers [214-216]. Also, loss of E-cadherin correlates with a worse 
prognosis in several cancer types [217]. E-cadherin expression or membrane 
localization is for example lost in most lobular breast cancers [218]. However, it is often 
observed that tumor cells show a co-expression of epithelial and mesenchymal 
markers. Therefore, it is thought that rather a partial EMT might take place. It was for 
example shown, that CTCs co-express epithelial as well as mesenchymal markers 
[215]. Furthermore, the co-expression of epithelial and mesenchymal signatures has 
been found to correlate with enrichment of stem-like cells and a poor survival in luminal 
and basal breast cancer patients [219].  
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Figure 6. Schematic representation of the dissemination of cancer cells into distant organs. Cells 
from the primary tumor are thought to undergo EMT and thereby either as single cells or as clusters 
they invade the surrounding tissue, intravasate into the blood circulation, extravasate at a distant site 
and form micrometastasis. Those then undergo MET and establish macrometastasis. However by 
chemotherapy it might also be selected for cells that underwent EMT since they appear to be more drug 
resistant [213]. 
 
2.2.3.1 Wnt in EMT 
The canonical Wnt pathway is one of the pathways known to be able to regulate EMT. 
Several of its transcriptional downstream targets are involved in EMT and play a crucial 
role. One of the hallmarks of EMT is the downregulation of the cell-adhesion molecule 
E-cadherin and its loss at the cell membrane, thereby β-catenin can accumulate in the 
cytoplasm which can induce transcription of Wnt targets. Hence, E-cadherin by binding 
to β-catenin can compete with β-catenins transcriptional activity. Amongst the 
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canonical Wnt signaling target genes are Zeb1, Twist, Fibronectin and the 
transcriptional repressors Snai2 (Slug) and Snai1. Snai2 has been found being a direct 
target of the canonical Wnt pathway whereas Snai1 has been shown being regulated 
indirectly via GSK3β. GSK3β has been found being able to phosphorylate SNAI1 
resulting ultimately in its degradation. Hence, upon activation of the canonical Wnt 
pathway, GSK3β activity is inhibited resulting in an increased expression of Snai1 [220, 
221]. Transcription factor zinc-finger E-box bonding homeobox 1 (Zeb1), another Wnt 
target gene, is also able to repress E-cadherin expression but was furthermore found 
to induce the expression of mesenchymal genes [222]. Transcription factor, Twist can 
also transcriptionally repress E-cadherin but also downregulates other epithelial 
markers like claudins and occludins. Furthermore, Twist is able to upregulate the 
expression of the mesenchymal markers N-cadherin, Vimentin, MMPs, and Fibronectin 
[193, 223, 224]. Notably, Fibronectin and Mmp7 themselves are direct targets of 
canonical Wnt signaling. Matrix metalloproteases (MMPs) degrade the ECM and cell-
cell contacts thereby facilitating the detachment and migration of cells [225, 226]. Other 
target genes, which however might be indirectly regulated are enzymes involved in 
regulating cell adhesion stability, like Tiam1, and some are components of cell 
junctions, such as L1cam and Nr-cam, whereby the latter has been found to be a direct 
Wnt target gene [227]. Also Vimentin has been identified as a target of the canonical 
Wnt pathway in human breast cancer cell lines. Hence, many of the canonical Wnt 
target genes are involved in EMT and abrogating the canonical Wnt pathway has been 
found to affect EMT [162, 228-231]. However, even though the canonical Wnt 
pathways seems to be necessary to induce EMT in at least a subset of cells, it does 
not seem to be sufficient [232].   
 
2.2.4 Mouse models of metastatic breast cancer 
Mouse models enabled and significantly contributed to testing and elucidating 
mechanisms and genes involved in tumor progression and metastatic spread. 
Furthermore, they provide means to test novel therapeutic strategies. The ease of 
breeding them and maintaining them as well as the high level of molecular, genetic, 
cellular and physiological conservation between vertebrates make them a powerful tool 
for cancer research. However, mice also often respond differently than humans. 
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Carcinogens in mice are not per se carcinogenic for humans, and they can also 
respond distinctly to treatments. Furthermore, mimicking human genetic diseases in 
mice might results in different phenotypes. Hence, one has to make use of the 
similarities and to consider the present and known differences. Researchers now have 
access to a plethora of mouse models, each with its own advantages and limitations. 
This also true for mouse models for breast cancer [233, 234]. Tumor xenografts can 
be performed to investigate tumor growth and metastasis formation of human cell lines 
or patient material (PDX) in vivo. However, for such experiments immunocompromised 
or humanized mice have to be used. Further transplantation methods can be used as 
cancer cells can also be transplanted from one mouse to another genetically identical 
or closely related allowing the investigation of the contribution of an intact immune 
system (syngeneic transplantation). Furthermore, allotransplantation is the 
transplantation of mouse cells, tissues or organs in immunoproficient mice with the 
same genetic background. The site of injection or implantation also plays a crucial role 
in the outgrowth of the tumors or tumor cells and metastasis formation. Another 
possibility for studying human cancer is the use of genetically engineered mouse 
models (GEMM). In transgenic mice, cloned oncogenes can be expressed or the 
expression of specific genes can be ablated in knockout mice or modified in knock-in 
mice. Furthermore, different promotors can be used to drive the expression of 
oncogenes and transgenes [234, 235]. There are also different promotors driving the 
expression specifically or mainly in the mammary gland and hence can be used to 
examine breast carcinogenesis in mice. One of those promotors is the mammary tumor 
virus long terminal repeat  (MMTV LTR) leading to the expression mainly in the 
mammary epithelium, but also to low levels in other tissues as the ovaries and salivary 
glands [235, 236]. In this study we used the MMTV-PyMT mouse model, in which the 
expression of the oncoprotein polyoma middle T antigen (PyMT), is under the control 
of the MMTV LTR. Polyoma middle T antigen activates different signaling transduction 
pathways, including Src, Ras and PI3K. These pathways were also detected to be 
activated in human cancers. In this mouse model, multiple tumor foci can be found in 
all mammary glands. The progression from a premalignant to malignant stages is well 
recapitulated in these mice. At around 4 weeks of age, tumor growth is induced by 
steroid hormones during lactation. At the beginning, one primary focus around the main 
duct and sometimes some adjacent foci develop. The initially hyperplastic lesions are 
composed of lobules formed on the duct. Around 8 to 9 weeks of age, the progression 
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to the adenoma stage is visible by an increased proliferation of the epithelial cells with 
a still intact basement membrane and the cells start to fill the lumen. A transition to the 
malignant early carcinoma stage can be detected around 8 to12 weeks of age. Around 
10 weeks of age, in half of the mice, a progression to the late carcinoma stage can be 
found were no acinar structures are visible anymore and the tumors are composed of 
solid epithelial sheets. As the tumors progress through the different stages, expression 
of ER and PR is gradually lost, while an increase in the expression of ERBB2/HER2 
as well as Cyclin-D1 is observed. Furthermore, β-integrin expression, which has a role 
in cell proliferation, apoptosis and differentiation, is found being altered during tumor 
progression in this mouse model (Fig. 6). Hence this model shows many similarities to 
observations found in the progression of human breast cancer, in morphology but also 
with regard to biomarker expression and metastasis formation. Furthermore, this 
model shows a high penetrance, short latency and the formation of lung metastases, 
thereby it provides a tool to examine tumor progression as well as metastasis formation 
in breast cancer [237, 238]. 
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Figure 6. MMTV-PyMT tumor mouse model, tumor progression and biomarker expression. Four 
tumor stages are observed in the MMTV-PyMT breast cancer mouse model. The earliest stage 
(hyperplasia) starts around 4 weeks of age, further progressing via the adenoma stage with a visibly 
increased proliferation of the epithelial cells to an early- and then late carcinoma stage where the tumors 
are composed of solid epithelial sheets. Gross shows the development of the lesions in the mammary 
glands. H&E depicts the corresponding histology at the different stages of tumor progression. The 
cellular morphology panel schematically illustrates changes in the cytology and the integrity of the 
basement membrane. The Biomarkers panel depicts the changes in the biomarkers during tumor 
progression in the MMTV-PyMT mouse model [238]. 
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2.3 Aim of the study 
The canonical Wnt signaling pathway is often found to be aberrantly activated in human 
breast cancer and the expression of several components of the pathway is changed. 
Furthermore, nuclear β-catenin was found to correlate clinically in breast cancer 
patients. Therefore, in this project we aimed to examine the contribution of β-catenin 
signaling in mammary tumor progression and metastasis formation. In order to 
delineate the contribution of β-catenin and its interaction domains, β-catenin knockin 
mutant strains established by Valenta and colleagues, were used and examined [137]. 
The β-catenin-D164A mutation abrogates the binding of the N-terminal cofactors 
BCL9/9L to β-catenin whereas the β-catenin-ΔC mutant abrogates the binding of a 
plethora of coactivators binding to the C-terminus of β-catenin. The β-catenin-D164A-
ΔC strain combines both mutations which prevents the binding of N- and C-terminal 
coactivators and thereby should inhibit the canonical Wnt singling output. Those 
mutant forms do not abrogate the binding of E-cadherin and hence do not affect β-
catenin’s function in cell adhesion. Next to those mutant forms, conditional knockout 
mice carrying β-catenin floxed (fl) alleles were analyzed. Recombination in the 
mammary gland mediated by Cre under the control of the mouse mammary tumor virus 
(MMTV) long terminal repeat (LTR), allowed the examination of the loss of both of β-
catenin’s functions, in signaling as well as cell adhesion on mammary tumor profession 
and metastasis formation. Thereby we aimed to dissect the requirement of β-catenin 
for cell adhesion as compared to its transcriptional function. In order to delineate the 
effect of these modulations in breast carcinogenesis and metastasis formation a 
MMTV-PyMT transgenic mouse model was used. Female mice were examined at 12 
weeks of age and the weight of the tumors, the number of lung metastasis as well as 
tumor progression by quantification of the different tumor stages in the mouse models 
used, has been determined. Furthermore, for the mice carrying mutant forms of β-
catenin tumor cell proliferation and apoptosis was examined by immunofluorescence 
staining to determine the causes for alterations in tumor weight. From the tumors of 
the various genotypes, cell lines have been established to further examine the 
observed changes in vivo. Using the established cell lines, we aimed to assess β-
catenin’s transcriptional activities using a reporter assay to find out if the mutant forms 
are able to activate the canonical Wnt pathway to the same extent as the wild type 
cells upon Wnt3a treatment. Moreover, by treatment with transforming growth factor β 
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(TGFβ) and subsequent analysis we attempted to examine if altering the canonical 
Wnt output affects EMT, which might contribute to changes observed in metastasis 
formation. Additionally, by performing RNA sequencing we aimed to elucidate which 
target genes and signaling pathways are affected by the specific modulations of 
nuclear Wnt signaling upon activation of the pathway by Wnt3a and during EMT 
induced by TGFβ. By comparing the gene expression of wild type cells and the different 
β-catenin mutant forms we wanted to identify expression patterns and target genes 
specifically affected by the loss of N- and/or C-terminal coactivators. Thereby we 
wanted to distinguish target genes that are no more regulated in cell lines expressing 
the mutant forms of β-catenin and the target genes specifically regulated by N- or C-
terminal coactivators which might contribute to observed differences. Moreover, we 
sought to examine the effect of the complete abrogation of the canonical Wnt output 
using the dm form of β-catenin. Additionally, ChIP sequencing was performed to be 
able to generate a list of direct Wnt targets affected by the different mutations as 
compared to the wild type. Combining RNA and ChIP sequencing data will allow the 
detection of gene signatures or specific target genes affected by canonical Wnt 
signaling which might constitute promising novel therapeutic targets.   
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2.4.1 Abstract 
Aberrations in the Wnt signaling pathway have been found in correlation with poor 
prognosis in breast cancer patients. Although mutations in β-catenin and other 
canonical Wnt signaling components are only rarely found in breast cancer, there is 
evidence for aberrant Wnt signaling and β-catenin stabilization. However its role in 
breast cancer remains poorly defined. β-catenin exerts a dual role, it is the key nuclear 
effector of canonical Wnt signaling and is as well a crucial component of the E-cadherin 
mediated cell-cell adhesion complex. To provide a better understanding of β-catenin’s 
function in breast tumor progression and metastasis formation, functional in vivo 
analyses in a MMTV-PyMT mouse model were performed. The effect of a conditional 
β-catenin conditional knockout was analyzed and to further dissect the requirement of 
β-catenin for cell adhesion as compared to its transcriptional function, we used mice 
expressing mutant forms of β-catenin which retain its function in cell adhesion but lack 
the N- and/or C-terminal transcriptional outputs. Assessment of the tumor mass and 
number of lung metastases revealed a reduction in tumor mass in mice expressing 
mutant forms of β-catenin. The number of lung metastases was significantly reduced 
in the mutant strains in which the binding of N-terminal coactivators BCL9//9L is 
abrogated. Complementary in vitro experiments showed a significant reduction in 
canonical Wnt activity and the inability to bind to BCL9/9L affected EMT in vitro. RNA 
sequencing analyses of tumor-derived cell lines identified candidate genes, which 
seem to be either regulated by N- and C-terminal or specifically by N- or C-terminal 
coactivators upon Wnt3a or during EMT induced by TGFβ treatment. Furthermore, 
abrogating the binding of N- and C- terminal coactivators to β-catenin resulted in the 
almost complete abrogation of the canonical Wnt pathway output, showing only minor 
changes in some known Wnt target genes as well as pathway components. In 
conclusion, we show that abrogating the binding of N- and/or C-terminal β-catenin 
coactivators without affecting β-catenin’s function in cell adhesion, affects tumor 
growth in vivo, proliferation and alters the transcriptional output. On the other hand, β-
catenin knockout and thereby the complete loss of β-catenin’s signaling and adhesion 
function leads to apoptosis in mammary tumor cells in vitro and in vivo, which suggests 
a key role of its adhesion function in cell survival. Furthermore, the observations 
indicate that the inability of β-catenin to bind BCL9/9L are critical for a subset of Wnt 
target genes involved in EMT.  
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2.4.2 Introduction 
The canonical Wnt/β-catenin pathway is known to be important for several processes 
during the development, amongst them are stem cell maintenance, differentiation, 
homeostatic self-renewal and regulation of growth. Aberrations in this pathway have 
been found to cause a wide range of pathologies in humans [1]. Though, mutations 
affecting members of the Wnt signaling pathway are observed in many different cancer 
types, mutations in β-catenin or other canonical Wnt signaling components are only 
rarely found in breast cancer. However, aberrant activation of the Wnt/β-catenin 
signaling pathway resulting in translocation of β-catenin to the nucleus and the 
subsequent transcription of its target genes is found in the majority of breast cancers. 
Several components of the Wnt signaling pathway have been found to be differentially 
expressed in breast cancer [2-6]. Consistent with these findings Wnt1 was the first 
oncogene identified [7, 8]. The oncogenic potential of Wnts and other canonical Wnt 
pathway components has from then on been confirmed in the mammary gland [5]. For 
example, expression of stabilized β-catenin, overexpression of Lrp (low density 
lipoprotein receptor-related protein 5/6) or loss of Apc (adenomatous polyposis coli) in 
the mammary gland of transgenic mice have been shown to lead to hyperplasia or 
tumor formation [9-12]. Experimental evidence in patients suggests, that the Wnt 
pathway in breast cancer may be changed by the loss of expression of negative 
pathway regulators or overexpression of individual Wnt ligands. Negative pathway 
regulators like Wnt inhibitory factor 1 (WIF1), secreted frizzled-related protein (SFRP), 
Dickkopf 1 (DKK1) as well as APC, AXIN1 and AXIN2 have been found to be 
hypermethylated and their expression to be significantly reduced in breast cancer [13-
17]. Consistently, increased nuclear β-catenin can be detected in many breast tumors 
[5, 6]. β-catenin itself has a dual function: it is a crucial component of the E-cadherin 
mediated cell-cell adhesion complex needed for structural integrity and functional 
polarization of epithelia as well as the key nuclear effector of the canonical Wnt 
signaling pathway. Without Wnt ligand binding to the transmembrane receptors 
Frizzled (Fzd) and the single-pass transmembrane co-receptors LRP5/6, the pathway 
is in an off state and free cytosolic β-catenin is targeted and phosphorylated by the so-
called destruction complex. This complex is composed out of the scaffold proteins 
AXIN and APC and the kinases GSK3β (glycogen synthase kinase 3β), CK1α (casein 
kinase 1α) which phosphorylate β-catenin at amino-terminal serine and threonine 
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residues. Subsequently, β-catenin is degraded by the ubiquitin proteasome pathway. 
Whereas the binding of a canonical Wnt ligand to the transmembrane receptor Frizzled 
and its co-receptor LRP5/6 ultimately results in the destabilization of the destruction 
complex. Unphosphorylated β-catenin can accumulate in the cytoplasm and 
translocate to the nucleus where it binds to the TCF/LEF transcription factors [18, 19]. 
Different coactivators binding to β-catenin can modulate the transcriptional activity. At 
the C-terminus of β-catenin several coactivators have been found to bind which are 
not β-catenin specific. Amongst them are CBP (CREB binding protein, CREBBP), p300 
(E1A binding protein P300) and TIP60 (lysin acetyltransferase 5, KAT5) which can 
affect chomatin structure (chromatin remodeling complexes), SWI/SNF 
(SWItch/Sucrose Non-Fermentable) and ISWI (imitation Switch) which can affect 
nucleosome rearrangement or the Mediator complex which connects β-catenin to the 
transcriptional machinery. Whereas, at the N-terminus, the β-catenin specific cofactor 
BCL9/9L binds which in turn recruit Pygopus [19-22]. β-catenin’s dual function made it 
difficult to specifically study its signaling function and effect on tumor progression and 
metastasis formation. Therefore, to specifically characterize β-catenin’s role in Wnt 
signalling, it is required to separate those two functions. Valenta and colleagues have 
generated specific β-catenin mutant forms that only affect the transcriptional Wnt 
signaling activity of β-catenin but not its cell adhesion function. The D164A mutation 
abrogates the binding of the N-terminal β-catenin specific cofactor BCL9/9L, the ΔC 
mutation leads to a truncation of the C-terminus of β-catenin and thereby prevents the 
binding of C-terminal transcriptional cofactors involved in chromatin remodeling and 
transcriptional activation. The double-mutant (dm) combines both those mutations and 
thereby completely abrogates Wnt/ β-catenin signaling but preserves β-catenin’s 
function in cell adhesion [20]. Those mutant forms were compared to conditional 
knockout mice carrying β-catenin floxed (fl) alleles by which its function in cell adhesion 
and signaling are lost. In this study we exploit the functional role of β-catenin and its 
nuclear N- and C- terminal co-factors in breast tumor growth and metastasis formation 
in a MMTV-PyMT tumor mouse model in vivo and during EMT in cell culture assays in 
vitro. We show that loss of β-catenin and thereby its adhesion as well as signalling 
function, results in apoptosis in vitro and in vivo. Whereas, selective abrogation of the 
N- and/or C-terminal transcriptional output of β-catenin affects tumor progression and 
tumor cell proliferation. Lack of the N-terminal transcriptional output only or the 
complete abrogation of Wnt signaling activity in the double-mutant form of β-catenin 
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also affects metastasis formation in vivo and an epithelial-to-mesenchymal transition 
(EMT) in vitro. The results show that, as compared to the β-catenin knockout cells, cell 
deprived of only β-catenin’s transcriptional activity were viable, suggesting a key role 
of β-catenin’s adhesion function in cell survival. Additionally, the β-catenin mutant 
forms displayed a dominant-negative effect. Moreover, we wished to assess whether 
the nuclear Wnt signaling and some of its target genes could serve as potential 
diagnostic factors in vivo and as potential therapeutic targets for the specific ablation 
of Wnt signaling in metastatic cancer. RNA sequencing performed by using tumor-
derived cell lines showed that the different mutant forms of β-catenin alter the 
transcriptional output and target genes were identified which seem to be regulated 
either by N- and C-terminal or specifically by N- or C-terminal coactivators of β-catenin 
upon Wnt3a or during EMT induced by TGFβ treatment. Furthermore, abrogating the 
binding of coactivators to β-catenin in the double-mutant cell line resulted in almost 
complete abrogation of the canonical Wnt pathway output.  
 
2.4.3 Knockout of β-catenin leads to apoptosis in vitro and in vivo 
To evaluate the role of β-catenin in tumor progression and metastasis formation, β-
cateninfl/fl; MMTV-PymT; MMTV-Cre conditional knockout mice were generated. β-
cateninfl/fl; MMTV-PyMT; MMTV-Cre mice did not show significant differences in tumor 
weight, the number of lung metastases, the metastasis index or the different tumor 
stages comparing twelve-week-old Cre+ to Cre- control mice (Supplementary Fig. 1A, 
1B). Immunofluorescence (IF) staining of tumor sections revealed that β-catenin was 
still present in tumors of β-cateninfl/fl; MMTV-PyMT; MMTV-Cre conditional knockout 
mice (Supplementary Fig. 1C).  Also genotyping of the tumors demonstrated an 
incomplete deletion of the β-catenin gene in tumors (Supplementary Fig. 1D). The 
ability of Cre to delete β-catenin was also examined using GFP-reporter mice. 
Quantifying the recombination in 5- and 12-week-old mice revealed an incomplete and 
similar recombination efficiency between wild-type and β-catenin knockout mice at 5 
weeks of age. At 12 weeks of age the percentage of GFP-positive cells per tumor was 
reduced in β-catenin knockout mice whereas similar levels were observed in the wild 
type mice (Supplementary Fig. 1F). This revealed an incomplete deletion and suggests 
an outgrowth of GFP-positive wild-type cells, whereas GFP-positive β-catenin 
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knockout cells are eliminated. However, exogenous addition of Adenovirus-Cre-IRES-
GFP on primary tumor cell lines derived from β-cateninfl/fl; MMTV-PyMT tumors 
eliminated the β-catenin gene as assessed by genotyping and led to an increase in the 
amount of cleaved caspase-3 positive cells compared to the cells transduced with a 
control Adenovirus-IRES-GFP or to β-cateninwt/wt; MMTV-PyMT cells (Fig. 1A, 1B, 
Supplementary Fig. 1E). These results indicate that the presence of β-catenin is 
essential for tumor cell survival and that loss of its signaling as well as its adhesion 
function leads to cell death in vitro. Increased cleaved caspase-3 staining was also 
found in vivo, in tumor sections of β-catenin conditional knockout mice (5 weeks old, 
just after Cre activation) compared to β-catenin wild-type mice (Fig. 1C). These results 
suggest that there is a selection pressure during tumor progression, favoring the 
outgrowth of β-catenin-positive cells and reveal that β-catenin is required for mammary 
tumor cell survival.  
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Figure 1. Knockout of β-catenin leads to apoptosis in vitro and in vivo. (A) Infection of β-cateninwt/wt 
(Py2T) and β-cateninfl/fl cells with either Adeno-CRE-IRES-GFP or Adeno-IRES-GFP. GFP positive cells 
were lost only in β-cateninfl/fl cells upon infection with the Adeno-CRE-IRES-GFP virus. Scale bar: 100 
μm. (B) β-cateninwt/wt (Py2T), β-cateninwt/fl and β-cateninfl/fl cells were infected with either Adeno-CRE-
IRES-GFP or Adeno-IRES-GFP. The number of infected (GFP positive) and apoptotic (Cleaved 
Caspase 3 positive) cells revealed a significant increase in the amount of apoptotic cells upon knockout 
of β-catenin. Data are displayed as mean ± SEM. The results represent four independent experiments. 
Statistical analysis was performed using ordinary one-way ANOVA multiple comparison test: **** P < 
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0.0001. (C) Cleaved Caspase-3 quantification in vivo in mice at 5 weeks of age demonstrated a 
significant increase in the amount of apoptotic cells upon β-catenin knockout. White arrows indicate 
cleaved caspase-3 positive cells. DAPI was used to visualize nuclei. Scale bar: 100 μm. Data are 
displayed as mean ± SEM. n=5. Statistical analysis was performed using Mann-Whitney U test; **** P 
< 0.0001. 
 
2.4.4 Abrogating the binding of BCL9/9L to β-catenin affects tumor 
growth and metastasis formation 
To assess the importance of the binding of BCL9/9L, the β-catenin-specific cofactors 
for malignant breast tumor progression and metastasis formation, we examined the 
tumor growth and metastasis formation of mice harboring the D164A mutant form of β-
catenin. This point mutation leads to the abrogation of the binding of BCL9/9L to β-
catenin (Fig. 2A). Composite transgenic β-cateninD164A/fl; MMTV-PyMT as well as β-
cateninD164A/fl; MMTV-PyMT; MMTV-Cre 12-week-old mice showed a significantly 
lower tumor mass, less lung metastases  as well as a decrease in the metastasis index 
compared to age-matched control mice (β-catenin fl/fl; MMTV-PyMT) (Fig. 2B). 
Quantification of cleaved caspase-3 (apoptosis) and phospho-histone H3 (pH3, 
proliferation) IF staining on tumor sections revealed that the differences in tumor 
growth between mice expressing the D164A mutant allele and control mice seemed to 
be due to less proliferation (Fig. 2C), whereas no alteration in cleaved caspase-3 
expression was found (Supplementary Fig. 2A). When analyzing different stages of 
tumor progression of the PyMT tumor model (hyperplasia, adenoma and carcinoma) 
[238] it became apparent that mice with the D164A mutation have a lower carcinoma 
burden compared to control mice, suggesting a delay in tumor progression (Fig. 2D). 
Co-staining for E-cadherin and β-catenin showed co-localization at the cell membrane 
in mice expressing the D164A mutant β-catenin protein (Fig. 2E). This suggests that 
β-catenin D164A still maintains its function in the cell adhesion complex. Taken 
together these results show that binding of BCL9/9L to β-catenin is important for tumor 
cell proliferation, tumor progression as well as metastasis formation. Furthermore, the 
D164A mutation appears to exert a dominant negative effect, thereby reducing the 
tumor weight, metastasis formation and proliferation in vivo. 
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Figure 2. The β-catenin D164A mutation affects tumor growth, progression and metastasis 
formation. (A) Schematic representation of wild-type and mutant versions of β-catenin (left) used in this 
study and the abrogation of the binding of coactivators (right). Wild-type β-catenin can be divided into 
three distinct domains: an N-terminal region, which binds BCL9; a central Armadillo (Arm) repeat region 
(ovals), which binds TCF/LEF and E-cadherin; and a C-terminal region that binds several transcriptional 
coactivators. The D164A mutation (D>A)  in the first Arm repeat leads to an amino acid change from 
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aspartic acid to alanine resulting in the abrogation of the binding of BCL9 (β-catenin specific cofactor-
cell CLL/lymphoma 9) and BCL9L (β-catenin specific cofactor-cell CLL/lymphoma 9-like) to the N-
terminus. The ΔC mutation leads to a truncation of the C-terminus of β-catenin and thereby prevents 
the binding of C-terminal transcriptional coactivators. Finally, the double-mutant (dm) strain, β-catenin-
D164A-ΔC combines both, the D164A mutation and the C-terminal deletion and thereby completely 
abrogates Wnt signaling. Black crosses represent the abrogated interactions. The unique and important 
feature of these mutant forms of β-catenin is that they lack either the N- or C-terminal transcriptional 
output or both but retain the cell adhesion function of β-catenin. (B) The mammary glands and the lungs 
of twelve week old (Cre+ and Cre-) mice of the  D164A mutant mouse strains were dissected and the 
tumor weight as well as the number of lung metastases were compared to β-cateninfl/fl; PyMT (wild type) 
control mice. The β-catenin D164A mutation causes a reduction in the size of the tumors (β-cateninfl/fl 
n=21, β-cateninD164A/fl n=27, β-cateninD164A/fl; MMTV-Cre (MCre) n=29), the number of lung metastases 
as well as in the metastasis index. β-cateninfl/fl n=15, β-cateninD164A/fl n=18, β-cateninD164A/fl; MCre n=21. 
(C) Immunofluorescent staining and quantification for pH3 to assess proliferation on tumor sections of 
the different mouse genotypes. White arrows indicate pH3 positive cells. Tumor sections from mice 
expressing the D164A mutant allele have less proliferating cells (pH3) compared to control mice. DAPI 
was used to visualize nuclei. Scale bar: 100 μm. n=10.   (D) Quantification of tumor stages, mice with 
the D164A mutation have less carcinoma than the control mice. β-cateninfl/fl n=7, β-cateninD164A/fl n=7, β-
cateninD164A/fl; MCre n=12. (E) Immunofluorescence staining on tumor sections for E-cadherin and β-
catenin, showed co-localization at the cell membrane in mice expressing the D164A mutant β-catenin 
protein. DAPI was used to visualize nuclei. Scale bar: 100 μm. Data are displayed as mean ± SEM. 
Statistical analysis was performed using ordinary one-way ANOVA multiple comparison test: * P < 0.05, 
** P < 0.01, *** P < 0.001, **** P < 0.0001. 
 
2.4.5 Binding of C-terminal coactivators is essential for tumor 
growth but not for metastasis formation 
To evaluate the importance of C-terminal coactivators binding to β-catenin and their 
effect on tumor growth and metastasis formation, we examined the effect of the ΔC 
mutant form of β-catenin. This mutation abrogates the interaction with a multitude of 
coactivators that bind to the C-terminus of β-catenin thereby affecting the canonical 
Wnt signaling output (Fig. 2A). When analyzing mice with the ΔC mutation, we found 
that the β-cateninΔC/fl; MMTV-PyMT and the β-catenin ΔC/fl; MMTV-PyMT; MMTV-Cre 
mice have significantly smaller tumors compared to the β-catenin fl/fl; MMTV-PyMT 
mice. Hence, the ΔC mutant protein also seems to have a dominant negative effect. 
Yet surprisingly, no difference was seen comparing the amount of metastases in the 
lungs or in the metastasis index (Fig. 3A). To examine if the observed differences in 
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tumor size between the genotypes are due to changes in proliferation and/or apoptosis, 
pH3 and cleaved caspase-3 immunofluorescence staining were conducted, a 
significant decrease in proliferation was observed comparing the mice expressing the 
ΔC mutant allele to the control mice (Fig. 3B, Supplementary Fig. 2B). Moreover, 
analysis of the different tumor stages did not reveal any significant changes (Fig. 3C). 
Additionally staining for E-cadherin and β-catenin showed co-localization at the cell 
membrane in mice expressing the ΔC mutant form of β-catenin (Fig. 3D). In conclusion, 
these results show that the diverse cofactors of β-catenin binding to the C-terminus 
are important for tumor growth and proliferation, whereas the target genes of canonical 
Wnt signaling affected by this mutation do not seem to be important for tumor 
progression and metastasis formation. Moreover, in regards to proliferation and tumor 
weight, a dominant negative effect is observed. 
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Figure 3. Abrogating the binding of C-terminal coactivators to β-catenin reduces tumor growth. 
(A) The mammary glands and the lungs of twelve week old (Cre+ and Cre-) mice of the ΔC  mutant 
mouse strains were dissected and the tumor weight as well as the number of lung metastases were 
compared to β-cateninfl/fl; PyMT (wild type) control mice. The β-catenin ΔC mutation causes a reduction 
in the weight of the tumors (β-cateninfl/fl n=20, β-cateninΔC/fl n=34, β-cateninΔC/fl; MMTV-Cre (MCre) n=30) 
but does not affect metastases formation or the metastasis index. β-cateninfl/fl n=20, β-cateninΔC/fl n=24, 
β-cateninΔC/fl; MCre n=22. (B) The truncated C-terminus results in a reduction of proliferating cells as 
compared to wild type mice. White arrows indicate pH3 positive cells. DAPI was used to visualize nuclei. 
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n=10. (C) The quantification of tumor stages did not show differences comparing the ΔC and wild type 
mice. β-cateninfl/fl n=6, β-cateninΔC/fl n=7, β-cateninΔC/fl; MCre n=8. (D) Immunofluorescence staining on 
tumor sections for E-cadherin and β-catenin, showed co-localization at the cell membrane in mice 
expressing the ΔC mutant β-catenin protein. DAPI was used to visualize nuclei. Scale bar: 100 μm. Data 
are displayed as mean ± SEM. Statistical analysis was performed using ordinary one-way ANOVA 
multiple comparison test: ** P < 0.01, **** P < 0.0001. 
 
2.4.6 Block of transcriptional β-catenin output decreases tumor 
growth and metastasis formation 
In order to investigate the effect of complete abrogation of canonical Wnt signaling 
without affecting β-catenin’s function in cell adhesion, we made use of the double-
mutant (dm) form of β-catenin (Fig. 2A). In dm mice harboring both mutations (the 
D164A as well as the ΔC), we also observed smaller tumors, significantly less 
metastases in the lungs and a decrease in the metastasis index of both, the β-catenin 
dm/fl; MMTV-PyMT; MMTV-Cre and the β-catenin dm/fl; MMTV-PyMT mice compared to 
the β-catenin fl/fl; PyMT mice (Fig. 4A). To understand the differences in tumor weight, 
IF stainings for pH3 and cleaved caspase-3 were conducted. A significant decrease in 
the amount of pH3-positive cells and a significant increase in the amount of cleaved 
caspase-3-positive cells was observed in tumors of both β-catenin dm/flox; MMTV-PyMT; 
MMTV-Cre and the β-catenin dm/flox; MMTV-PyMT mice compared to the β-catenin fl/fl; 
MMTV-PyMT mice (Fig. 4B, Supplementary Fig. 2C). In addition, analysis of the 
different tumor stages revealed a trend towards less carcinoma in the mice harboring 
the dm mutation compared to the control mice (Fig 4C). In addition, also the β-catenin 
dm mutant form displayed a dominant-negative effect on tumor growth, tumor 
progression and metastasis formation. Moreover, the double mutation does not seem 
to affect β-catenin’s function at the cell membrane, since it still colocalizes with E-
cadherin as assessed by IF staining (Fig. 4D). These results show that a complete 
abrogation of the canonical Wnt signaling output represses tumor growth by affecting 
again proliferation but also apoptosis and it reduces metastasis formation and 
malignant tumor progression. 
 It should be noted that the mutant versions of β-catenin all seem to exert a dominant-
negative effect, since the expression of the mutant forms in the presence of the wild-
type allele results in a similar phenotype as the sole expression of the mutant alleles. 
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The notion of a dominant-negative effect was tested by transient transfection of β-
cateninwt, β-cateninD164A, β-cateninΔC and β-cateninD164A-ΔC and a GFP expressing 
vector construct in a β-catenin wild-type cell line (Py2T). The number of transfected 
and proliferating cells was quantified by MYC and pH3 staining, which revealed a 
reduced proliferation of cells transfected with the β-catenin mutant (D164A, ΔC and 
D164A-ΔC) forms (Supplementary Fig. 2D). This data showed that the mutant forms 
of β-catenin exert a dominant negative effect on proliferation also in vitro. 
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Figure 4. Blocking the canonical Wnt signaling output reduces tumor growth, tumor progression 
and metastasis formation. (A) The mammary glands and the lungs of twelve week old (Cre+ and Cre-) 
mice of the dm mutant mouse strains were dissected and the tumor weight as well as the number of 
lung metastases were compared to β-cateninfl/fl; PyMT (wild type) control mice. The β-catenin double 
mutation causes a reduction in the size of the tumors (β-cateninfl/fl n=20, β-catenindm/fl n=15, β-catenindm/fl; 
MMTV-Cre (MCre) n=16), the number of lung metastases and the metastasis index. β-cateninfl/fl n=16, 
β-catenindm/fl n=14, β-catenindm/fl; MCre n=16. (B) Assessment of the amount of proliferating or apoptotic 
cells by immunofluorescent staining on tumor sections revealed, that the double mutation causes a 
reduction in the amount of proliferating cells compared to wild type mice. White arrows indicate pH3 
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positive cells. DAPI was used to visualize nuclei. n=10. (C) A reduction in the amount of carcinoma 
stage was found in the dm mice as compared to wild type tumor sections. β-cateninfl/fl n=14, β-catenindm/fl 
n=12, β-catenindm/fl; MCre n=12. (D) Immunofluorescence staining on tumor sections for E-cadherin and 
β-catenin, showed co-localization at the cell membrane in mice expressing the dm mutant β-catenin 
protein. DAPI was used to visualize nuclei. Scale bar: 100 μm. Data are displayed as mean ± SEM. 
Statistical analysis was performed using ordinary one-way ANOVA multiple comparison test: * P < 0.05, 
** P < 0.01, *** P < 0.001. 
 
2.4.7 Loss of N- and C-terminal coactivators completely abrogates 
canonical Wnt activity and the inability of β-catenin to bind BCL9/9L 
results in an abrogated EMT response 
In order to further examine the effects of the different β-catenin mutant forms on 
canonical Wnt activity and to validate the results in the transgenic mouse models by in 
vitro experimentation, we established cell lines from the different mouse genotypes. 
Epithelial cell lines were established from the different mutant β-catenin heterozygous 
tumors and the floxed alleles were removed by infection with Adeno-CRE-IRES-GFP 
virus and subsequent flow cytometry sorting for GFP-positive cells (Supplementary Fig. 
3A, 3B). To determine if the alterations in cell proliferation observed in vivo can also 
be observed in vitro, growth curve analysis for the different cell lines established was 
performed. The results revealed a slower proliferation rate and a higher doubling time 
of the cells solely expressing the mutant forms of β-catenin compared to a wild-type 
cell line (Fig. 5A). In the previous study,  Valenta and colleagues showed in HEK293T 
and MEF cells as well as in vivo during mouse embryonic development that the binding 
of N- and C-terminal coactivators are important for proper transcriptional activity of the 
canonical Wnt pathway and that it can be completely abrogated by expression of the 
dm protein [137]. To examine the canonical Wnt signaling output in vitro in mammary 
tumor-derived cell lines, the canonical Wnt signaling pathway was induced by addition 
of Wnt3a. Analysis using the Wnt reporter assay (superTOPflash/superFOPflash) 
revealed a decreased activation capacity of the canonical Wnt pathway of the cell lines 
solely expressing the mutant forms of β-catenin compared to wild-type cell lines (Fig. 
5B). These results show that the N- and C-terminal coactivators both contribute to the 
transcriptional output and the dm form blocks β-catenin’s signaling function. 
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Since EMT is regarded a possible mechanism underlying metastatic spread, we 
assessed whether the loss of β-catenin coactivator binding in the different β-catenin 
mutant forms might affect EMT. Therefore, a 4-day TGFβ treatment was performed 
comparing wild-type cells and the cell lines only expressing the mutant alleles for their 
ability to undergo EMT. Morphological differences were apparent between the cell lines. 
The β-catenin wild-type cell lines became more mesenchymal upon 4 days of TGFβ 
treatment and the same was true for the β-cateninΔC/- cell line. The morphology of the 
β-cateninD164A/- cells became more elongated as well, but they still grew as a cluster of 
cells, whereas the β-catenindm/- cell line remained in their epithelial clusters and only 
seemed to form filopodia (Fig. 5C). Also long-term (20d) TGFβ treatment did not further 
alter the morphology of the β-cateninD164A/- and β-catenindm/- cell lines (Supplementary 
Fig. 5C). Further analysis by IF staining for different EMT-related markers after 4 days 
of TGFβ treatment (E-cadherin, β-catenin, Zonula occludens (ZO-1) and Vimentin) 
revealed an augmented expression of the mesenchymal marker Vimentin and the 
reduced expression of the epithelial markers E-cadherin together with β-catenin and 
ZO-1 at the cell membrane in the wild-type as well as the β-catenin ΔC/- cell line. In 
contrast, β-cateninD164A/- and β-catenindm/- cell lines seem to undergo a partial EMT by 
retaining the expression of E-cadherin/β-catenin and ZO-1 at the cell membrane, but  
the β-cateninD164A/- cells were still able to upregulate the expression of Vimentin, 
whereas the dm cells only showed a mild increase (Fig. 5D, Supplemental Fig. 3D). 
Moreover, co-immunoprecipitation showed that the interaction of β-catenin with E-
cadherin was retained and not affected by the β-catenin mutations (Supplementary Fig. 
3E). Those results seem to confirm the observations in vivo showing that the D164A 
as well as the dm form of β-catenin lead to a reduction in metastasis formation, 
whereas the ΔC mutation did not have a significant effect. Consequently, the results 
show alteration of the canonical Wnt output by the D164A or ΔC mutation have a mild 
effect on the Wnt/β-catenin activity, whereas it is completely abrogated by the  double 
mutation. In addition, the D164A and the dm mutant β-catenin-expressing cell lines 
have a reduced capability to undergo EMT which might account for the reduced 
metastatic burden observed in vivo. Furthermore, since we were able to obtain cell 
lines only expressing the mutant forms of β-catenin but not cell lines without any β-
catenin, we conclude that β-catenin’s adhesion function is critically required for 
mammary tumor cell survival, while its transcriptional output promotes tumor cell 
proliferation and survival, tumor growth, EMT and metastasis formation. 
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Figure 5. Expression of β-catenin mutant forms results in a reduced growth and capability to 
activate the canonical Wnt signaling pathway as well as an abrogated EMT response by 
inhibition of BCL9/9L binding. (A) Comparing the growth curves of β-cateninfl/fl, β-cateninD164A/-, β-
cateninΔC/- and β-catenindm/-  cell lines revealed that cell lines expressing mutant forms of β-catenin grow 
slower and have an higher doubling time. (B) Wnt reporter assay (superTOPflash/ superFOPflash). β-
catenin mutant forms have a reduced response to TCF/LEF-dependent Wnt signaling upon Wnt3a 
treatment. The double-mutant (dm) form blocks the transcriptional β-catenin signaling output. The 
results represent four independent experiments. Data are displayed as mean ± SEM. Statistical analysis 
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was performed ordinary one-way ANOVA multiple comparison test: ** P < 0.01, **** P < 0.0001. (C) The 
β-catenin wild type cell line shows a mesenchymal morphology upon TGFβ treatment and the same was 
true for the β-cateninΔC/- cell line. The morphology of the β-cateninD164A/- became more elongated as well, 
but they still grew as a cluster of cells whereas the β-catenindm/- cell line only seem to form filopodia. 
Scale bar: 100 μm. (D) Further analysis by immunofluorescence stainings for β-catenin and the EMT 
related marker (E-cadherin) revealed a reduced expression of the epithelial markers E-cadherin at the 
cell membrane in the wild type as well as β-cateninΔC/- cell lines. In contrast, β-cateninD164A/- and β-
catenindm/- cell lines are retaining some expression of E-cadherin and β-catenin at the cell membrane. 
DAPI was used to visualize nuclei. Scale bar: 100 μm. 
 
2.4.8 β-catenin N- and C- terminal coactivators contribute to the 
expression of specific Wnt target genes and alter the regulation of 
Wnt pathway components 
In order to better comprehend and examine alterations in the activation of target genes 
as well as canonical Wnt signaling pathway components affected by the various mutant 
forms of β-catenin in our breast tumor cell lines, we performed RNA sequencing. This 
could give more insights on which canonical Wnt target genes might contribute to the 
observed alterations in vivo and in vitro.  The cells were treated for three or four days 
with Wnt3a or TGFβ, respectively, to analyze the impact of the β-catenin mutant forms 
on canonical Wnt signaling and EMT. Thereby, we wanted to examine which canonical 
Wnt target genes induced by Wnt3a or TGFβ treatment are no more regulated in the 
mutants and which target genes are specifically regulated by the interaction with N- or 
C- terminal coactivators. Unsupervised hierarchical clustering of the cell lines 
according to the top 500 most variable genes revealed, that the cell lines cluster 
according to the β-catenin mutation but not according to the treatment (Fig. 6A). 
Moreover, comparative gene expression profiling was performed, and a selected list of 
direct Wnt target genes (genes with TCF binding sites in their promoter regions)  was 
examined (taken from     https://web.stanford.edu/group/nusselab/cgi-
bin/wnt/target_genes) and supplemented with known Wnt target genes previously 
identified in the mammary gland (Fig. 6C, 6D) [140].  Furthermore, the expression of 
Wnt pathway components was analyzed (Lrp 5/6, Fzd1-10, Dvl1-3, Axin1/2, Apc, Ck1α, 
Pp2a, Gsk3β, Ctnnb1, Bcl9/9l, Pygo1/2, Tcfs and Lef1 as well as Wnt ligands) 
(Supplementary Fig. 4A, 4B). For the TGFβ-treated cells, additionally the expression 
of EMT-related Wnt targets was examined (Fig. 6E). Comparison of untreated (control) 
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to Wnt3a-treated wild-type cells revealed the upregulation upon Wnt3a treatment of 
426 and the downregulation of 1177 genes. In the mutant cell lines, less genes are 
differentially expressed upon Wnt3a treatment: In the β-cateninD164A/-   cell line 306 
genes were up- and 179 down-regulated, in the β-cateninΔC/- 66 and 404 genes were 
up- and down-regulated, respectively. In the β-catenindm/- cells, however, only 33 genes 
were up- and 24 genes were down-regulated (Fig. 6B). Hence, the Wnt3a treatment 
resulted only in minor changes in the transcriptional output of the double-mutant cell 
line. In terms of Wnt target genes, some seemed to be regulated via the N- as well as 
C-terminal coactivators, since the target genes Axin2, Tcf7 showed a diminished, but 
still significant upregulation in the β-cateninD164A/- and β-cateninΔC/- cell line. Thus, the 
C-terminal as well as the N-terminal coactivators seemed to contribute to their 
expression. However, some genes appeared to be specifically regulated by the N-
terminal (Procr) or C-terminal coactivators (Lbh, Notum), since the upregulation of 
these genes was lost in the β-cateninD164A/- and β-cateninΔC/- cell lines, respectively. In 
terms of known Wnt target genes the β-catenindm/- cells showed a significant 
upregulation of Tcf7, Stra6 (stimulated by retinoic acid 6) and Wisp1. However, these 
target genes are not as strongly upregulated as in the wild-type cells. Hence, in the β-
catenindm/- cell line, the regulation of most canonical Wnt targets seems to be prevented 
(Fig. 6C). Expression changes of canonical Wnt pathway components were observed 
in all cell lines. Some of these are known to be Wnt target genes as well and thereby 
constitute possible feedback regulation of the pathway. β-catenindm/- cells mainly 
showed a trend towards upregulation of the Wnt cell membrane receptor Fzd2 and an 
upregulation of the transcription factors Tcf7 and Tcf7l2. In the β-cateninD164A/- and the 
β-cateninΔC/- cells less genes were differentially regulated as compared to the wild-type 
cells, they either showed no regulation or only a trend in expression as the wild-type 
cells (Supplementary Fig. 4A). Taken together, with this approach we were able to 
identify candidate genes, which seem to be either regulated by N- and C-terminal or 
specifically by N- or C-terminal coactivators binding to β-catenin. Furthermore, 
abrogating the binding of coactivators to β-catenin in the β-catenindm/- cell line results 
in the almost complete abrogation of the canonical Wnt pathway showing only minor 
changes in some known Wnt target genes as well as pathway components. A complete 
list of Wnt target genes upon Wnt3a treatment will be generated from ChIP results and 
thereby direct target genes lost by the specific β-catenin mutant forms will be identified.  
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Next, we sought to elucidate the effect of the different mutant forms during EMT upon 
TGF treatment to identify genes that are transcriptionally regulated by β-catenin. Here, 
also several Wnt target genes showed differential expression upon EMT induction. In 
this experiment, the target genes Axin2 and Notum showed the completely opposite 
trend, a downregulation upon TGFβ treatment as compared to the increased 
expression upon Wnt3a treatment. Furthermore, the significant downregulation of 
Notum seemed to be ablated by the loss of binding of the N-terminal cofactor, whereas 
a significant regulation of Axin2 was only observed in the wild-type cells. Interestingly, 
Procr was as well specifically regulated by the N-terminal coactivators upon TGFβ 
treatment, since it was only up-regulated in wild-type and in β-cateninΔC/- cells. Vegfa 
showed a significant up-regulation in the wild-type and in β-cateninD164A/- cells, while 
this was not the case for the β-cateninΔC/- and β-catenindm/-cell lines, suggesting a 
regulation mainly by C-terminal coactivators (Fig. 6D). Examining EMT-related Wnt 
targets revealed that E-cadherin is only significantly down-regulated in the wild-type 
cells, whereas mesenchymal markers like Fn1, Vimentin, Zeb1 and Zeb2 were up-
regulated in all cell lines. Furthermore, Snai2 expression was up-regulated in the wild-
type cells, whereas it showed the opposite trend towards downregulation in the mutant 
cell lines (Fig. 6E). With regard to the expression of the Wnt components, many more 
changes were observed upon TGF treatment than upon Wnt3a treatment. Differential 
expression was observed in all cell lines, although the wild-type and β-catenindm/-cell 
lines showed the most significant differences, for cell membrane receptors Fzds, 
transcription factors Tcf7, Tcf7l1 and Tcf72l and Wnt ligands which included non-
canonical Wnt ligands.  
These results show, that upon TGFβ treatment we see alterations in Wnt pathway 
components as well as in Wnt target genes. However, some genes show an opposite 
expression trend as upon Wnt3a treatment and hence regulation might be context-
specific. Moreover, mesenchymal markers, as for example vimentin and fibronectin as 
well as EMT-related transcription factors show upregulated expression in both, the 
mutant forms and wild-type cells, yet for example Snai2 shows a differential regulation 
in the mutant cell lines (Fig. 6D, 6E). In conclusion, we see many alterations in the Wnt 
pathway upon TGFβ treatment. Furthermore, there seems to be a context-specific up 
or down-regulation of certain Wnt target genes. We detect target genes that seem to 
be specifically regulated by either the N- or the C- terminal coactivators during EMT. 
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The mutant forms of β-catenin are able to alter and partially ablate the EMT response 
as compared to wild-type β-catenin, however, the cell lines are still able to upregulate 
most of the mesenchymal genes examined. To further explain the morphological 
differences and the alterations observed by immunofluorescent staining for EMT-
related markers, (Fig. 5C, 5D), the direct Wnt target genes detected in the ongoing 
ChIP experiment will be analyzed which may help to understand the mechanistic role 
of β-catenin during EMT. 
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Figure 6. Ablating the binding of N- and/or C- terminal coactivators to β-catenin affects the 
expression of specific Wnt target genes. (A) Dendrogram and heatMap for Unsupervised Hierarchical 
Clustering of cell lines treated with Wnt3a (+ Wnt3a) or TGFβ (+TGFβ) and their respective untreated 
controls (- Wnt3a, - TGFβ). Samples cluster into 4 major clusters according to their genotype. The 
colours indicates the correlation value. (B) Number of differentially expressed genes upon Wnt3a or 
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TGF-β treatment in the different cell lines. Red represents up-regulated expression and blue down-
regulated expression. P ≤ 0.05 and fold change ≥ 1.5. (C) Heatmap showing the log2 fold changes of 
examined Wnt target genes,that are significantly differentially expressed in at least one of the cell lines 
upon Wnt3a treatment. (D) Heatmap showing the log2 fold changes of Wnt target genes and (E) EMT 
related Wnt targets examined, being significantly differentially expressed in at least one of the cell lines 
upon TGFβ treatment. Red represents up-regulated expression and blue down-regulated expression. P 
≤ 0.05 and fold change ≥ 1.5. 
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2.5 Discussion 
2.5.1 Effect of β-catenin knockout in mammary tumor cells 
The canonical Wnt signaling pathway is often found aberrantly activated in human 
carcinomas. This is also true in breast cancer were aberrations in the Wnt signaling 
pathway have been found to correlate with poor prognosis in breast cancer patients. 
To provide a better understanding of β-catenin’s function in breast tumor progression 
and metastasis formation, in this study we performed functional in vivo analyses in the 
MMTV-PyMT transgenic mouse model of metastatic breast cancer. To further 
characterize the functional impact of ablating the canonical Wnt signaling output, we 
used cell lines established from the different genotypes from our mouse model. The 
examination of the canonical Wnt signaling pathway has several obstacles: the 
pathway is important for many different mechanisms during development and shows a 
complexity on different levels. From the 19 Wnt ligands, several are able to activate 
the canonical Wnt pathway and some of which can also activate the non-canonical Wnt 
signaling pathways. There are also several Wnt receptors and by distinct receptor-
ligand pairings can either activate the canonical or non-canonical pathway [68, 239]. 
Components of the destruction complex in the cytoplasm like GSK3β have regulatory 
roles in many other cellular processes. There are also multiple members of the 
TCF/LEF family which are cell context-dependent and exhibit individual specificities 
and, without binding of β-catenin, together with Groucho/TLE act as transcriptional 
repressors [75]. Hence, for all these components different spatial temporal 
combinations exist. β-catenin is the non-redundant component of the canonical Wnt 
pathway. However it also plays an important function in the E-cadherin-mediated cell 
adhesion complex. To be able to specifically dissect its signaling role, Valenta and 
colleagues have generated β-catenin mutant alleles which retain β-catenin’s function 
in cell adhesion but alter its signaling activity [137]. We first examined the complete 
loss of β-catenin and its effect on tumor progression and metastasis formation in the 
MMTV-PyMT mouse model of metastatic breast cancer. Notably, knockout of β-catenin 
in the mammary epithelium by expression of MMTV-Cre did not affect tumor weight or 
the number of lung metastasis (Supplementary Fig. 1A). Though, IF staining of tumor 
sections revealed that β-catenin was still present in the β-catenin conditional knockout 
mice (Supplementary Fig. 1C). Furthermore, genotyping of the tumors also 
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demonstrated incomplete deletion which was confirmed in GFP reporter mice 
(Supplementary Fig. 1D, 1F). However, we found that loss of β-catenin in vitro as well 
as in vivo led to mammary tumor cell apoptosis (Fig. 1A, 1B, 1C, Supplementary Fig. 
1E). Similar observations have been made in mouse embryonic stem cells where β-
catenin loss also lead to increased cell death [228]. Also in head and neck squamous 
cell carcinomas (HNSCC) and lung cancer cell lines, β-catenin silencing has been 
found to induce cell death [229, 230]. Hence knockout of β-catenin and with this the 
loss of its signaling as well as its adhesion function leads to apoptosis.  
 
2.5.2 Wnt signaling in mammary tumor growth, tumor progression 
and metastasis formation 
Ablation of the binding of BCL9/9L resulted in smaller tumors due to less proliferation, 
less metastasis, a lower metastasis index and a delay in tumor progression (Fig. 2B, 
2C, 2D). BCL9 knockdown has been found to result in reduced tumor load and 
decreased number of metastases in xenograft mouse models using myeloma and 
colon cancer cell lines [151]. Hence the binding of BCL9/9L seems to be important for 
MMTV-PyMT tumor growth and metastasis formation. Abrogating the binding of the 
plethora of cofactors to the C-terminus of β-catenin also resulted in decreased tumor 
weights due to a decrease in proliferation, but had no effect on tumor progression or 
metastasis formation (Fig. 3A, 3B, 3C). Inhibition of the binding of CREB to β-catenin 
has also previously been found to inhibit proliferation in lung cancer cell lines [230]. 
Together, these results show that ablation of the binding of N- or C- terminal 
coactivators to β-catenin affects tumor growth and tumor progression differentially. The 
question remains whether the cofactors enhance the β-catenin transcriptional output 
in a selective fashion by affecting specific target genes or just by a general 
enhancement of the output.  The complete abrogation of the canonical Wnt activity 
using the dm mutant form of β-catenin showed an effect on tumor weight, tumor 
progression, on metastasis formation as well as on the metastasis index (Fig. 4A, 4C). 
In the dm mutant mice, the tumor weight seemed to be affected again by a decrease 
in proliferation but a slight increase in the amount of apoptotic cells was observed as 
well (Fig. 4B, Supplementary Fig. 2C). In conclusion, all the mutant forms of β-catenin 
have an effect on tumor proliferation whereas only by abrogating the binding of 
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BCL9/9L in the D164A and the dm mutant have an effect on tumor progression and 
metastasis formation. Furthermore, all mutant versions of β-catenin exert a dominant-
negative effect, this notion has been observed in vivo and was then tested in vitro (Fig. 
2B, 3A, 4A, Supplementary Fig. 2D). By following analyses of the heterozygous cell 
lines (mutant β-catenin/floxed), which have been included in the RNA sequencing 
experiment as well, it can be further examined on how the dominant negative effect 
alters the activation of the canonical Wnt pathway. 
 
2.5.3 The contribution of N- and C-terminal coactivators of β-catenin 
to Wnt signalig activity and EMT 
Further in vitro analysis were performed by establishing cell lines from the different 
tumor genotypes to examine the mechanisms affected in more detail. Examination of 
the growth of the different cell lines showed a reduced growth of the mutant cell lines 
compared to a wild-type cell lines (Fig. 5A). This confirmed the results observed in vivo 
that all the β-catenin mutant forms show a proliferation phenotype. Canonical Wnt 
signaling is known to be able to affect proliferation on different levels: among the 
targets genes of the canonical Wnt pathway are Cyclin-D1 and c-Myc which contribute 
to cell cycle progression, furthermore it has been found that specific kinases during 
G2/M phase can phosphorylate LRP6 to prime the pathway [231-233]. Moreover, it has 
been found that Wnt signaling not only stabilizes β-catenin but also many other 
proteins which are found to contain GSK3 phosphorylation sites triggering degradation. 
Thereby, Wnt signaling can inhibit GSK3 and stabilize other proteins, a mechanism 
termed Wnt-dependent stabilization of proteins (Wnt/STOP) [234]. β-catenin 
expression itself varies during the cell cycle. The cytoplasmic and nuclear fraction 
increase in S phase and peak at G2/M phase while decreasing as the cells re-enter 
G1. Additionally β-catenin has been found being involved in centrosome regulation and 
the formation of a bipolar mitotic spindle [235, 236]. Further analysis of the RNA 
sequencing might reveal which of the functions of the canonical Wnt signaling during 
mitosis are affected by the β-catenin mutations. Subsequently we wanted to examine 
how strong the β-catenin mutations affected the canonical Wnt signaling output. A Wnt 
reporter assay revealed a reduced response to Wnt3a in the D164A and the ΔC mutant 
cell lines as compared to the wild type cells.  The double-mutant (dm) form completely 
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blocked the transcriptional β-catenin signaling output (Fig. 5B). These observations 
confirm the results of Valenta and collegues where similar observations have been 
reported in mouse embryonic fibroblasts (MEFs). In their study they have shown, that 
in mice the output of the canonical Wnt signaling seems to be more dependent on the 
presence of the C-terminus than on the binding of BCL9/9L to β-catenin. Also in our 
cell lines, the ΔC mutation shows a stronger effect. Hence the individual contribution 
of the N- and C-terminal coactivators to the signalling output seems to differ. In the 
experiment presented by Valenta and collegues, the double mutation has also 
completely abrogated canonical Wnt signaling activity [137].  
Epithelial-to-Mesenchymal transition (EMT) is a process that plays an important role 
during embryonic development and is thought to contribute to tumor progression and 
metastasis formation. Since in our in vivo experiments we detected reduced metastasis 
formation in D164A and dm mutant mice, we proceeded to examine the effect of the 
β-catenin mutations on EMT in vitro which thereby might account for the reduction in 
metastasis observed in vivo. To test this notion, the different cell lines were treated for 
4d with TGFβ which is a potent EMT inducing cytokine and several studies have 
already shown a cross-talk between the TGFβ and Wnt signaling pathways [240-242]. 
The β-catenin wild-type cell lines became more mesenchymal upon TGFβ treatment 
and the same was true for the β-cateninΔC/- cell line. The morphology of the β-
cateninD164A/- cells became more elongated as well, but they still grew as a cell cluster 
whereas the β-catenindm/- cell line only seem to form filopodia (Fig. 5C). Those results 
were confirmed by IF staining for EMT markers showing that the β-cateninD164A/-   and 
β-catenindm/- cell lines retained the expression of epithelial markers (E-cadherin, ZO-1) 
(Fig. 5D, Supplementary Fig. 3D). Also long-term treatment (20d) did not further alter 
the morphology of the cells showing that there is not only a delay but really an ablation 
of the EMT response due to the loss of the binding of BCL9/9L in the D164A and dm 
cell lines (Supplementary Fig. 3C). These results correlate with our observations in 
vivo, where we see an effect on metastasis formation in the D164A and dm mice, 
whereas the ΔC mutation does not seem to have an effect. This findings are in line 
with a previous study which has shown that Bcl9 knockdown in myeloma and colon 
carcinoma cell lines modulated the expression of EMT markers and also reduced their 
proliferation. Furthermore, it has been demonstrated that Bcl9 overexpression 
increased migration of a myeloma cell line, whereas the knockdown reduced the 
migratory capacity [161]. In conclusion, these results show that especially the binding 
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of BCL9/9L to β-catenin or the target genes affected by it promote tumor growth and 
progression as well as metastasis formation and, hence, these target genes may 
constitute interesting interference points for treatment. On the other hand the β-catenin 
knockout and hence loss of its adhesion and signaling function affects cell survival in 
vitro as well as in vivo. The cell lines expressing the different β-catenin mutant forms 
however, are able to survive, show an abrogated Wnt signalling output but are still able 
to bind to E-cadherin (Fig. 5B, Supplementary Fig. 3E). The double-mutant shown to 
block the transcriptional signalling output indicates that the critical role in cell survival 
is not the signaling function itself but rather its function in cell adhesion or the loss of 
both functions combined. 
 
2.5.4 Wnt target genes and pathway components affected by 
ablation of coactivator binding to β-catenin 
To further examine alterations in the expression of target genes after activation of 
canonical Wnt3a treatment or during EMT, ChIP sequencing and RNA sequencing was 
performed using the established cell lines expressing wild type β-catenin or its various 
mutant alleles after treatment with Wnt3a or TGFβ. Unsupervised hierarchical 
clustering of the cell lines according to the top 500 most variable genes revealed, that 
the cell lines cluster according to the β-catenin mutation but not according to the 
treatment (Fig. 6A). This shows that the mutations themselves have a hierarchical 
higher effect than the treatments. In order to better comprehend and examine the 
corresponding alterations in the canonical Wnt pathway upon Wnt3a or TGFβ 
treatment, a preliminary analysis involved the examination of known canonical Wnt 
targets, canonical Wnt pathway components and Wnt ligands. In the mutant cell lines, 
especially in the β-catenindm/- cells, the number of differentially expressed genes upon 
Wnt3a treatment was dramatically reduced as compared to wild-type cells (Fig. 6B). 
This confirms the observations made in the luciferase reporter assay, that the β-
cateninD164A/- and the β-cateninΔC/- cell lines have a reduced response to Wnt3a 
treatment and that the double-mutant (dm) form blocks the transcriptional β-catenin 
signaling output (Fig. 5B).  
By Wnt3a-mediated induction of the canonical Wnt pathway, some Wnt targets genes 
seem to be regulated specifically by either N- or C-terminal coactivators (Fig. 6C). This 
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is consistent with the observations in vivo and in vitro that specific ablation of N- or C-
terminal coactivators can lead to different phenotypes. Additionally, there are some 
target genes like Axin2 and Stra6 where the N- and C-terminal coactivators of β-
catenin conjointly contribute to their expression. STRA6 is a cell membrane receptor 
for retinol-binding protein (RBP) and is able to further activate the JAK/STAT signaling 
cascade. It has been found to be upregulated in human breast and colon cancer and, 
together with RBP, it seems to affect proliferation and promote oncogenic properties 
like migration, invasion and colony formation [243]. Its expression has been reported 
to be regulated synergistically by Wnt1 and retinoic acid [244]. Among the genes found 
to be regulated by the C-terminal coactivators are Notum and Lbh. The transcription 
cofactor LBH has been found to be deregulated in aggressive human basal breast 
cancer and to affect differentiation [192]. Notum deacylates Wnt proteins and thereby 
inhibits the signaling activity and hence acts as a negative feedback loop. In colorectal 
cancer cell lines, knockdown of Notum has been found to inhibit proliferation as well 
as migration. On the other hand, Procr seems to be specifically regulated by the 
binding of BCL9/9L to β-catenin. This gene is thought to be a stem cell marker and has 
been found to stimulate several signaling pathways like ERK, PI3K–Akt, and RhoA. 
Furthermore, its expression is associated with distant metastasis and also cell 
proliferation [245, 246]. Since the abrogation of the binding of BCL9/9L results in a 
proliferation phenotype in vivo and in vitro as well reduces the amount of lung 
metastasis, PROCR seems to be one of the downstream effectors contributing to these 
phenotypes. Also in mouse intestinal tumors, a subset of Wnt target genes has been 
found to be downregulated in Bcl9−/−/Bcl9l−/− tumors as compared to wild-type tumors, 
suggesting an important role for BCL9/9L in regulating canonical Wnt target genes also 
in other tumor mouse models [162]. In conclusion, our results show that the single 
mutants retain transcriptional activity affecting specific genes, whereas with the double 
mutation the regulation of almost all target genes is lost. The upregulation of Tcf7 and 
Stra6 in the β-catenindm/- cells might also be mediated via other mechanisms. 
Interestingly, the well-known Wnt target genes cyclin D1 and c-Myc are not regulated 
in all cell lines upon Wnt3a treatment. However, it is known that they are regulated as 
well by other pathways [191, 247]. To be able to generate a list of β-catenin target 
genes in our model and to determine which of those target genes are affected by the 
different mutations, β-catenin ChIP sequencing was performed. The analysis of this 
data is still ongoing and the results will then be compared and placed into context with 
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the RNA sequencing results. So far, the results suggest that the N- and C-terminal 
coactivators contribute in critical ways to the Wnt signaling output and affect some 
specific target genes. Also, different alterations in the pathway components in the 
mutant cell lines as compared to the wild type cell line have been observed. The 
exclusive upregulation of Tcf7 and Fzd1/2 in the β-catenindm/- could reflect a 
compensatory effect of the cells trying to maintain/restore canonical Wnt output. 
Compared to wild-type cell lines, in the β-cateninD164A/- and β-cateninΔC/- less pathway 
components are differentially expressed suggesting a deregulation of the feedback 
control due to a reduction in activity/output of the pathway (Supplementary Fig. 4A). 
Feedback loops permit better control of signal amplitude or duration. The extent of 
those alterations will be determined by first analysing the effect on the canonical Wnt 
signaling output by identifying the direct target genes using ChIP. 
The examination of genes that are transcriptionally regulated by canonical Wnt 
signaling during the process of EMT showed that many more genes are up- or down-
regulated in all cell lines examined as compared to the Wnt3a treatment (Fig. 6B). Also, 
Wnt target genes are differentially expressed suggesting regulation of those during 
EMT. The Gap junction protein alpha 1 (Gja1) gene encodes for Connexin43, being 
important for gap junctions which facilitate cell-cell communication. Its function is still 
debated, as it has been suggested to act as a tumor suppressor as well as in promoting 
tumor progression [248]. It is thought to be a direct Wnt target gene but was found to 
be upregulated upon TGFβ  treatment in all cell lines, also in the β-catenindm/-  cell line, 
suggesting a canonical Wnt-independent upregulation [249]. In wild-type cells, Axin2 
and Notum were downregulated upon TGFβ treatment, whereas they were 
upregulated upon Wnt3a treatment. This suggests a context-specific up- or down-
regulation of Wnt target genes. Furthermore, the upregulation of Notum via Wnt3a 
treatment seems to be regulated via C-terminal coactivators, however upon TGFβ 
treatment the down-regulation of Notum seems to be dependent on N-terminal 
coactivators of β-catenin. Hence the regulation of target genes via N- or C- terminal 
coactivators might also be context-dependent or also regulated via other mechanisms 
(Fig. 6D). Furthermore, some EMT-related transcription factors and mesenchymal 
markers that have been shown to be regulated by canonical Wnt signaling were 
upregulated in all cell lines upon TGFβ treatment (Fig. 6E) [75, 250]. These results are 
in line with the results of the IF staining showing that all mutant cell lines are still able 
to upregulate mesenchymal markers and are able to undergo at least a partial EMT 
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(Fig. 5D). Snai2 however, was only upregulated in the wild-type cells showing an 
opposite trend towards down-regulation in the mutant cell lines. Additionally, E-
cadherin was only downregulated in the wild type cells even though 
immunofluorescence staining suggested a downregulation in the β-cateninΔC/- cells as 
well. Nevertheless, not only the expression levels but also the localization of EMT 
markers like E-cadherin has to be considered. The expression of further epithelial 
markers might reveal differences observed between the cell lines during EMT. The 
observation that binding of BCL9/9L might be important for EMT has also been found 
by Deka and colleagues showing that some EMT-inducing transcription factors were 
downregulated in Bcl9−/−/Bcl9l−/− colon tumors as compared to wild-type tumors [162]. 
TGFβ also induced changes in the expression of Wnt pathways components, i.e. 
mainly the expression of Wnt ligands, transcription factors (Tcf7, Tcf7l1, Tcf7l2 and 
Lef1), and Fzds was affected (Supplementary Fig. 4B). Also, non-canonical Wnt 
ligands were upregulated suggesting an activation of the non-canonical Wnt signaling 
pathways. Since several of the canonical Wnt target genes are also canonical Wnt 
pathway components, altering the transcriptional output is also having an effect on the 
expression of the pathway components, as observed [77, 89-93]. Several studies 
already have shown the interaction of Wnt and TGFβ signaling, however, which Wnt 
target genes are affected and what role canonical Wnt signaling plays in EMT and 
metastasis formation will have to be further examined [208, 251, 252]. Especially target 
genes affected by abrogating the binding of BCL9/9L to β-catenin will be interesting 
candidates for further examination, since they seem to contribute to alterations in EMT 
and reduced metastasis formation. 
In ongoing studies, gene set enrichment analysis (GSEA) will be performed to identify 
significantly enriched gene sets comparing the different cell lines upon Wnt3a and 
TGFβ treatment most related to the observed effects. Moreover, Integrated System for 
Motif Activity Response Analysis (ISMARA) will be performed to identify the motifs that 
are enriched in specific mutant cell lines. A list of canonical Wnt target genes will be 
generated from ChIP sequencing results to detect target genes which are no more 
regulated by the different β-catenin mutant forms and will be compared to the RNA 
sequencing results. This allows the detection of interesting target genes which 
contribute to the observed phenotypes of reduced tumor growth or effects on 
metastasis formation and can be examined in patient data available.  
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In this study we show that abrogating the binding of N- and/or C-terminal β-catenin 
coactivators without affecting β-catenin’s function in cell adhesion, affects tumor 
growth in vivo, proliferation in vitro and alters the transcriptional output. Whereas, the 
complete loss of β-catenin’s signaling and adhesion function leads to apoptosis in 
mammary tumor cells in vitro and in vivo, suggesting a key role of its adhesion function 
in cell survival. Furthermore, the observations indicate that the inability of β-catenin to 
bind BCL9/9L are critical for a subset of Wnt target genes involved in EMT. Canonical 
Wnt target genes examined so far seem to be either dependent on both, the N- and C-
terminal coactivators or specifically dependent on one of those. Nevertheless, the 
double mutation shows the strongest effects suggesting that coactivators binding to 
both transactivation domains contribute to the transcriptional output and ablating their 
binding inhibits the transcriptional output.  
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2.6 Material and Methods 
Antibodies and Reagents 
Antibodies:  
E-cadherin Monoclonal Antibody (ECCD-2) 
(13-1900, Thermo Fisher Scientific, used for immunofluorescence stainings), E-
cadherin (610182, Transduction Laboratories, used for immunoblotting), Monoclonal 
Anti-α-Tubulin antibody mouse (T-9026, Sigma-Aldrich), anti-Fibronectin rabbit (F3648 
Sigma-Aldrich), Vimentin (NB300-223, Novus Biologicals), ZO-1 (617300, Thermo 
Fisher Scientific), Alexa Fluor™ 568 Phalloidin (A12380; Invitrogen),  β-catenin (06-
734, Cell Signaling Technology, used for immunofluorescent stainings),  β-catenin 
(NBP-32239, Novus Biologicals, used for IP and ChIP), Caspase-3 (Asp 175) (5A1E) 
(9664, Cell Signaling Technology), Anti-phospho-Histone H3 (Ser10) (06-570, Merck) , 
Myc-Tag (9B11) Mouse mAb (2276, Cell Signaling Technology), 4′,6-diamidino-2-
phenylindole (DAPI, D9542, Sigma-Aldrich). 
Reagents:  
Recombinant Murine Wnt-3a (315-20, PeproTech), Recombinant Human TGF-beta 1 
Protein (240-B, R&D Systems). 
 
Mouse experiments 
Mouse colonies were kept at the animal facility of the Department of Biomedicine, 
University of Basel, Switzerland. All animal experiments were carried out in 
accordance with the guidelines of the Swiss Federal Veterinary Office (SFVO) and the 
Cantonal Veterinary Office of Basel-Stadt. To examine conditional knockout of β-
catenin in breast cancer, β-cateninfl/wt mice (a kind gift of Konrad Basler, UZH, Zürich, 
Switzerland) were crossed with MMTV-PyMT (a kind gift of N. Hynes, FMI, Basel, 
Switzerland) [236, 238] and MMTV-Cre (a kind gift of Lothar Hennighausen, NHI, 
Bethesda, USA) mice [253]. β-cateninfl/fl; MMTV-PyMT, and MMTV-Cre mice obtained 
were then crossed with the β-catenin knock-in mutant mouse strains (β-cateninD164A/wt, 
β-cateninΔC/wt and β-catenindm/wt lines) (kindly provided by Konrad Basler, backcrossing 
was performed using speed congenics by Taconic, New York, USA). In the 
experiments, mice were compared to their littermate controls. To monitor MMTV-Cre 
mediated recombination, β-cateninfl/fl; MPY, MMTV-Cre mice were crossed with GFP-
reporter mice (R26-LSL-GFP, kindly provided by Verdon Taylor, DBM, Basel, 
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Switzerland). Before, the reporter mice were crossed ten generations into the FVB/N 
background and then used for the experiments. For the quantification of the 
recombination, the whole tumor section was imaged with a Zeiss Axio Imager Scanning 
Microscope (10x magnification). The GFP positive area and total tumor area (DAPI 
positive area) was determined using ImageJ. All experiments were performed on 
female mice. For analysis of the mammary gland, mice were sacrificed at 5 weeks or 
12 weeks of age, before a tumor volume of 1500mm3 was reached, usually at 12-13 
weeks of age. 
 
Tissue histology 
For tissue histology, tissues (mammary tumors and lungs) were fixed in 4 % 
paraformaldehyde overnight at 4 °C followed by ethanol/xylene dehydration and 
subsequent embedding in paraffin. Paraffin-embedded samples were cut at 5 µm 
thickness and subjected to Hematoxylin and Eosin (H&E) staining. To determine lung 
metastases, 9 slides per organ spaced 50 µm were stained with H&E and the number 
of lung metastases was counted under the microscope with a 10x magnification.  
 
Immonofluorescence on tumor sections 
Tumors were fixed at 4 °C in 4 % paraformaldehyde for 2 h followed by 
cryopreservation overnight in 20 % sucrose/PBS prior to embedding in OCT-
Compound freezing medium. The cryosections were cut at 7 µm thickness and air-
dried for 15 min prior to rehydration in PBS. Tissue sections were permeabilized with 
0.2 % TritonX-100/PBS and blocked for 30 min in 5 % normal goat serum/PBS followed 
by incubation with the indicated primary antibodies with the appropriate dilution in 
blocking buffer overnight at 4°C. The next day sections were incubated with 
fluorophore-coupled secondary antibody (Alexa Fluor, Invitrogen) for 1 h at room 
temperature in the dark. The cell nuclei were counterstained with DAPI (D5942, Sigma-
Aldrich). After staining, the coverslips were mounted in Fluorescence Mounting 
Medium (S302380-2, Dako) on microscope slides and imaged using a fluorescence 
microscope (Leica DMI 4000) using 20x magnification. 
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Cell line derivation 
Cells were isolated from breast tumors (mammary gland 2/3) of twelve-week-old 
MMTV-PyMT transgenic female mice (FVB/N background). A small piece of the tumor 
was minced and 10 ml of predigestion buffer (10 mM Hepes pH 7.4, 142 mM NaCl, 
0.67 mM KCl, 1mM EDTA supplemented with with 50 g/ml gentamycin (Sigma, G1397) 
and 1X antibiotic-antimycotic (15240062, Thermo Fisher Scientific) were added and 
incubated for 30 min at 37°C on a shaker. After washing with PBS the samples were 
digested using 6 ml digestion buffer (10 mM Hepes pH 7.4, 142 mM NaCl, 0.67 mM 
KCl, 0.67 mM CaCl2, 20 mM Glucose supplemented with 1 mg/ml Collagenase D 
(Roche, 11088858001), 50 g/ml gentamycin (Sigma-Aldrich, G1397) and 1x antibiotic-
antimycotic (15240062, Thermo Fisher Scientific) and incubated for 30 min at 37°C on 
a shaker. Subsequently the samples were washed with PBS and then resuspended in 
growth medium and plated into 10 cm plates. The medium was changed regularly and 
fibroblasts in culture were removed by differential trypsinization until only epithelial 
cells remained. The different cell lines were thereof cultured in DMEM supplemented 
with glutamine, penicillin, streptomycin, and 10% FBS (F7524, Sigma Aldrich). To 
establish cell lines only expressing the mutant alleles, the established cell lines were 
seeded into 10 cm plate and on the next day infected either with the Adeno-CRE-IRES-
GFP or as a control with the Adeno-IRES-GFP virus using the FuGENE® HD 
Transfection Reagent (E2311, Promega). On the next day, the medium was changed 
and after 3 days the cells were sorted for GFP positive cells into 24 well plates using 
BD FACSAria Flow Cytometer (BD Biosciences). Detachment of the cells was 
performed using trypsinization followed by two-times washing in 1x PBS and 
resuspension in 2 % FBS, PBS and syringe filtering (40 µm mesh filter) immediately 
before FACS sorting into a polystyrene round bottom tube (352054, FALCON) filled 
with DMEM medium. After centrifugation, the supernatant was discarded and the cells 
were resuspended and seeded into a 24 well plate. Genotyping by PCR was performed 
to confirm the removal of the floxed allele. PCR products were run on an agarose gel. 
 
Adenovirus infection 
Cells were plated onto 6 cm dishes in duplicates and transfected on the next day with 
the Adeno-CRE-IRES-GFP or as a control with the Adeno-IRES-GFP virus (1710 and 
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1761, Vector Biolabs) using Fugene HD transfection reagent (E2311, Promega). The 
following day, the medium was changed. 
 
Genotyping 
To extract genomic DNA, cells from a confluent 10 cm petri dish were trypsinized, 
washed in PBS and pelleted by centrifugation. The DNA extraction was performed 
using the GenElute™ Mammalian Genomic DNA Miniprep Kits (G1N70, Sigma-
Aldrich) according to the manufacturer’s protocol. Standard PCR procedure was then 
performed. To detect the β-catenin floxed and mutant allele, sense primer RM41 (5- 
AAG GTA GAG TGA TGA AAG TTG TT -3) and antisense primer RM42 (5- CAC CAT 
GTC CTC TGT CTA TTC -3) were used, generating 324 bp and 221 bp products from 
the floxed and mutant alleles, respectively. To detect the deletion of the floxed allele, 
sense primer RM68 (5- AAT CAC AGG GAC TTC CAT ACC AG -3) and antisense 
primer RM69 (5- GCC CAG CCT TAG CCC AAC T -3), were used generating a 631 
bp product from the deleted allele. [254] 
 
Cell culture  
The established cell lines from the different mouse genotypes and the Py2T cells 
(Waldmeier et al. 2012) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
(D5671, Sigma-Aldrich) supplemented with 10% Fetal Bovine Serum (FBS 10 % 
(F7524, Sigma-Aldrich), 2 mM L-Glutamine solution (G7513, Sigma-Aldrich), 100 U 
penicillin and 0.1 mg/ml streptomycin (P4333, Sigma-Aldrich). All cell lines were grown 
at 37°C, 5% CO2, 95% humidity. To activate Wnt/β-catenin mediated transcription, 
cells were treated with 100 ng/ml Recombinant Murine Wnt3a (315-20, PeproTech) for 
the indicated time-points. For EMT experiments, cells were treated with 2 ng/ml 
Recombinant Human TGF-beta 1 Protein (TGFβ) for the time-points indicated every 
2nd day.  
 
Transfection with rescue constructs 
The retroviral constructs used were kindly provided by Tomas Valenta (University of 
Zürich, Switzerland).  A cDNA encoding EGFP was subcloned from pEGFP-N3 
(Clontech) into the retroviral vector pBabe-puro (as described in Jay P.Morgenstern 
and Hartmut Land, 1990). 4 µg plasmid were used o transfection. Transient 
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transfection was performed was performed with Lipofectamine 3000 Reagent (L3000-
015, Invitrogen) according to the manufacturer’s instructions. Medium was changed 
the day after transfection. 
 
Luciferase reporter assay 
To assess Wnt/β-catenin mediated transcription, the firefly luciferase reporter 
superTOPflash/ superFOPflash (kindly provided by Konrad Basler, UZH Zürich) was 
used. Cells were plated in duplicates in 24-well plates and transfected the following 
day with 500 ng of the reporter plasmid reporter and 10 ng of plasmids encoding Renilla 
luciferase encoding plasmid using Lipofectamine 3000 Reagent (Invitrogen) according 
to the manufacturer’s instructions. The luciferase activity was measured by using the 
Dual-Luciferase® Reporter Assay System (E1960, Promega). The measured firefly 
luciferase values were normalized to the Renilla luciferase control values. 
 
Cell IQ 
To measure the growth curves and doubling times the cells were seeded into 12 well 
plates in duplicates. On the next day the medium was changed and the cells were put 
into the Cell IQ (Model v.2) for 3 days. For the analysis the Cell IQ analysis software 
was used.   
 
Immunofluorescence of cultured cells 
Cells were grown on uncovered glass coverslips (#1, 12 mm round, Menzel–Glaser) 
and treated for 3 days with Wnt3a or 4 days with TGFβ. Following the cells were 
washed with PBS and then fixed with 4% paraformaldehyde/PBS for 15 min at room 
temperature, followed by permeabilization with 0.2 % TritonX-100/PBS for 5 min. 
Subsequent blocking was performed with 3 % BSA/0.01 % Triton X-100/PBS for 1 h. 
The indicated primary antibodies were then added in the appropriate dilution with 3 % 
BSA/ 0.2 % PBS-T for 2 h at room temperature. Afterwards incubation with a 
fluorophore-coupled secondary antibody (Alexa Fluor, Invitrogen) was performed for 1 
h at room temperature in the dark. Cell nuclei were counterstained with DAPI (D5942, 
Sigma-Aldrich). After staining, the coverslips were mounted in Fluorescence Mounting 
Medium (S302380-2, Dako) on microscope slides and imaged using a fluorescence 
microscope (Leica DMI 4000) using a 20x magnification . 
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Immunoblotting 
The cells were lysed in RIPA buffer (R0278, Sigma-Aldrich) supplemented with 1 mM 
DTT, 1 mM NaF, 2 mM sodium orthovanadate and 1x protease inhibitor cocktail 
(Sigma-Aldrich) for 30 min on ice followed by scraping into tubes and centrifugation for 
10 min at 10,000 rpm at 4 °C. The supernatant was saved and the protein 
concentration was determined using the Bio-Rad Bradford solution according to the 
manufacturer’s instructions. Equal amounts were prepared, diluted in loading buffer 
(10 % glycerol, 2 % SDS, 65 mM Tris, 0.01 mg/ml Bromphenolblue, 1% beta-
mercaptoethanol) and loaded onto a SDS polyacrylamide gel. Proteins were then 
transferred onto a nitrocellulose membrane (10600002, Sigma-Aldrich) by wet transfer 
for 2 h at constant current (0.33 A). Following blocking for 1 h in 5% milk prepared in 
TBS/0.05 % Tween 20, the membranes were incubated with the indicated primary 
antibodies overnight at 4 °C. On the next day, the membranes were washed and the 
blots were incubated with HRP-conjugated secondary antibodies (Jackson 
Immunoresearch Laboratories and donkey anti goat IgG-HRP, sc-2020, Santa Cruz) 
for 1 h at room temperature and developed with Immobilon Western Chemiluminescent 
HRP Substrate (WBKLS0500, Millipore) with a Fusion Fx7 chemoluminescence reader.   
 
Co- Immunoprecipitation 
β-cateninfl/fl, β-cateninD164A/-, β-cateninΔC/- and β-catenindm/-  grown in a 15 cm plate 
were washed with cold PBS, then scraped off in 300 µl IP lysis buffer (20mM Tris pH 
7.5, 10 mM NaCl, 10 % glycerol, 1 % NP-40, 2 mM EDTA, 1x PIC (protein inhibitor 
cocktail)) and collected in an Eppendorf tube. Incubation was performed at 4 °C 
rotating for 20 min. Subsequently samples were centrifuged at 4 °C (10 min, 16’000 g) 
and the supernatant was transferred to a new tube. Protein concentration was 
measured using the Bio-Rad Bradford solution according to the manufacturer’s 
instructions. An input sample was taken and frozen. Per IP, 5 µg anibody or IgG as a 
control were diluted in 200 µl PBS/0.02 % Tween-20 (PBS-T). Per IP 40 µl 
DynaMagnetic Beads were prepared by washing 2 two times with 500 µl PBS-T.  The 
beads were collected using a magnetic stand the antibody dilution was added and 
torated for 15 min at room temperature. The liquid was aspirated on the magnetic stand 
and the lysate (1 mg) was added and incubated overnight at 4 °C while rotating. The 
next day, the beads were washed three times with 500 µl IP wash buffer (15mM Tris-
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HCl pH 7.8, 100 mM NaCl, 1x PIC). Following beads were diluted in 40 µl 1x SDS-
PAGE sample buffer and boiled or 5 min. Empty beads were collected and the 
supernatant was loaded on an SDS-Gel. Samples were analyzed by SDS-PAGE. 
 
RNA sequencing and analysis 
The established cell lines (β-cateninfl/fl, β-cateninD164A/fl, β-cateninD164A/-, β-cateninΔC/fl, 
β-cateninΔC/-, β-catenindm/fl, β-catenindm/-)  were treated either with 100 ng/ml Wnt3a for 
2 days or with 2 ng/ml TGFβ for 4 days. Untreated cells served as control. Biological 
duplicates were prepared for RNA-Sequencing. Total RNA was isolated from the 
samples using the miRNeasy Mini Kit (Qiagen, 217004) with on-column DNAse 
digestion according to the manufacturer’s instructions. RNA quality control was 
performed using RNA ScreenTape on the Agilent 4200 TapeStation and the 
concentration was measured by using the Quanti-iT RiboGreen RNA assay Kit (Life 
Technologies). RNA-sequencing libraries were prepared from total RNA using poly(A) 
enrichment with the TruSeq stranded mRNA Sample prep from Illumina using 200 ng 
input RNA. QC was performed with a fragment analyzer using DNF-473-33-SS NGS 
Fragment 1-6000bp kit. The RNA-sequence libraries were sequenced on a NextSeq 
500 using 75 cycles kit High Output (Illumina). Obtained single-end RNA-seq reads 
were mapped to the mouse genome assembly, version mm10, with RNA-STAR 
(PMID:23104886), with default parameters except for allowing only unique hits to 
genome (outFilterMultimapNmax=1) and filtering reads without evidence in spliced 
junction table (outFilterType="BySJout"). Using RefSeq mRNA coordinates from 
UCSC (genome.ucsc.edu, downloaded in December 2015) and the qCount function 
from QuasR package (version 3.12.1) (PMID:25417205) we quantified gene 
expression as the number of reads that started within any annotated exon of a gene. 
The differentially expressed genes were identified using the edgeR package (version 
1.10.1) (PMID:19910308). Genes with fdr ≤ 0.05 and minimum log2 fold change of +/- 
1.0 were considered statistically significant and used these genes for downstream 
functional analysis. 
 
Functional enrichment analysis 
Functional enrichment analysis of differentially expressed genes for biological 
processes for pathways was performed in R using several publically available 
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Bioconductor resources including GO.db (version 3.4.1), GOstats (version 2.42.0) 
(PMID: 17098774), KEGG.db (version 3.2.3) and ReactomePA (version 1.20.2) (PMID: 
26661513). The significance of each biological processes or pathways identified was 
calculated using the hypergeometric test (equivalent to Fisher’s exact test) and those 
with p values ≤0.05 were considered significant.  
  
ChIP 
ChIP was performed using an adapted protocol [255]. For the ChIP experiments the 
established cell lines (β-cateninfl/fl, β-cateninD164A/-, β-cateninΔC/-, β-catenindm/-)  were 
seeded into 1 cm plates and treated with 100 ng/ml Wnt3a for 2 days. Untreated cells 
served as control. Samples were washed with PBS, following PBS was added and 
crosslinking was performed by addition of 2 mM Ethylene glycol bis (21565, Thermo 
Fisher) for 30 min at room temperature. After 20 min 4 % formaldehyde (28908, 
Thermo Fisher) was added for the remaining 10 min. The reaction was quenched using 
125 mM Glycin (in DMSO) and incubated for 10 min at 4 °C. The cells were rinsed 
three times with on with pre-cooled PBS, the cells were scraped off and collected. After 
centrifugation for 5 min at 600 g (4°C) the supernatant was discarded and the pellet 
snap-frozen in liquid-nitrogen. For further processing the samples were thawed on ice 
and resuspended in ChIP lysis buffer I (10 mM HEPES pH 6.5, 10 mM EDTA, 0.5 mM 
EGTA, 0.25% Triton X-100, 1x PIC) and incubated for 5min on ice. After centrifugation 
(5 min at 600 g (4°C)) the pellets were resuspended in ChIP lysis buffer II (10 mM 
HEPES pH 6.5, 10 mM EDTA, 0.5 mM EGTA, 200 mM NaCl, 1x PIC) and incubated 
for 5 min. This washing step was repeated a second time. Then the pellet was lysed 
by resuspending in 400 µl Chip lysis buffer III (50 mM Tris-HCl pH 8.0, 1 mM EDTA, 
0.5% Triton X-100, 0.5 % SDS, 1x PIC)and incubation for 10 min on ice. 300 µl aliquots 
of  400 ng/µl chromatin in lysis buffer III were then sonicated using the Bioruptor 
sonicator dianode). Samples were centrifuged at 14‘000 g for 10 min at 4 °C and the 
supernatant was saved. Proper fractionation was tested by loading samples on an 
agarose gel. Subsequently, 100 µg chromatin were diluted in 200 µl Dilution buffer  
16.7 mM Tris-HCl pH 8.0, 1.2 mM EDTA, 167 mM NaCl, 1.1% Triton X-100, 0.01 % 
SDS, 1x PIC)and lysis buffer III was added total of 600 µl. 6 μl were saved and frozen 
as input samples. 2 μg antibody or IgG control were added and incubated o.n. at 4 °C 
overhead shaking. On the same day the DynaMagnetic Beads (10003D, Thermo 
Fisher Scientific) were washed twice with 1 ml TE buffer (10 mM Tris-HCL pH 8.0, 1 
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mM EDTA). Thereafter, the beads were resuspended in 1 ml TE buffer and 100 μl BSA 
(10 mg/ml) and 50 µl tRNA (10 mg/ml, AM7119, Invitrogen) or preblocking, were added. 
The beads were then incubated for 2h at 4°C overead shaking and subsequently 
washed three times with TE buffer before resuspending them in beads volume TE 
buffer and then kept at 4 °C. The next day 30 µl preblocked breads were added to the 
samples and incubated for 2 h at 4°C overhead shaking. Following the samples were 
washed using a magnetic beads stand: once with ChIP wash buffer I (20 mM Tris-HCl 
pH 8.0, 2 mM EDTA, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, 1 PIC), two times 
with 500 µl Chip wash buffer II (20 mM Tris-HCl pH 8.0, 2 mM EDTA, 500 mM NaCl, 
0.1% SDS, 1% Triton X-100, 1x PIC), two times using ChIP wash buffer III  III (10 mM 
Tris-HCl pH 8.0, 1 mM EDTA, 250 mM LiCl, 1% sodium deoxycholate, 1% NP-40, 1x 
PIC) and two times using TE buffer. Thereafter, the bound complexes were eluted by 
two sequential incubations with 200 μl elution buffer (1% SDS, 0.1 M NaHCO3) at 
65 °C for 10 min while shaking. The input fractions saved the day before were thawed 
on ice, resuspended in 400 µl TE buffer and from here on processed together with the 
other samples. 0.2 mg/ml RNAse A (R6148, Sigma-Aldrich) was added and the 
samples incubated for 30 min at 37°C on a shaker. Subsequently10 mM EDTA, 40 mM 
Tris pH 6.5 and 50 µg/ml Proteinase K (03115879001, Thermo Fisher Scientific) were 
added to each sample and incubated at 55°C for 2.5 h while shaking. Afterwards the 
temperature was rised to 65°C the samples were incubated overnight without shaking. 
The next day, the samples were transferred to a 2 ml Eppendorf tube and DNA 
extraction was performed (adapted from  using the QIAquick Gel extraction Kit (28704, 
Qiagen). 3 volumes of QG buffer and 1 volume of isopropanol were added, followed 
by heating at 55 °C for 3 minutes. Samples were then loaded onto a QIAquick column 
and centrifugation for 1 min (13’000 rpm) was perfomed and the low through was 
discarded. Subsequently 750 µl PE buffer were added and after letting the column 
stand with the lid open for 2 min at room temperature, the columns were centrifuged, 
again (1 min, 13’000 rpm). To completely remove the PE buffer, columns were 
centrifuged for additional 2 min at 13’000 rpm. Elution was then performed twice, once 
by adding 30 µl buffer EB and a second round by adding 15 µl EB buffer. ChIP libraries 
were prepared using the APA Hyper Prep Kit from Kapa Biosystems with different 
amounts of input (from 2ng to 10ng). Samples were sequenced on a NextSeq 500 with 
using a High Output kit with 75 cycles. 
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Statistics 
Statistical analyses and graphs were generated using GraphPad Prism 7.02 software. 
All data are presented as mean ± S.E.M.  
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2.7 Supplementary data   
 
Supplementary Figure 1. Incomplete deletion of β-catenin in murine mammary tumors does not 
affect tumor growth, metastasis formation or tumor progression. (A) β-catenin conditional 
knockout (MMTV-Cre, MCre) did not affect PyMT tumor growth (β-cateninfl/fl n=19, β-cateninfl/wt n=18, β-
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cateninfl/wt; MCre n=24, β-cateninfl/fl; MCre n=31), the number of lung metastasis or the metastasis index 
(β-cateninfl/fl n=15, β-cateninfl/wt n=16, β-cateninfl/wt; MCre n=23, β-cateninfl/fl; MCre n=24). Data are 
displayed as mean ± SEM. Statistical analysis was performed using ordinary one-way ANOVA multiple 
comparison test (B) Quantification of the different tumor stages revealed that the knockout of β-catenin 
does not affect tumor progression compared to β-catenin wt mice. β-cateninfl/fl n=7, β-cateninfl/fl; MCre 
n=11. Data are displayed as mean ± SEM. Statistical analysis was performed using a Mann-Whitney U 
test.  (C) Immunofluorescence (IF) staining of tumor sections revealed that β-catenin was still present 
in the β-cateninfl/fl; PyMT; MMTV-Cre conditional knockout mice suggesting an escape phenotype. DAPI 
was used to visualize nuclei. Scale bar: 100 μm (D) Genotyping of the tumors demonstrated an 
incomplete deletion of the β-catenin gene (E) Exogenous addition of Adenovirus-Cre-IRES-GFP on 
primary tumor cell lines derived from β-cateninfl/fl; PyMT tumors resulted in the elimination of the infected 
cells as compared to cells infected with the control Adeno-IRES-GFP virus. DAPI was used to visualize 
nuclei. Scale bar: 100 μm. (F) Quantification of the recombination efficiency of MMTV–Cre in the 
mammary gland using GFP reporter mice comparing β-cateninwt/wt PyMT; MMTV-Cre to β-cateninfl/fl; 
PyMT; MMTV-Cre mice at 5 and 12 weeks of age . Scale bar: 100 μm. n=5. Data are displayed as mean 
± SEM.  
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Supplementary Figure 2. Comparison of apoptosis in vivo and the dominant-negative effect in 
vitro of the different mutant forms of β-catenin. Immunofluorescence staining and quantification of 
cleaved caspase 3 to assess apoptosis on tumor sections of the different mouse genotypes. (A) On 
tumor sections from mice expressing the D164A mutant allele the amount of apoptotic (cleaved casp.3) 
cells is not affected compared to wild type mice. β-cateninfl/fl n=10, β-cateninD164A/fl n=11, β-cateninD164A/fl; 
MCre n=10. (B) The truncated C-terminus does not affect apoptosis. β-cateninfl/fl n=10, β-cateninΔC/fl 
n=10, β-cateninΔC/fl; MCre n=10. (C) The doube mutation causes an increase in the amout of apoptotic 
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cells compared to wild type mice. β-cateninfl/fl n=10, β-catenindm/fl n=10, β-catenindm/fl; MCre n=10. White 
arrows indicate cleaved caspase-3 positive cells. DAPI was used to visualize nuclei. Scale bar: 100 μm. 
Data are displayed as mean ± SEM. Statistical analysis was performed using ordinary one-way ANOVA 
multiple comparison test: * P < 0.05. (D) Transient transfection of MYC-tagged β-cateninwt, β-
cateninD164A, β-cateninΔC and β-cateninD164A-ΔC or an empty GFP vector construct in a β-catenin wild type 
cell line (Py2T). The number of transfected and proliferating cells was quantified by MYC and pH3 
staining, which revealed a reduced proliferation of cells transfected with the β-catenin mutant (D164A, 
ΔC and D164A-ΔC) forms compared to GFP or wild type. Data are displayed as mean ± SEM. n=3. 
Statistical analysis was performed using ordinary one-way ANOVA multiple comparison test.  **** P < 
0.0001. Scale bar: 100 μm. 
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Supplementary Figure 3. Inability of β-catenin to bind BCL9/9L results in an abrogated EMT 
response. (A) Established cell lines from different dissected tumors. Floxed alleles were removed by 
infection with the Adeno-Cre-IRES-GFP virus and then FACS sorting for GFP+ cells. (B) Epithelial 
morphology of the established cell lines before and after removal of the floxed allele. Scale bar: 100 μm. 
(C) Morphology of the cell lines after 20 days of TGFβ treatment. The β-catenin wild type cell line still 
shows a mesenchymal morphology upon TGFβ treatment and the same was true for the β-cateninΔC/- 
cell line. The β-cateninD164A/- cells still grew in clusters but were more elongated. The β-catenindm/- cell 
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line did not show a mesenchymal morphology only the formation of some phylopodia. Scale bar: 100 
μm. (D) Immunofluorescent staining for Vimentin (Vim) and ZO-1 after 4d of TGFβ treatment. β-cateninfl/fl 
and β-cateninΔC/- upregulate the mesenchymal marker Vimentin and lost the expression of ZO-1 at the 
cell membrane. The β-cateninD164A/- and the β-catenindm/- cell lines however, still retained ZO-1 
expression at the cell membrane. Vimentin signal was increased in the β -cateninD164A/- cell line,whereas 
the  β-catenindm/- only show a slight increase in Vimentin. DAPI was used to visualize nuclei. Scale bar: 
100 μm. (E) Co-immunoprecipitation (IP) was performed with an antibody against β-catenin or rabbit 
IgG as a negative control in the established cell lines. It was determined if β-catenin was pulled down 
together with E-cadherin by immunoblotting analysis. Tubulin served as a loading control. 
 
 
Supplementary Figure 4. The β-catenin mutant cell lines show different alterations in the 
expression of canonical Wnt pathway components as compared to the wild type cells. (A) 
Heatmap showin the log2 fold changes of Wnt ligands and canonical Wnt pathway components being 
significantly differentially expressed in at least one of the cell lines upon Wnt3a or (B) TGF-β treatment. 
Red represents up-regulated expression and blue down-regulated expression. P ≤ 0.05 and fold change 
≥ 1.5. 
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3. Project II: Mechanisms of evasive resistance to sorafenib 
in hepatocellular carcinoma 
3.1 Summary  
Hepatocellular carcinoma (HCC) is the second most common cause for cancer-related 
death worldwide. There is need for more effective medical therapies, so far the 
standard treatment for patients with advanced HCC is sorafenib, a multikinase inhibitor 
which prolongs the time of tumor progression and improves the overall survival of the 
patients by two to three months. However, the use of Sorafenib is hampered by the 
occurrence of drug resistance leading to progression of the tumor after initial response 
to chemotherapy. To examine the escape of such therapies by the activation of 
compensatory pathways or via other mechanisms was therefore the aim of this study. 
We aimed to investigate the molecular mechanisms involved in evasive resistance to 
sorafenib in HCC. Therefore, we determined the IC50 for sorafenib of a number of 
HCC cell lines. This enabled us to differentiate between more sensitive cell lines and 
intrinsically drug resistant ones. We established sorafenib-resistant HCC cell lines out 
of the most susceptible ones, using two different approaches and investigated their 
changes in morphology, gene expression and migratory capacity. The resistant cells 
seemed to undergo an EMT since they became more mesenchymal as well as more 
migratory. Furthermore, they decreased the expression of diagnostic HCC markers 
and increased the expression of stem cell markers. However, those changes seemed 
to be epigenetic, since sorafenib withdrawal partially reverted the observed effects. 
Therefore, treatment with HDAC inhibitors was tested on intrinsically resistant cell lines 
with a mesenchymal morphology. Initial tests suggested a reversion of the 
mesenchymal to an epithelial morphology of those cells and a synergistic effect on cell 
growth of the co-treatment of pan-HDAC inhibitors together with sorafenib. To compare 
the differences in gene expression between the parental- and the established resistant 
cell lines and to able to identify pathways or genes contributing to evasive resistance 
to sorafenib, RNA sequencing has been performed. The results revealed changes in 
pathways involved in ECM organization and cell surface interactions which are also 
associated with EMT as well as pathways associated with epigenetic alterations and 
cell cycle control. Taken together, this study provides a model to examine evasive 
resistance and preliminary results show overlapping mechanisms between different 
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cell lines. Sorafenib-resistant cell lines seem to undergo an EMT and become more 
migratory. This cell model was further used in preliminary experiments to investigate 
the restoration of the morphology and sensitivity to sorafenib using HDAC inhibitors. 
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3.2 Introduction 
3.2.1 Hepatocellular carcinoma (HCC) 
Liver cancer is the second most common cause of cancer-related deaths worldwide. 
Hepatocellular carcinoma (HCC) is the most frequent type of liver cancer representing 
around 90% of cases and is more common in men than in women [256]. The main risk 
factors for the development of HCC are Hepatitis B and C virus (HBV and HCV) 
infections, alcohol-related liver disease and non-alcoholic fatty liver disease (NAFLD). 
HCV is an RNA virus that does not integrate into the host genome, whereas HBV as a 
DNA virus can integrate. HCV can induce pathway alterations caused by viral factors 
or by the immune response which is mediated by a chronic state of inflammation [257]. 
HBV on the other hand can directly integrate into the genome and can thereby cause 
genomic instability and alteration of gene expression. Also, viral proteins HBx and HBs 
as well as chronic inflammation due to infection can contribute to the carcinogenic 
process [258]. Alcohol abuse can induce liver damage by oxidative stress and 
inflammation which might have an effect on pathways promoting development of HCC 
[259]. NAFLD is the increased storage of fat in the liver due to other reasons than 
alcohol which represents a broad spectrum of disorders like diabetes and obesity. 
Thereby liver injury and cancer-promoting mutations can result in the development of 
HCC [260]. Thus, patients with cirrhotic liver damage are prone to develop HCC, but it 
can develop also in patients without liver cirrhosis [256, 261, 262]. HBV infection 
accounts for around 33% of deaths in HCC patients, whereas HCV infection accounts 
for 16% and alcohol abuse for 30%, respectively [263]. The knowledge of such risk 
factors also gives the possibility of prevention and surveillance of the development of 
HCC. Preventions of HCC development include vaccination against HBV infection, 
reduction of alcohol abuse or save transfusions and injections. Dysregulation of a 
number of signaling pathways affected by those risk factors have been linked to HCC, 
including the Wnt/-catenin pathway, the p53 pathway, and importantly, the growth 
factor-activated receptor tyrosine kinase pathways PI3K/Akt/mTOR and RAS/MAP 
kinase [256, 264]. 
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3.2.2 HCC treatment 
The clinical symptoms of HCC patients include abdominal pain and swelling, weight 
loss, fever and early satiety. However, patients at early stages of HCC are mainly 
asymptomatic and thus mostly diagnosed at later stages [265]. Early diagnosis of HCC 
has been shown to be an important factor to increase therapeutic success and 
prolonged patient’s survival rate and several imaging techniques are available to detect 
HCC. Furthermore, laboratory tests are used in HCC screening. A widely used marker 
is serum alpha-fetoprotein (AFP), a glycoprotein expressed by fetal hepatocytes in 
HCC cells. Serum AFP levels are often increased during HCC but not in all patients 
[266, 267]. Upon diagnosis, tumor staging to determine growth, spreading and 
progression is necessary for specific and optimized treatment. For HCC different 
staging systems are available for example the Okuda staging system based on 
presence of ascites, tumor size, albumin and bilirubin levels or the widely used 
Barcelona clinic liver cancer classification taking into account tumor extension, liver 
functional reserve, physical status and cancer-related symptoms (Fig. 1) [268, 269]. 
 
Figure 1. BCLC Barcelona Clinic Liver Cancer staging system for the management of HCC. M, 
metastasis classification; N, node classification; PS, performance status; Child-Pugh score, liver 
function score; RFA, radiofrequency ablation; TACE, transarterial chemoembolization [268, 270]. 
The therapeutic possibilities for HCC are divided into curative and palliative and 
comprise surgical resection, liver transplantation and the so-called locoregional 
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therapy encompassing percutaneous ablation and intra-arterial chemoembolo therapy. 
Surgical resection and liver transplantation are the first line treatment options for early 
stage HCC. The percutaneous ablation is the direct application of alcohol, heating or 
freezing to the tumor tissue by needle injection. Intra-arterial chemoembolo therapy 
constitutes the treatment by chemotherapy or radiation and their application into the 
hepatic artery supplying the tumor called transcatheter arterial chemoembolization 
(TACE) or radioembolization (selective internal radiation therapy, SIRT) respectively. 
Thereby the toxicity for the metabolism and patient is kept as low as possible since it 
is known that liver tumors draw their blood supply almost exclusively from the hepatic 
artery. The standard chemotherapeutic treatment and only approved systemic therapy 
for patients with advanced HCC is sorafenib [271, 272]. This compound is a multi-
kinase inhibitor and targets c-Raf, platelet-derived growth factor receptor (PDGFR), 
epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor 
(VEGFR), FMS-like tyrosine kinase-3 (FLT-3) and c-KIT and thereby suppresses 
angiogenesis and proliferation. The SHARP (Sorafenib HCC Assessment Randomized 
Protocol) study published in 2008 has shown that sorafenib delays the time of tumor 
progression and improves the overall survival of the patients by two to three months 
(Fig. 2) [273, 274].  
 
 
Figure 2.  SHARP (Sorafenib HCC Assessment Randomized Protocol) trial including 602 patients. 
Overall survival study of patients with advanced-stage HCC of whom 299 received sorafenib treatment 
and 303 placebo. Sorafenib treatment significantly increased the overall survival rate (10.7 months) 
compared to the control group (7.9 months). 
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However, the application of sorafenib is hampered by two phenomena: the severe side 
effects and the development of drug resistance leading to progression of tumor 
formation after initial response. Side effects found in sorafenib treated patients 
amongst others are diarrhoea, weight loss, hand-foot skin reaction (HFSR), fatigue, 
hypertension and rashes [274, 275]. Sorafenib treatment is only beneficial in about 
30% of patients and acquired resistance develops within 6 months [274]. Due to 
primary as well as acquired resistance and also to reduce its adverse effects by 
applying lower doses, co-treatment with other drugs are being tested. 
 
3.2.3 Drug resistance 
Several possible resistance mechanisms have been found and proposed. Cells might 
be intrinsically resistant (called primary resistance) which can be due to tumor 
heterogeneity favoring the outgrowth of a subset of cells. The expression levels of 
several genes have meanwhile been found to potentially predict the sensitivity to 
sorafenib treatment. Amongst them are EGFR, phosphor-ERK (pERK), JNKs (C-Jun-
N-terminal kinases), VEGF (vascular endothelial growth factor A) and Glutamine 
synthetase (GS). Testing the effect of sorafenib treatment on different cell lines, (Huh7, 
Hep3B, HepG2, SNU‐182, SNU‐398 and SNU‐449) has revealed, that the cell lines 
more resistant to sorafenib showed a higher EGFR activity in an antibody array 
compared to more sensitive ones. Hence, EGFR is proposed as a possible determinant 
of the sensitivity of HCC cells to sorafenib treatment. Sorafenib and EGFR inhibitors 
showed a synergistic effect on proliferation inhibition [276, 277]. Supporting this 
hypothesis, EGFR has also been found to be frequently overexpressed in patient-
derived HCC samples. However, also in resistant cells aberrant activation of EGFR 
and its dimerization partner HER3 (human epidermal growth factor receptor 3, HGNC: 
ERBB3, erb-b2 receptor tyrosine kinase 3) as well as overexpression of EGFR ligands 
have been observed. Silencing EGFR together with HER3 increased the effect of 
sorafenib on proliferation in vitro. Thus this might constitute also an adaptive response 
to sorafenib [278, 279]. Another study has revealed that the effect of sorafenib on cell 
proliferation correlated with basal expression levels of pERK. Cells with lower 
expression levels of pERK were less sensitive to sorafenib treatment [280]. In a phase 
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II study, the pERK level in pre-treated tumors has been found to correlate with the 
progression time upon sorafenib treatment [281]. Furthermore, by analyzing the 
association of JNK activation and the therapeutic response to sorafenib, it has been 
observed that the progression time and overall survival of patients significantly 
correlated with low c-Jun expression in samples before treatment [282]. In some 
human and mouse HCCs genomic VEGFA amplification has been discovered. Those 
tumors showed a higher proliferation, higher vessel density and a higher macrophage 
content compared to tumors without VEGFA amplification. Since sorafenib also inhibits 
VEGFRs and BRAF (B-Raf proto-oncogene), treatment reduced tumor growth in vivo 
in VEGFA–amplified tumors. Also, in patients the improved survival correlated with 
VEGFA expression [283]. In the liver, the expression of GS seems to be regulated by 
canonical Wnt signaling. β-catenin mutations and/or aberrant activation of the 
canonical Wnt signaling pathways have frequently been found in HCC and pathway 
activation induced by APC (adenomatous polyposis coli) loss was found to be 
sufficient to induce hepatocarcinogenesis. Analysis of five different HCC cell lines 
has shown that cells with high GS expression were more sensitive to sorafenib 
treatment. Upon silencing GS expression, the cells became more resistant. GS 
expression seemed to induce autophagy in HCC cells since silencing reduced and 
overexpression of GS induced autophagic activity. Furthermore, sorafenib treatment 
increased autophagic activity which was reduced by shRNA mediated silencing of 
GS [284-286].  
Otherwise adaptive/evasive resistance can emerge. Thereby cancer cells escape 
therapeutic treatments by activating compensatory pathways. EMT is one such 
mechanism by which it is thought that cells can become more resistant to 
chemotherapeutics. The investigation of serum response factor (SRF) in HCC, known 
to play a role in carcinogenesis and tumor progression as well as EMT, has shown 
that its overexpression in HLE cells led to an increased expression of mesenchymal 
markers and a weaker effect of sorafenib treated cells. In contrast, the inhibition of 
SRF led to a diminished expression of mesenchymal marker, restored E-cadherin 
expression and enhanced the apoptotic effect of sorafenib treatment [287]. Even 
though, sorafenib has also been found to be able to inhibit EMT suggesting that once 
overcoming this inhibition, EMT might contribute to chemoresistance [288, 289]. For 
example, sorafenib was found to reverse the changes in histone modifications that 
occur during EMT. The expression of several HDACs as increased during EMT, also 
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H3K4me3 and H3K9ac levels within the promoter region of E-cadherin were 
decreased and these changes could be blocked by sorafenib treatment [289]. 
Another study has demonstrated that established sorafenib-resistant HCC cells by 
long term treatment, became more mesenchymal, had an increased invasive 
potential and showed a downregulation of liver-specific markers alpha-fetoprotein 
and glypican [290]. Long-term treatment of HCC cell lines with sorafenib also resulted 
in a mesenchymal phenotype and drug resistance of the cells. Furthermore, 
knockdown of SNAI1 or MDR1 in the resistant cells reversed drug resistance. Snai1 
knockdown reversed the EMT phenotype, whereas MDR1 knockdown did not. 
Moreover, cells stably expressing SNAI1 also showed a higher expression of EMT-
related markers, downregulation of E-cadherin and an increased resistance to 
sorafenib. Furthermore, the resistance was mediated by the PI3K/AKT signaling 
pathway, and treatment with the Akt inhibitor MK-2206 lead to a reversion of the EMT 
[291]. Also Chen and co-workers have found that the activation of PI3K/Akt signaling 
pathway mediated the acquired resistance to sorafenib in Huh7 HCC cells, and MK-
2206 reverted resistance to sorafenib and sensitized the cells to sorafenib-induced 
apoptosis [292]. In another study, an in vivo shRNA screen has identified the 
activation of Mek-Erk and Atf2 signaling by MAPK14 as a resistance mechanism by 
which cells react to sorafenib treatment. Accordingly, the pharmacological inhibition 
of MAPK14 increased sorafenib efficiency in vitro and in vivo suggesting a possible 
combinatorial treatment [293].  
Changes in gene expression during EMT can lead to numerous phenotypic changes, 
such as cell morphological changes, loss of adhesion and gain of stem cell features 
[294]. It is thought that cancer growth is also dependant on a few progenitor cells 
which show pluripotency and self-renewal properties. Such cancer stem cells (CSCs) 
are thought to be more resistant to radio/chemotherapy and therefore to contribute 
and thus being associated with recurrence of cancers [295]. Also in liver cancer, the 
presence of such stem cells has been proposed [296-298]. Current radio- and 
chemotherapies destroy the vast majority of cancer cells, but are often not able to 
eliminate the critical CSCs, which are protected by specific resistance mechanisms. 
Comparing the response to sorafenib of six different liver cancer cell lines has 
revealed an increased resistance of cells with a rather mesenchymal phenotype and 
high expression of CD44 whereas rather epithelial cells expressing EPCAM or 
CD133 were more sensitive [299]. The expression of the stem cell marker CD44 
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together with active TGFβ/β-catenin pathways was thereby found to be a marker for 
predicting the efficiency of sorafenib treatment [299]. Moreover, examining 
chemoresistance of cells showed that poorly-differentiated CD133(-)/ALDH(low) HLE 
cells were more resistant to cisplatin, doxorubicin or sorafenib [300]. In another study, 
two different HCC cell lines that have been established from the same patient have 
showed differences in the morphology. These cell lines were compared as one was 
showing an epithelial and the other one a mesenchymal phenotype. The 
mesenchymal cell line was more migratory and invasive in vitro and also more 
resistant to sorafenib or erlotinib treatment as compared to the mesenchymal 
phenotype cell line [301]. 
Adaptation to a hypoxic microenvironment has also been found to contribute to drug 
resistance which is often mediated by hypoxia inducible factor-1α (Hif-1α). 
Uncontrolled tumor growth reduces the availability of nutrients and oxygens for some 
cells needed for growth, function and survival. Adaptation to such stress factors also 
seem to enhance tolerance to drug treatments [302, 303]. In a study in 2013 by Liu 
and colleagues, it has been found that sorafenib-resistant HCCs from patients showed 
increased hypoxia compared with HCCs before treatment or HCCs that were sensitive 
to sorafenib treatment. Enhanced anti-tumoral effects were achieved by combined 
sorafenib treatment with additional inhibition of HIF-1α. Similar observations have also 
been made in in vitro and in vivo mouse models [304]. Hif1-α stabilization can then 
also lead to the activation of MDR1 (ATP-binding cassette, subfamily b, member 1; 
HGNC: ABCB1) which can reduce intracellular drug concentrations and might depict 
another mechanism of resistance [305]. Furthermore, autophagy as a process by 
which cells can digest and degrade dysfunctional or damaged components seems to 
be able to play a protective role against cancer treatments. In HCC cell lines, sorafenib 
has been found to induce the accumulation of autophagosomes and autophagy and 
thereby might increase cell survival. Moreover, autophagy inhibition enhanced the 
effect of sorafenib in vitro as well as in xenograft mice in vivo [306].  
Resistance can also be acquired by enhanced efflux or decreased uptake of drugs that 
can be achieved by increased expression of drug transporters. Drugs used for 
treatment of HCC like sorafenib and anthracyclines are found to be substrates for such 
transporters [307, 308]. Several studies have found altered expression of such 
transporters in HCC that can confer resistance to treatment [307, 309-311]. 
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Transfection of a renal cell line with MRP2 (Multidrug resistance-associated protein 2; 
HGNC: ABCC2, ATP-binding cassette, subfamily C, member 2) showed significantly 
decreased sorafenib concentrations and increased the IC50 compared to the control. 
This suggests that sorafenib is a substrate of MRP2 and its expression can contribute 
to resistance formation [312]. Also MRP3 (ATP-binding cassette, subfamily c, member 
3, also ABCC3) has been found as a possible mediator of sorafenib resistance. 
Established sorafenib-resistant PLC cells showed an increased expression of MRP3, 
and its knockdown lead to sensitization [313]. Also the inhibition of ABCG2 (ATP 
binding cassette subfamily G member 2) resulted in a higher susceptibility of HCC cells 
to sorafenib treatment [314]. 
 
3.2.3.1 Epigenetic regulation involved in drug resistance 
Epigenetic regulation of translation works through reversible but heritable states of 
gene expression due to specific gene silencing by methylation and other non-mutating 
mechanisms thus causing phenotypic alterations without affecting the genotype. 
Epigenetic changes act on gene expression by affecting chromatin architecture. 
Euchromatin where chromatin structure allows accession for gene transcription to 
happen can be changed to heterochromatin, where transcription is structurally 
hampered and repressed. Epigenetic alterations leading to aberrant gene expression 
have also been found to play a pivotal role in cancer. EMT, has as well been found to 
be regulated by epigenetic modifications and in HCC several epigenetic alterations like 
histone modifications, DNA methylation and non-coding microRNA patterns have been 
discovered [315, 316]. 
 
DNA methylation 
DNA methylation is the covalent attachment of a methyl group predominately to 
cytosines (5-methyl-C) catalyzed by DNA methyltransferases (DNMTs) in CpG islands 
[317]. In HCC, promotor hypermethylation has been found being involved in the 
inactivation of tumor suppressor genes which play an important role in carcinogenesis 
[318]. With regard to EMT, the promotor hypermethylation of CDH1 (E-cadherin) was 
found in malignant breast and prostate carcinomas [316]. Methylation of estrogen 
receptor-alpha and E-cadherin promotors was also found to increase during breast 
tumor progression. [319] Also in HCC, frequent hypermethylation of the CDH1 
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promotor and thereby downregulation of CDH1 has been reported [320]. Furthermore, 
a genome wide methylation profiling has found distinctive methylation patterns 
comparing HCC to adjacent normal liver samples. Another study has found five genes 
(APC, cyclin dependent kinase inhibitor 2A (CDKN2A), homeobox A9 (HOXA9), Ras 
association domain family member 1 (RASSF1), and runt related transcription factor 
(RUNX) to be more frequently methylated in malignant tissues than in normal liver 
tissue [321].  
 
Histone modifications  
Histone modifications affect chromatin structure and gene expression. This includes 
phosphorylation, ubiquitination, methylation and acetylation that occurs on N-terminal 
domains of histones. These modifications can either activate or repress gene 
expression. Histone acetylation mediated by histone acetyltransferases (HATs) leads 
to an active state which is opposed by histone deacetylases (HDACs) [318, 322]. In 
humans, 18 different HDAC isoforms have been identified which are divided into two 
families and classified into four classes according to sequence similarities. The 
classical HDAC family comprises the class I HDACs encompassing HDAC1-3 and 
HDAC8, as well as the class II HDACs, HDAC4-7, 9 and 10 and the class IV HDAC11. 
The second family contains the NAD+ dependant sirtuins, SIRT1-7 belonging to class 
III. [323, 324] Again E-cadherin was a target found to be affected by HBx (hepatitis B 
virus (HBV)-encoded X antigen) expression leading to aberrant histone acetylation and 
downregulation of E-cadherin in an HCC cell line. Inhibiting the histone deacetylation 
using the HDAC inhibitor trichostatin A (TSA) was able to restore E-cadherin 
expression [325].  
Histones can be methylated by histone methyltransferases (HMTs). They are classified 
according to their substrate specificity by either methylating lysine (lysine 
methyltransferases) or arginine (arginine methyltransferases). Histone methylation 
mediated by histone methyltransferases (HMTs) can lead to activation as well as 
repression and histone demethylation by histone demethylases (HDMs) can revert it 
[318, 326, 327]. Treatment of rats with  2-acetylaminofluorene (2-AAF), a genotoxic rat 
liver carcinogen resulted in liver carcinogenesis and subsequent analysis of the histone 
methylation revealed an increased H3K27 tri-methylation in tumor suppressor gene 
promoter regions of Rassf1, Cdkn2a, Socs1(suppressor of cytokine signaling 1), Gjb2 
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(gap junction protein beta 2; old nomenclature: Cx26) and again Cdh1 [328]. In different 
cancer types, altered gene expression of cancer-related genes induced by an altered 
histone modification profile has been found. Examining HCCs also revealed an 
aberrant expression of HDACs and HMTs. For example, the expression of HDAC1, 
HDAC2, HDAC3 and HDAC6 as well as SIRT1 were found to be upregulated in HCC 
[329-332]. The expression of HDACs 1-3 showed a high correlation with upregulation 
of Ki-67 and the tumor grade. The expression of HDAC2 was found being associated 
with poor survival in low-grade and early-stage tumors [333]. In another study 
expression of HDAC1 and 2 were also found to correlate with worse survival of the 
patients [334]. 
HDAC inhibitors inhibit the enzymatic activity of HDACs and thereby lead to the 
transcriptional activation of target genes. They can be grouped according to their 
structure into four different groups: hydroxamates, cyclic peptides, short chain fatty 
acids and benzamides. Up to date four HDACis are FDA approved: vorinostat (SAHA) 
and romidepsin (FK228) and belisostat (PXD101) have been approved for treating 
CTCl (Cutaneous T-Cell lymphoma) patients. Panobinostat (LBH589) has been 
approved for treatment of multiple myeloma. Those inhibitors as well as others are 
currently also tested for treatment of HCC [335]. SAHA was found to inhibit proliferation 
of HepG2.2.15 cells and to induce apoptosis [336]. Romidepsin treatment was found 
to induce cell cycle arrest and apoptosis in Huh7 HCC cell line mediated by the 
activation of the MAPK/ERK pathways and JNK/MAPK pathways. Furthermore, it 
reduced tumor growth in mouse xenografts [337]. Moreover, also combinatory 
treatments of HDACis and several chemotherapeutic drugs are being tested. 
Synergistic effects have been observed. In a recent study, sorafenib has been found 
to have inhibitory activities on HDACs in HCC, HepG2 and PLC/PRF/5 (PLC5) cell 
lines. It seemed to reduce the expression of HDAC 2, and in HEPG2 cells and of 
HDAC3 and HDAC4 in PLC5 cells. Liu and colleagues also have shown that patients 
with high expression of HDAC1 or HDAC2 had a shorter overall survival. Therefore is 
was thought that amplification the inhibitory effects of sorafenib on HCCs could 
enhance its effects [334]. Treatment of Huh7, Hep3B and HepG2 cells with 
panobinostat had an effect on cell viability and proliferation. Co-treatment with 
sorafenib showed an additive effect on viability of the HEPG2 and Hep3B cells. 
Besides panobinostat also seemed to induce autophagy in Huh7 cells. Also in vivo, 
using HCC xenografts it was shown that panobinostat alone or together with sorafenib 
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reduced respectively additively reduced tumor volume and increased survival in vivo 
[338]. Also combinatorial treatment of sorafenib together with vorinostat resulted in 
additive effects on eliminating hepatic, renal and pancreatic adenocarcinoma cells 
[339]. Furthermore, resminostat was found to induce apoptosis in HCC cell lines and 
the cytotoxic effect of sorafenib was enhanced by the co-treatment with resminostat 
[340]. In a preclinical study, it has been observed that the treatment with resminostat 
was effective alone or together with sorafenib in patients that showed progression 
under first-line treatment with sorafenib [341]. Furthermore, a synergistic effect of 
sorafenib and resminostat was found in mesenchymal HCC cell lines rather insensitive 
to sorafenib treatment. Moreover, resminostat treatment decreased expression of 
mesenchymal markers in those cells and increased the expression of epithelial 
markers, furthermore their stemness and invasive properties were decreased [342]. 
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3.3 Aim of the study 
Hepatocellular carcinoma (HCC) is the second most common cause for cancer-related 
death worldwide. The standard treatment for patients with advanced HCC is sorafenib, 
which is a multikinase inhibitor and was found to prolong the time of tumor progression 
and improved the overall survival of the patients by two to three months. However, the 
use of Sorafenib was found to be hampered by two phenomena, by severe side effects 
and by the development of drug resistance leading to progression of the tumor after 
initial response to chemotherapy. Several observations suggested activation of 
compensatory pathways upon drug treatment leading to the so-called evasive 
resistance. Therefore, in this project, we wanted to examine how cancer cells respond 
to sorafenib and to delineate the mechanism of evasive resistance to sorafenib in HCC. 
These results might shed light on improving the efficacy of sorafenib in HCC patients 
and additionally on overcoming the development of evasive resistance to sorafenib 
therapy. Therefore, we made use of available cultured cell lines derived from HCC 
patients. In a first attempt, we wanted to determine the IC50 for sorafenib of a number 
of HCC cell lines. This enabled us to differentiate between the more sensitive cell lines 
and intrinsically drug resistant ones. We then sought to establish sorafenib resistant 
cell lines out of the most susceptible ones by treating the cells either with constant high 
or slowly increasing sorafenib concentrations. Following, we wanted to characterize 
them using different cellular assays, qRT-PCRs and immunofluorescent staining. 
However, the main goal was to identify genes and pathways altered which contribute 
to and might mediate evasive resistance to sorafenib. Therefore, we performed RNA 
sequencing comparing the established resistant to control cells. This allowed the 
identification of pathways and genes involved in evasive resistance to sorafenib and 
which might function as predictive biomarkers. Those will be further analyzed and 
functional tested in cellular assays in vitro and in transplantation experiments in vivo. 
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3.4 Results 
3.4.1 Development of sorafenib-resistant cell lines 
In order to examine evasive resistance mechanisms to sorafenib, in this project we set 
out to establish sorafenib-resistant cell lines. In a first step, the growth curves and the 
corresponding IC50 values for sorafenib treatment of several HCC cell lines were 
determined, in order to differentiate more sensitive cell lines from intrinsically drug-
resistant ones (Fig. 1A, 1B). The four most treatment-susceptible cell lines, Huh7, 
Huh6, HepG2 and Hep3B, were treated with either stepwise increasing concentrations 
(called I.R.) of sorafenib or constant high concentrations (called C.R.) to establish 
resistant cell lines. We were successful in establishing sorafenib-resistant Huh7 and 
Hep3B cell lines with both approaches (Fig. 1C, 1D). With the I.R. approach, the IC50 
of the Huh7 cell line was raised from initial 1.9 µM to 10.7 µM and for the Hep3B cell 
line from 3.1 µM to 6.8 µM. Using the C.R. approach IC50 levels were raised to 10.8 
µM and 6.6 µM for the Huh7 and Hep3B cell line, respectively, resulting in constant 7 
µM and 5 µM sorafenib applied to Huh7 and Hep3B cells, respectively (Fig. 1D). These 
IC50 concentrations are close to the clinically relevant concentration of  approximately 
10 μM [343]. Additionally, the Huh1 cell line was made resistant by treating them with 
increasing sorafenib concentrations (I.R.) resulting in an increase of the IC50 from 3.9 
μM to 7.6 μM (Fig. 1D). 
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Figure 1. Establishment of sorafenib-resistant cell lines. (A) List of HCC cell lines used in this study. 
(B) Summary of IC50s measured for sorafenib treatment. (C) Approaches used to establish sorafenib 
cell lines. Increasing (I.R) or constant high (C.R.) sorafenib concentrations were applied to the cells 
resulting in an increase of the IC50. Table with IC50 values of the Huh7 and Hep3B resistant cell lines 
that were developed and the values for their corresponding control lines determined in three 
independent experiments. (D) Dose response curve and IC50 determination for sorafenib of Huh7 (n=4, 
for Huh7 C.R. n=3), Hep3B (n=3) and Huh1 (n=1) cells. (E) Morphological changes induced in the 
established sorafenib-resistant cell lines. Phase contrast microscopic image of Hep3B, Huh7, Huh1 
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parental, control (DMSO) and established resistant (I.R.) cells as well as Hep3B and Huh7 I.R. after 
three weeks of sorafenib withdrawal. Scale bar: 100 μm. 
 
3.4.2 Characterization of the resistant cell lines 
Compared to the parental and control (DMSO) cells, the resistant cell lines had a more 
mesenchymal morphology (Fig. 1E) and tend to detach easier from the plate surface 
upon trypsinization and grew much slower. However, after three weeks of sorafenib 
withdrawal the Huh7 I.R. cell line changed back to a more epithelial morphology and 
the IC50 was decreased to 7 μM. Moreover, the morphology of the Hep3B cell line 
reverted as well upon withdrawal (Fig. 1E). Since the resistant cells depicted a more 
mesenchymal morphology, immunofluorescence (IF) staining for EMT-related markers 
(E-cadherin, Vimentin, Zonula Occludens-1 (ZO-1) and F-actin) were performed. In the 
Huh7 I.R. cells, it revealed the expression of mesenchymal features compared to the 
vehicle-treated control and parental cells that appeared to be rather epithelial. The 
expression of E-cadherin and ZO-1 was lost at the cell membrane and Vimentin was 
found to be upregulated in the resistant cells. Furthermore, in the control cells cortical 
actin fibers, whereas in the resistant cells actin stress fibers were found (Fig. 2A).  
These results were further confirmed by quantitative RT-PCR which showed an 
upregulation of mesenchymal markers (N-cadherin, Vimentin, Snail2, Fibronectin, 
Zeb1 and Twist) and a downregulation of E-cadherin compared to the vehicle-treated 
control (Fig. 2B). In line with these results, Huh7 I.R. cells revealed an approximately 
three-fold increase in migratory capacity in a scratch wound as well as in a transwell 
migration assay (Fig. 2C, 2D). Upon removal of sorafenib for three weeks the migratory 
capacity decreased again. Furthermore, the Huh7 and Hep3B resistant cell lines 
showed a reduced expression of the differentiation and diagnostic HCC marker alpha-
fetoprotein (AFP) as well as for two other diagnostic HCC markers, Glypican-3 (GPC3) 
and heat shock protein 70 (HSP70). Albumin, a hepatocyte marker was found to be 
downregulated as well. Upon withdrawal of sorafenib, the expression of HSP70 was 
found to be again similar to the control cells (Fig. 3A, 3B).  Furthermore, CD44 and 
CD133, well-known stem-cell markers, are upregulated in the Huh7 I.R. and C.R. cell 
lines (Fig. 3C). In summary, these results show that the resistant cells seem to undergo 
an EMT-like process and become more migratory. Furthermore, they reduce the 
expression of diagnostic HCC markers and upregulate stem cell markers which might 
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hint to the acquisition of stem cell properties rendering the cells more resistant to 
sorafenib. Moreover, the sorafenib-induced stress seems to result in reversible 
mechanistic adaptation, indicating that sorafenib-induced resistance in our models is 
most likely due to epigenetic, transcriptional and/or translational changes rather than 
genetic mutations. 
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Figure 2. Sorafenib-resistant cells become more mesenchymal. (A) Immunofluorescence staining 
for EMT-related marker (E-cadherin, F-actin (Phalloidin), Vimentin and ZO-1 comparing Huh7 I.R. to 
Huh7 control (DMSO) cells. Loss of the epithelial markers at the cell membrane and upregulation of 
Vimentin were observed as well as changes from cortical actin to actin stress fibres in the resistant cells. 
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DAPI was used to visualize nuclei. Scale bar: 100 μm. (B) qRT-PCR for EMT related markers comparing 
Huh7 control to established resistant (I.R.) cells. Reduced expression of E-cadherin as well as 
upregulation of mesenchymal markers N-cadherin, Fn1, Snai2, Zeb1 and Twist were found. n=2. Data 
are displayed as mean ± SEM. (C) Migration assay performed comparing Huh7 control DMSO), Huh7 
I.R. and Huh7 I.R. after three weeks of sorafenib withdrawal. I.R. cell show an around three-fold increase 
in the number of migrated cells which is again reduced to the level of the control after sorafenib 
withdrawal. Data are displayed as mean ± SEM. Statistical analysis was performed using ordinary one-
way ANOVA multiple comparison test. n=4; ** P < 0.01, *** P < 0.001. (D) Cell IQ images of a scratch 
wound assay performed to determine the migratory capacity comparing Huh7 control (DMSO) to Huh7 
I.R. cells. (E) Quantification of the scratch wound assay showing an around three-fold increase in the 
migratory capacity of the sorafenib-resistant cells. n=1. 
 
 
Figure 3. Expression of diagnostic HCC markers and stem cell markers in resistant cell lines. (A) 
qRT-PCR for hepatocyte and diagnostic HCC marker in Huh7 DMSO, I.R. C.R. and I.R. cells after three 
weeks of sorafenib withdrawal. n=2. Albumin expression has not yet been analysed for the Huh7 I.R. 
after three weeks of sorafenib withdrawal. A reduced expression of AFP, GPC and Albumin was found 
in the established resistant cells as compared to the control. In the I.R. cells also the expression of 
HSP70 is reduced which increased again upon sorafenib withdrawal for three weeks. (B) qRT-PCR for 
hepatocyte and diagnostic HCC marker in Hep3B DMSO, I.R. and C.R. cells. The expression of AFP, 
Hsp70, GPC3 and Albumin is reduced in the established resistant cells as compared to the DMSO 
treated control. n=2 (C) Examination of the expression of stem cell markers CD44 and CD133. Huh7 
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I.R. and C.R. cells show an upregulation of the expression as compared to the control. n=2. . Data are 
displayed as mean ± SEM. 
 
3.4.3 HDAC inhibitor treatment reverts the mesenchymal 
morphology of resistant HCC cells and sensitizes them to sorafenib 
treatment 
EMT also seems to be regulated by epigenetic modifications and also in HCC several 
epigenetic alterations like histone modifications, DNA methylation and non-coding 
microRNA patterns have been found [344]. Furthermore, in our laboratory it has 
already been observed that HDAC inhibition restores the epithelial cell morphology of 
an established stable mesenchymal cell line (Kilinc et al., submitted for publication). 
Thus, we wanted to test HDAC inhibitors in HCC to examine if the morphology of the 
established sorafenib-resistant cells as well as of the intrinsically resistant HCC cell 
lines might revert from mesenchymal to epithelial and if the cells thereby become more 
susceptible to sorafenib. Treatment of either sorafenib-sensitive (PLC) as well as 
intrinsically resistant (SNU-449, SNU-475) cell lines with the pan-HDAC inhibitor 
pracinostat had an inhibitory effect on proliferation in all cell lines tested (Fig. 4A). Co-
treatment of intrinsically resistant HCC cell lines with the pan-HDAC inhibitors 
trichostatin A (TSA) or pracinostat with sorafenib for three days showed an additive 
effect on cell growth inhibition and decreased the IC50 for sorafenib (Fig. 4B). The 
IC50 decreased from 6.8 μM to 2.5 μM with TSA and to 4.5 μM with pracinostat co-
treatment in SNU-445 cells. Short treatment (3 days) of SNU-449 cells with TSA had 
no effect on the morphology or the expression and localisation of EMT related marker 
as assessed by immunofluorescence staining (data not shown). However, upon long-
term (7 days) HDACi treatment with TSA or entinostat (HDAC1 and HDAC3 inhibitor), 
a subset of cells showed a more epithelial morphology (Fig. 4C). These results show 
that HDAC inhibitors might be able to increase the sensitivity of the resistant cells to 
sorafenib and revert them to a more epithelial morphology, indicating that histone 
acetylation-dependent epigenetic modifications might play an important role in 
mediating sorafenib resistance. 
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Figure 4. HDACi treatment to sensitize sorafenib-resistant cells. (A) Growth curves of sorafenib-
sensitive PLC and intrinsically sorafenib-resistant cell lines SNU-449, SNU-475 upon treatment with 
pan-HDAC inhibitors TSA and Pracinostat. A growth inhibition was found in all cell lines treated with the 
HDAC inhibitors. (B) Dose response curve and IC50 determination for sorafenib by co-treatment with 
pan-HDAC inhibitors TSA or pracinostat in intrinsically resistant SNU-449 cells. Synergistic effect of 
sorafenib with both HDAC inhibitors was found. (C) Changes in morphology of SNU-449 cell upon 
HDACi treatment with TSA or Entinostat. A subset of cells became more epithelial upon HDACi 
treatment for three days. n=1. Scale bar: 100 μm. 
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3.4.4 Pathway analysis of differentially expressed genes common to 
the established resistant cell lines 
To determine the differences in gene expression between the control (DMSO)-treated 
and the established sorafenib-resistant cell lines, gene expression profiles were 
established by next generation RNA sequencing. Gene expression between the 
established Huh7 and Hep3B I.R. and C.R. as well as the third established Huh1 I.R. 
cell line were compared to two intrinsically resistant cell lines (SNU-449, SNU-475) to 
identify shared genes and pathways between the acquired resistant cell lines and the 
intrinsically resistant cell lines. Hierarchical clustering distinguishes the Huh7 and 
Hep3B control (DMSO)-treated samples and the established as well as the intrinsically 
sorafenib-resistant cell lines from each other. The intrinsically resistant cells cluster 
together independent of the treatment using DMSO (control) or sorafenib for three days. 
The established resistant cell lines cluster together irrespectively of their origin (Fig. 
5A).  
Further analysis investigated commonly affected pathways as well as differentially 
expressed genes (DEGs) in the established resistant cell lines compared to their 
controls. There were 191 genes commonly up and 119 genes commonly 
downregulated in the established resistant cell lines. Subsequently, to better 
understand the biological function of the DEGs, pathway analysis was performed of 
the transcriptome data to determine which pathways were most significantly altered 
between the two groups. Using the Reactome database, of the top 20 significantly 
enriched upregulated pathways, several were involved in ECM organisation and cell 
surface interactions which were also associated with EMT. Among the top upregulated 
were pathways, such as extracellular matrix (ECM) organization, non-integrin 
membrane-ECM interactions, MET (MET Proto-Oncogene, tyrosine-protein kinase 
Met) promotes cell motility, signaling by MET, collagen formation, metalloprotease 
DUBs (deubiquitinating enzymes), interleukin-7 signalling, ECM proteoglycans, 
laminin interactions and syndecan interactions (Fig. 5B). These results show that in 
the resistant cells multiple membrane-related signaling events are happening that are 
related to EMT, suggesting a major role of EMT in sorafenib resistance formation. 
Downregulated genes belonged mainly to pathways associated with epigenetic 
alterations, among them are HATs acetylate histones, HDACs deacetylate histones 
and PRC2 methylates histones, and DNA methylation (Fig. 5C). However, genes 
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falling into these pathways were mainly histone components, such as HIST1H2AD, 
HIST1H2AB, HIST2H2AA3, HIST2H2AC, HIST1H2BL, HIST1H2BN, HIST1H2BC, 
HIST1H2BO, HIST2H2BE, HIST2H4A, HIST2H4B and HIST2H2AA4. Further 
pathways significantly affected were associated with cell cycle control: M phase, G2/M 
checkpoints, cell cycle checkpoints, G2/M DNA damage checkpoints, and meiosis and 
mitotic prophase. In summary, the RNA sequencing results show so far that the 
established resistant cells share some alterations and mechanisms. Several pathways 
are associated with EMT in line with the previous cell culture observations. 
Furthermore, the reversibility of the resistance by sorafenib withdrawal together with 
the affected pathways involved in chromatin structure, further confirm the previous 
results (Fig. 1E) that rather epigenetic changes might be causal for the resistance in 
or established cell lines than genomic mutations. The RNA sequencing data are 
currently being further analyzed, and novel pathways and genes which might be 
involved in mediating evasive resistance to sorafenib will be further examined and 
functionally tested. Therefore, and to further narrow down genes mediating evasive 
resistance, a synthetic lethal screen with a genome-wide shRNA library has recently 
been performed by colleagues in the laboratory and novel genes of interest will be 
validated and investigated by further in vitro experiments. 
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Figure 5. Transcriptome analysis of sorafenib-resistant cells. (A) Unsupervised hierarchical 
clustering of gene expression profiles of intrinsically resistant SNU-449 and SNU-475 cells treated for 
three days with sorafenib or vehicle (DMSO), established resistant cell lines Huh1 I.R., Huh7 and Hep3B 
I.R. and C.R. and their vehicle treated (DMSO) controls. The colours indicates the correlation value. (B) 
DEGS pathway enrichment using Reactome database. Top upregulated 20 REACTOME pathways 
selected by statistical significance in terms of common DEGs in the established resistant cells as 
compared to their control. (C) DEGS pathway enrichment using Reactome database. Top 20 
downregulated REACTOME pathways selected by statistical significance in terms of common DEGs in 
the established resistant cells as compared to their control. Depicted in blue are up-regulated pathways, 
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in red down-regulated pathways. The number of DEGs per pathway is depicted. 
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3.5 Discussion 
Sorafenib is the sole systemic treatment for patients with advanced HCC that shows 
survival benefit. However, sorafenib treatment may cause side effects and patients 
eventually show progression after initial response due to the development of therapy 
resistance. Therefore, in this project, we wanted to elucidate these effects by 
developing sorafenib-resistant cell lines to further delineate the mechanisms which 
might lead to evasive resistance in those cells. This has been accomplished by two 
different approaches. By slowly increasing the sorafenib concentrations we have 
positively selected for intrinsically resistant cells but also allowed stepwise adaptation 
to the increasing concentration. The treatment with initially high concentration might 
better represent the situation in patients, those cells might develop different 
mechanisms of resistance compared to the ones selected via increasing doses.  
 
3.5.1 Sorafenib resistance and EMT 
At first, we have observed that the resistant cells adapted a more mesenchymal 
morphology as compared to the control cells. This has then been confirmed by 
immunofluorescent stainings and qRT-PCR in Huh7 I.R. cells for EMT markers. In our 
resistant cells there seems to be an increased expression of N-cadherin, SNAI2, ZEB1 
and TWIST and a slight downregulation of E-cadherin. SNAI2, ZEB1 and TWIST have 
been shown to be able to silence E-cadherin expression [193, 222, 345]. Similar 
observations have meanwhile been made for the Huh7 C.R. cell line by a colleague in 
the laboratory (M. Morini., unpublished results). The Huh7 I.R. resistant cells also 
became more motile and this notion has to be analyzed further as well for the other 
cell lines. However, those changes do not seem to be due to genomic mutations, since 
the Huh7 I.R. and Hep3B I.R. resistant cell lines reverted back into a more epithelial 
morphology upon sorafenib withdrawal, including a decreased sorafenib IC50, and 
showed a lower migratory capacity. Sorafenib withdrawal and its effect has also to be 
analyzed for the other established cell lines. In general, also the intrinsically resistant 
cell lines show a more mesenchymal morphology compared to the more sensitive cell 
lines. This suggests an important contribution of EMT to sorafenib resistance. Similar 
observations for sorafenib resistance have been made in renal cell carcinoma cell lines 
in which the sorafenib resistance was also reversible [346]. EMT is the mechanism 
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allowing epithelial cells to gain mesenchymal properties important for example during 
embryonic development. Epithelial immobile cells show apical-basal polarity and intact 
cell-cell junctions that connect neighboring cells. Mesenchymal cells are motile cells 
showing an elongated phenotype. The epithelial marker E-cadherin has been found to 
be lost in 69% of HCC patients [347]. Moreover, high expression of TWIST, which acts 
as a negative regulator of E-cadherin has been found in many primary HCCs and 
metastasis. TWIST expression has also been found to be significantly increased in 
metastatic HCC cell lines compared to non-metastatic ones [348]. TGF  is a potent 
inducer of EMT and TGF signatures in patients have been demonstrated to correlate 
with an invasive phenotype and HCC metastasis. Also a late TGFβ signature which 
has been established in mouse primary hepatocytes, has been found to correlate with 
a more aggressive and invasive phenotype of HCC tumors in patients [349]. In HCC, 
different studies have already shown the potential role of EMT in development of 
resistance. Sorafenib itself has also been found to influence and alter the cytoskeleton 
by inhibiting actin polymerisation in Hep3B and PLC cell lines [350]. However, 
sorafenib has also been found to suppress EMT which has been induced by 
insufficient radiofrequency ablation (RFA) [351]. In another study, two different HCC 
cell lines established from one patient have been analysed to examine drug efficacy, 
one showing an epithelial, the other one a mesenchymal morphology revealing that 
the mesenchymal cell line was more resistant to sorafenib and erlotinib treatment as 
compared to the epithelial cell line [301]. In addition to an increase in mesenchymal 
markers and decrease in epithelial markers, the Huh7 I.R. and Hep3B I.R. resistant 
cells also showed reduced expression of diagnostic HCC and hepatocyte marker. 
HSP70, GPC3, GS and Albumin are commonly used clinical biomarkers for HCC. AFP 
is a glycoprotein found being expressed by fetal hepatocytes as well as in HCCs and 
shows an increase in many HCC patients. HSP70, GPC3, and GS are used as 
biomarkers by immunohistochemistry staining of biopsies to distinguish hepatocellular 
carcinoma from dysplastic hepatocellular nodules. Albumin can be detected in human 
plasma and is a marker for hepatocytes. High plasma values have been found to 
correlate with increased HCC recurrence rates in patients [266, 267, 352-357]. The 
loss of these markers and the increased expression of stem cell markers (CD44, 
CD133) in Huh7 I.R. and C.R. cells might suggest a dedifferentiation of therapy-
resistant cells. Several studies have already shown the connection between an EMT 
and the acquisition of stem cell properties [165, 223]. Additionally, the expression of 
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CD44 linked to active TGFβ signalling has been found to confer a lack of response to 
sorafenib treatment [299]. In summary, these results show that therapy resistance 
results in EMT and the loss of HCC markers in vitro. The loss of diagnostic HCC marker 
expression hampers the monitoring of patients after initial sorafenib treatment for 
resistance formation. These notions have to be examined as well in all the established 
as well as in the intrinsically resistant cell lines to determine if these are common 
observations in sorafenib-resistant cells. To assess the contribution of EMT to 
sorafenib resistance, Huh1 cells have been long-term treated with TGFβ resulting in 
an EMT. These cells became more resistant to sorafenib as well and were included in 
the transcriptomic analysis (M. Morini, unpublished findings). The comparison of Huh1 
control, Huh1 I.R. and the TGFβ long-term treated cells will give further insights into 
the contribution of an EMT to sorafenib resistance. 
 
3.5.2 HDAC inhibition, EMT and sorafenib resistance 
Epigenetic changes such as DNA methylation, changes in histone modification and 
aberrant expression of mRNAs and long noncoding RNAs have been found to be 
associated with HCC. Such changes are also thought to play a role in development of 
resistance and EMT [344].  Since in our cellular models, cell morphology and 
resistance seem to be reversible upon sorafenib withdrawal, epigenetic changes might 
contribute to the underlying mechanism. Furthermore, inhibition of dysregulated genes 
contributing to tumor progression, metastasis formation and evasive resistance to 
treatment by using drugs affecting epigenetic structures might be an alternative or 
supplementary treatment approach. Previous studies have already revealed 
synergistic effects of co-treatments with HDACis and different chemotherapeutic drugs. 
A pre-clinical study has shown efficacy of treatment with resminostat alone or 
combined with sorafenib in patients that showed progression under first-line treatment 
with sorafenib [341]. Furthermore, EMT has been found to be reverted by treatment 
with HDACis [342]. During EMT several epigenetic changes have been observed, for 
example the hypermethylation of miR-200 family promotor was found to result in the 
increased expression of ZEB1 and ZEB2, correlating with mesenchymal 
characteristics in cancer cell lines [358]. In terms of histone modifications, acetylation 
of SNAI1 by the p300 lysine acetyltransferase has been found to induce EMT in lung 
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cancer cells. Knockdown of p300 led to a decrease of SNAI1 and increase of E-
cadherin expression [359]. p300 has furthermore been found highly expressed in 47 % 
of HCC patient-derived samples and correlated with worse survival, advanced staging 
and intrahepatic metastasis. The in vitro depletion of p300 resulted in an increased 
expression of E-cadherin together with a downregulation of SNAI1, Twist and HIF-1α 
and suppressed migration and invasion of the cells [360]. On the other hand, HDAC 
inhibitors like TSA and SAHA have been shown to induce an EMT phenotype in 
prostate cancer cells. Moreover, changes in the morphology as well as in the 
expression of EMT related markers and increased acetylation of proximal promoters 
of EMT-related genes have been observed [361]. Furthermore, a synergistic effect of 
sorafenib and resminostat has been found in mesenchymal HCC cell lines rather 
insensitive to sorafenib treatment. Moreover, resminostat treatment decreased the 
expression of mesenchymal markers in these cells and increased the expression of 
epithelial markers, whereas their stemness and invasive properties were decreased 
[342]. In this project we show, that treatment of HCC cell lines with pan-HDAC inhibitors 
alone already has an effect on the growth of the cell lines tested. Combinatorial 
treatment with sorafenib on intrinsically resistant cells resulted in a synergistic effect 
and seemed to affect cell morphology as well. This notion has to be further tested in 
the sorafenib-resistant cell lines established. Hence co-treatment with HDAC inhibitors 
might have a beneficial effect in treatment of HCC patients as well. Clearly, the 
interplay and interactions between HDACi, EMT and sorafenib resistance in our 
models merit further investigations. 
 
3.5.3 Transcriptomic analysis of sorafenib resistance 
RNA sequencing comparing parental sensitive to established resistant cells and 
intrinsically resistant cells demonstrates that the established resistant cells cluster 
together. The same is true for the intrinsically resistant cell lines. Hence there seem to 
be common mechanisms that might confer sorafenib resistance, which was further 
examined by functional enrichment analysis. Pathway analysis using Reactome 
revealed that amongst the pathways commonly upregulated in the established 
resistant cells are several that are involved in the extracellular matrix organisation and 
interactions which are associated with EMT. During EMT there are changes in the cell-
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cell and cell-ECM interactions and also ECM components themselves are found to be 
regulated during an EMT [208, 362]. One pathway found to be commonly upregulated 
is the MET pathway which is known to be able to stimulate cancer cell motility. In this 
pathway the binding of HGF (hepatocyte growth factor) to the transmembrane receptor 
c-MET (MET or HGFR) is able to activate the RAS-MAPK and PI3K/AKT signaling 
pathways. Expression of MET has been found to be increased in HCC as compared to 
normal liver tissue and to correlate with poor prognosis [363]. Additionally, high levels 
of p-MET have been found to be associated with resistance to sorafenib treatment in 
mice [364]. In vitro experiments have revealed that sorafenib-resistant HCC cells were 
overexpressing HGF and c-Met. Treatment using c-Met inhibitors enhanced the effects 
of sorafenib and showed growth inhibition of sorafenib-resistant HCC cells [365]. 
Knockdown of MET in HCC cell lines has furthermore been found to reduce 
proliferation, colony formation and migration in vitro and tumor growth as well as 
angiogenesis and metastasis formation in vivo [364]. Furthermore, many 
downregulated genes in our study seem to be associated with epigenetic regulation, 
especially with histone modification and cell cycle control. These results are compatible 
with our in vitro observations. However, when looking at the genes commonly and 
significantly up- or downregulated within the previously observed alterations in EMT-
related marker expression, only N-cadherin was found to be significantly upregulated. 
Not only the expression levels but also the localization of EMT markers like E-cadherin 
have to be considered. Therefore, IF staining would be needed to further evaluate the 
localisation of EMT-related markers in the established resistant cell lines. Moreover, 
expression of AFP, one of the clinical serum biomarkers for HCC, was not 
downregulated in all resistant cell lines, whereas HSP70 and GPC3 showed no change 
in expression levels. Similarly, the increased expression of CD44 and CD133 in the 
Huh7- and Hep3B I.R. cells by qRT-PCR was not found to be common for all the cell 
lines. Hence, mechanisms related to EMT and involving epigenetic changes might be 
shared, however, different genes might be affected and the common denominator 
conferring resistance still has to be identified. The PI3K pathway which has been 
previously reported to confer sorafenib resistance was not amongst the commonly 
altered pathways [291]. Also there are no ABC transporters amongst the common 
differentially expressed genes found that might promote sorafenib efflux [312, 314]. To 
further dissect these highly complex results, a synthetic lethal screen with shRNA 
libraries has been performed to narrow down the number of genes involved in 
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resistance development. The data is currently being analyzed and candidate genes 
are being tested in vivo and in vitro. It has to be further examined whether acquired 
sorafenib resistance is based on a similar or the same mechanism as the intrinsic 
resistance observed in some of our cell lines. Even though they do not cluster together, 
it is well possible and reasonable that they share common mechanisms of resistance 
development. One of these might involve epigenetic changes that promote EMT. 
Therefore, further and more stringent analysis of the RNA sequencing data and 
subsequent functional validation will be required to eventually pinpoint common 
denominators of sorafenib resistance in HCC cells. In conclusion, we demonstrate that 
sorafenib-resistant cell lines seem to undergo an EMT and become more migratory. 
The morphology as well as the sensitivity seems to be partially restored by treatment 
with HDACi. Furthermore, preliminary results show overlapping mechanisms between 
different cell lines. 
 
 
 
  
119 
 
3.6 Material and Methods 
Antibodies and Reagents 
Antibodies: Purified Mouse Anti-E-Cadherin (610182, BD Biosciences), ZO-1 
Polyclonal (617300, Thermo Fisher Scientific), Vimentin (NB300-223, Novus 
Biologicals), Alexa Fluor™ 568 Phalloidin (A12380, Thermo Fisher Scientific), 4′,6-
Diamidino-2-phenylindole (DAPI, D9542, Sigma-Aldrich),  
HDAC inhibitors: Trichostatin A (T8552, Sigma-Aldrich), Entinostat (MS-275, S1053, 
Selleckchem), Pracinostat (SB939, S1515, Selleckchem).  
 
Cell culture  
The cell lines Huh6, Huh7, PLC/PRF/5, Hep3B, SNU-182, SNU-387, SNU-449, and 
HLE were kindly provided by Dr. Luca Quagliata (Institute of Pathology, University of 
Basel). The Huh1 cell lines was obtained from CellBank Australia. HepG2 (ATCC HB-
8065), SNU-398 (ATCC CRL-2233), SNU-423 (ATCC CRL-2238), SNU475 (ATCC 
CRL-2236) cell lines were purchased from ATCC. The Huh6, Huh7 and the HLE cell 
lines were cultured in Dulbecco’s Modified Eagle’s Medium - high glucose (D5671, 
Sigma-Aldrich). Huh1 cells in Dulbecco’s Modified Eagle’s Medium - low glucose 
(D6046, Sigma-Aldrich), PLC, Hep3B and HepG2 in Minimum Essential Medium Eagle 
(, M8042, Sigma-Aldrich) and the SNU- cell lines in RPMI-1640 Medium (R8758, 
Sigma-Aldrich). All growth media were supplemented with 10% Fetal Bovine Serum 
(FBS, F7524; Sigma-Aldrich), 2 mM L-Glutamine (G7513, Sigma-Aldrich), 100 U 
penicillin and 0.1 mg/ml streptomycin (P4333, Sigma-Aldrich). All cell lines were grown 
at 37 °C, 5 % CO2, 95 % humidity. For experiments with HDACi, the cell lines were 
treated every day with the mentioned concentrations for three days. For long-term 
treatment every second day for seven days. 
 
Cell-IQ 
We determine the IC50 of all HCC cell lines for sorafenib, therefore cells were seeded 
into  24-well plates in duplicates. On the next day the cells were treated with increasing 
doses of sorafenib and put into the Cell-IQ (Model v.2., Chip-Man Technologies). 
Pictures were taken every 4 hours (hr) for three days and sorafenib was added every 
120 
 
day. To generate the growth curves, the Cell IQ analysis software was used and the 
IC50 was calculated. 
 
Development of sorafenib-resistant cell lines 
Establishment of sorafenib-resistant cell lines was performed by slowly increasing 
concentrations over time with a starting concentration just below the measured IC50 
value, or with constantly high concentrations of sorafenib. Control cell lines were 
treated simultaneously under the same conditions with either increasing or constant 
high DMSO concentrations. To establish sorafenib-resistant cell lines, two different 
approaches were executed. The indicated cell lines were either incubated with 
sorafenib concentrations just below their IC50 and the concentration was slowly 
increased during the following weeks and months. In the second approach, the cells 
were exposed to high sorafenib concentrations and maintained at this concentration to 
select for resistant cells to grow. As a control cells were treated the same way with the 
same DMSO oncentration and kept in culture as well. The established cell lines were 
then continuously cultured in the presence of DMSO (control) or sorafenib (resistant 
cells). 
 
Viability assay 
To determine the IC50 of the control (DMSO) and established resistant cells, the 
ApoTox-Glo™ Triplex Assay (G6320, Promega) was used. The cells were plated into 
a 96 well plate. On the next day, the cells were treated with increasing sorafenib 
concentrations and treated for three days by daily addition of sorafenib. The viability of 
the cells was then measured according to the manufacturer’s instructions and the 
measurements were performed using a plate reader (SPECTRAmax Gemini EM, 
Bucher Biotec) with subsequent calculation of the IC50. 
 
Immunofluorescence of cultured cells 
Cells were grown on uncovered glass coverslips (#1, 12 mm round, Menzel–Glaser) 
and treated for 3 days with sorafenib. After treatment, the cells were washed with 1x 
PBS and fixed with 4% paraformaldehyde/PBS for 15 min at room temperature. 
Following PBS washes, the cells were permeabilized with 0.2% TritonX-100/PBS for 5 
min. Subsequently, blocking was performed with 3% BSA/0.01% Triton X-100/PBS for 
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1 hour. The indicated primary antibodies was then added in the appropriate dilution in 
3% BSA/ 0.2 % PBS-T for 2 hr at room temperature. Afterwards incubation with a 
fluorophore-coupled secondary antibody (Alexa Fluor, Invitrogen) was performed for 1 
hr at room temperature in the dark. Cell nuclei were counterstained with DAPI (D9542, 
Sigma-Aldrich). After staining, the coverslips were washed and then mounted in 
Fluorescence Mounting Medium (S302380-2, Dako) on microscope slides and imaged 
using a fluorescence microscope (DMI 4000, Leica). 
 
Transwell Boyden Chamber Migration Assay 
Trypsinized and washed cells were resuspended in growth medium containing 0.2% 
FBS. 25,000 cells were suspended in 500 µl  0.2 % FBS/DMEM and seeded into 24-
trans-well migration (Corning, 353097) inserts in duplicates. The bottom chambers 
were filled with 750 µl of 20 % FBS/DMEM to create a chemo-attractant gradient. The 
cells were incubated in a tissue culture incubator at 37 °C with 5% CO2. After 16 hr, 
the inserts were washed and fixed with 4% PFA/PBS for 10 min. Cells that did not 
migrate were removed with a cotton swab, and the remaining migrated cells were 
stained with DAPI. Images of five fields per insert were taken with a Leica DMI 4000 
microscope and stained cells were counted using an ImageJ software plugin 
developed in-house.  
 
RNA isolation and real-time qPCR 
Total RNA was isolated using the guanidine isothiocyanate and phenol/chloroform 
method from TRI reagent (T9424, Sigma-Aldrich) harvested cells. Reverse 
transcription was performed using the ImProm-II™ Reverse Transcription System 
(A3803, Promega) according to the manufacturer’s instructions. mRNA expression 
was quantified by real-time quantitativePCR by using the PowerUp™ SYBR™ Green 
Master Mix (A25743, ThermoFisher Scientific) according to the manufacturer’s 
instructions. Human Riboprotein L19 (hRPL19) primers were used for normalization. 
qPCR assays were performed in duplicates, and the fold change was calculated using 
the comparative Ct method (ΔΔCt). Primer sequences are listed in Supplementary 
Table S1.  
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RNA sequencing and analysis 
Total RNA was extracted from the established resistant cell lines (Huh7 I.R., C.R.,  
Hep3B I.R., C.R. and Huh1 I.R.) their respective control cell lines as well as the 
intrinsically resistant SNU-449 and SNU-475 cell lines using miRNeasy Mini Kit 
(Qiagen, 217004) with on-column DNAse digestion according to the manufacturer’s 
instructions . Biological duplicates for Huh7 and Hep3B and triplicates for Huh1, SNU-
449 and SNU-475 were prepared for RNA sequencing. RNA quality control was 
performed using RNA ScreenTape on the Agilent 4200 TapeStation and the 
concentration was measured by using the Quanti-iT RiboGreen RNA assay Kit (Life 
Technologies). Libraries preparation for sequencing was prepared with 200 ng total 
RNA input using the TruSeq Stranded mRNA Library Prep kit (Illumina) and the quality 
was checked using the Fragment Analyzer standard sensitivity NGS kit (AATI). SR51 
sequencing was performed on an Illumina HiSeq2500 sequencing system (HiSeq SBS 
kit v4). 
 
Analysis of RNA sequencing data 
Obtained single-end RNA sequencing reads were mapped to the human genome 
assembly, version hg19, with RNA-STAR (PMID:23104886), with default parameters 
except for allowing only unique hits to genome (outFilterMultimapNmax=1) and filtering 
reads without evidence in spliced junction table (outFilterType="BySJout"). Using 
RefSeq mRNA coordinates from UCSC (genome.ucsc.edu, downloaded in December 
2015) and the qCount function from QuasR package (version 3.12.1) 
(PMID:25417205) we quantified gene expression as the number of reads that started 
within any annotated exon of a gene. The differentially expressed genes were identified 
using the edgeR package (version 1.10.1) (PMID:19910308). Genes with fdr ≤ 0.05 
and minimum log2 fold change of +/- 1.0 were considered statistically significant and 
used for downstream functional analysis. 
 
Functional enrichment analysis 
We performed functional enrichment analysis of differentially expressed genes for 
biological processes or pathways in R using several publicly available Bioconductor 
resources including GO.db (version 3.4.1), GOstats (version 2.42.0) (PMID: 17098774), 
KEGG.db (version 3.2.3) and ReactomePA (version 1.20.2) (PMID: 26661513). The 
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significance of each biological process or pathway identified was calculated using the 
hypergeometric test (equivalent to Fisher’s exact test) and those with p values ≤0.05 
were considered significant. 
 
Statistical analysis 
Statistical analyses and graphs were generated using GraphPad Prism 7.02 software. 
All data are presented as mean ± S.E.M. 
 
3.7 Supplementary Data 
 
Supplementary Table 1. Primer sequences used for qRT-PCR (5’-3’). 
  
Gene Forward primer Reverse primer
CDH1 AGAACGCATTGCCACATACACT TCTGATCGGTTACCGTGATCAA
CDH2 TAGTCACCGTGGTCAAACCAAT GTGCTGAATTCCCTTGGCTAAT
FN1 GAACTATGATGCCGACCAGAA GGTTGTGCAGATTTCCTCGT
SNAI1 GCTGCAGGACTCTAATCCAGA ATCTCCGGAGGTGGGATG
SNAI2 TGGTTGCTTCAAGGACACAT GTTGCAGTGAGGGCAAGAA
ZEB1 GCCAACAGACCAGACAGTGTT TCTTGCCCTTCCTTTCCTG
TWIST AAGGCATCACTATGGACTTTCTCT GCCAGTTTGATCCCAGTATTTT
AFP TGTACTGCAGAGATAAGTTTAGCTGAC TCCTTGTAAGTGGCTTCTTGAAC
HSP70 CAGCAGACACCAGCAGAAAA CCTTGGATCCAGCTTGAGAG
GPC3 TGATGAAGATGAGTGCATTGG GATCATAGGCCAGTTCTGCAA
Albumin AGAGGTCTCAAGAAACCTAGGAAA GGTTCAGGACCACGGATAGA
CD44 CTGCCGCTTTGCAGGTGTA CATTGTGGGCAAGGTGCTATT
CD133 GGAAACTAAGAAGTATGGGAGAACA CGATGCCACTTTCTCACTGAT
RPL19 GATGCCGGAAAAACACCTTG TGGCTGTACCCTTCCGCTT
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